

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

## Longitudinal trajectories of sedation level and clinical outcomes in mechanically ventilated patients: a prospective, multicenter, longitudinal, observational study

| Journal:                         | BMJ Open   |
|----------------------------------|--|
| Manuscript ID                    | bmjopen-2023-072628  |
| Article Type:                    | Original research  |
| Date Submitted by the<br>Author: | 10-Feb-2023  |
| Complete List of Authors:        | Hyun, Dong-gon; Asan Medical Center,<br>Ahn, Jee Hwan; University of Ulsan College of Medicine, Department of<br>Pulmonary and Critical Care Medicine<br>Gil, Ha-Yeong; pzfier<br>Nam, Chung Mo; Yonsei University College of Medicine, Preventive<br>Medicine<br>Yun, Choa; Department of Biostatistics & Computing, College of<br>Medicine, Yonsei University<br>Lim, Chae-Man; University of Ulsan College of Medicine, Department of<br>Pulmonary and Critical Care Medicine |
| Keywords:                        | Adult anaesthesia < ANAESTHETICS, EPIDEMIOLOGY, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Thoracic medicine < INTERNAL MEDICINE   |
|                                  |  |





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Longitudinal trajectories of sedation level and clinical outcomes in mechanically ventilated patients: a prospective, multicenter, longitudinal, observational study

Dong-gon Hyun<sup>1</sup>, Jee Hwan Ahn<sup>1</sup>, Ha-Yeong Gil<sup>2</sup>, Chung Mo Nam<sup>3</sup>, Choa Yun<sup>4</sup>, Chae-Man Lim<sup>1</sup>\*

<sup>1</sup>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>2</sup>Medical Research Project Team, IM Medical, Pfizer Korea Pharmaceuticals Ltd., Seoul, Republic of Korea

<sup>3</sup>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

<sup>4</sup>Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea

\*Corresponding author: Chae-Man Lim, M.D., Ph.D., FCCM

E-mail: cmlim@amc.seoul.kr

Word Count: 2743

## ABSTRACT

**Objectives:** Although low sedation depth level is recommended for intensive care unit (ICU) patients, actual sedation often deviates from this recommendation due to prolonged ICU stay. Therefore, we investigated changes in sedation levels over time and their association with clinical outcomes in a national cohort of mechanically ventilated patients.

**Design:** This was a multicenter, prospective, longitudinal, observational study.

Setting: Twenty ICUs spanning several medical institutions in Korea.

**Participants:** Patients who received mechanical ventilation and sedatives in the ICU within 48 h of admission between April 2020 and July 2021.

**Primary and secondary outcome measures:** The primary objective of this study was to identify the pattern of sedation practice. Also, we analyzed associations of trajectory groups with clinical outcomes as the secondary outcome.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**Results:** Sedation depth was monitored using the Richmond agitation-sedation scale. A groupbased trajectory model was used to classify 631 patients into four trajectories based on sedation depth: persistent suboptimal (13.2%), delayed lightening (13.9%), early lightening (38.4%), and persistent optimal (34.6%). The "persistent suboptimal" trajectory was associated with delayed extubation (hazard ratio [HR] 0.23, 95% confidence interval [CI] 0.16–0.32, p < 0.001), longer ICU stay (HR 0.36, 95% CI 0.26–0.51, p < 0.001), and hospital mortality (HR 13.62, 95% CI 5.99–30.95, p < 0.001) compared with the "persistent optimal". The "delayed lightening" and "early lightening" trajectories showed lower extubation probability (HR 0.30, 95% CI 0.23–0.41, p < 0.001; HR 0.72, 95% CI 0.59–0.87, p < 0.001, respectively) and ICU discharge (HR 0.44, 95% CI 0.33–0.59; p < 0.001 and HR 0.80, 95%CI 0.65–0.97; p = 0.024) compated to "persistently optimal".

**Conclusions:** Among the four trajectories describing longitudinal sedation depth, "persistent suboptimal" trajectory was associated with higher mortality.

Keywords: deep sedation; intensive care units; mortality; critical care; mechanical ventilators

## STRENGTHS AND LIMITATIONS OF THIS STUDY

 $\Rightarrow$  Large national data from 20 ICUs in Korea representing real-world practice.

 $\Rightarrow$  A Unique investigation into the level of long-term sedation in mechanically ventilated

patients.

 $\Rightarrow$  A group-based trajectory model identifying patterns of sedation over time.

 $\Rightarrow$  Misclassification of nondifferential group as inherent restriction of group-based trajectory

models with limited generalizability.

 $\Rightarrow$  Unclear causal relationship between trajectory and outcome.



#### **INTRODUCTION**

Sedation is cruical to promote tolerance in patients during mechanical ventilation in the intensive care unit (ICU).<sup>1</sup> Previously, ICU patients were considered unnecessarily oversedated, and the tools to assess the depth of sedation varied widely.<sup>2</sup> Inappropriate sedation was associated with adverse outcomes, such as prolonged ventilation, longer ICU stay, and higher post-ICU psychological concerns.<sup>3-6</sup> Over-sedation also predicted long-term mortality in critically ill patients.<sup>7</sup> Considering its essential role in the care of mechanically ventilated patients, international guidelines guide to improve sedation practice for favorable outcomes in ICU patients.<sup>8-10</sup>

Currently, sedation monitoring in the ICU is clinically recommended to achieve low levels of sedation,<sup>11</sup> though real-world implementation is debated.<sup>12</sup> Longitudinal studies on the level of sedation over long time are limited. Previous national surveys mainly focused on the type of sedatives and assessment tools.<sup>13-16</sup> Moreover, most studies are cross-sectional, evaluating the association between the sedation level for the first 2–3 days and clinical outcomes.<sup>17 18</sup> Therefore, we aimed to investigate long-term sedation levels in a national cohort of mechanically ventilated patients by classifying them into different longitudinal patterns. We further assessed the association between these patterns and clinical outcomes.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## **METHODS**

## Study design

We conducted a multicenter, prospective, longitudinal, and observational, cohort study in 20 ICUs in Korea between April 2020 and July 2021, which was sponsored by Pfizer Korea Pharmaceuticals Ltd. and involved 30 investigators (table S1). We designed a harmonized electric case report form that was centrally managed and combined into one database for data entry, day queries, and analysis. During the study period, patients were recruited according to

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

the number of available patients at each ICU. Principal investigators, research staff, and nurses at each participating center were trained in the study procedures. The decisions regarding a patient's care were at the discretion of the attending medical staff. Our inclusion criteria were as follows: patients aged >19 years, who had undergone mechanical ventilation and sedation in the ICU within 48 h, and were expected to remain sedated and on mechanical ventilation for >48 h. We excluded patients with a disease that was likely to cause death within 90 days, those whose treatment had been discontinued due to imminent death or non-effective therapy, and who needed non-selective deep sedation due to medical conditions, including brain damage and hemorrhage, spinal cord injury, drug overdose, burns, and nerve root block.

## Monitoring of sedation and measurement of outcome

We monitored sedation depth using the Richmond agitation-sedation scale (RASS), ranging from -5 to +4 every 8 h until ICU discharge or day 30.<sup>19</sup> The daily depth of sedation was calculated as the median RASS value for 1 day. The primary objective of this study was to identify the pattern of sedation practice. Group-based trajectory models have been widely employed for analyzing developmental trajectories.<sup>20</sup> They can address the dynamic profile of sedation by classifying patients into different trajectories of sedation level over time. We used a group-based trajectory model analyzing a scale form of RASS over the first 30 days after enrollment. To characterize each trajectory group, an analysis between the trajectory groups and the patients' characteristics was also performed. The secondary objective included associations of trajectory groups with clinical outcomes by adjusting for covariates.

## Covariates

Demographic, clinical, and laboratory data, including age, gender, reason for ICU admission, type of ICU admission, comorbidities, and illness severity (acute physiology and

#### **BMJ** Open

chronic health evaluation [APACHE] I score), were collected. Severe to moderate liver disease was defined as cirrhosis and portal hypertension with or without variceal bleeding history. Severe to moderate chronic kidney disease was defined as serum creatinine >3 mg/dL or on dialysis or post-kidney transplant status or uremia status. The need for vasopressors, renal replacement therapy, and neuromuscular blockade was also recorded. We collected and calculated the daily cumulative dose and the number of days prescribed for the sedatives and analgesics administered to patients during their ICU stay. Patients were followed up until hospital discharge, death, or day 30 in the ICU. Clinical outcomes, including ICU discharge, ventilator days, and survival status, were recorded.

## Patient and public involvement

Patient and the public were not involved in the design, conduct, reporting or NIC dissemination plans of this research.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## Statistical analysis

The pattern of sedation over time was described using a group-based trajectory model, which identified differential patterns of individual change in the populations. The final model was selected based on a combination of the Bayesian information criterion and the estimated trajectory group proportions that were sufficiently large. In this study, four-group solutions that best characterized the cohort were identified.

Data are presented as numbers and proportions for categorical variables and as means  $\pm$  standard deviations or medians (interquartile range) for continuous variables. Differences between groups were analyzed using the  $\chi^2$  test or Fisher's exact test and the independent twosample t-test or Mann–Whitney U test with a normal or non-normal distribution, as appropriate. The normality of the data was assessed by inspecting histograms. For time-to-event analysis,

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

the Kaplan–Meier method was used to estimate survival curves, whereas a log-rank test was used to test the significance of the differences. Univariable and multivariable Cox proportional hazards regression models were used to identify associations with clinical outcomes by adjusting known prognostic covariates, including age, gender, type of admission, type of ICU, vasopressor, and neuromuscular blockade. The results are presented as hazard ratios (HR) with 95% confidence interval (CI). Two-sided *p*-values <0.05 indicated significance. All analyses were performed using SAS (Statistical Analysis System) software version 9.4 (SAS Institute, Cary, NC).

## RESULTS

In 20 participating centers, 676 patients were recruited from April 2020 to July 2021 (figure S1). Of them, 45 were excluded because of missing data, an RASS date before mechanical ventilation, or were enrolled  $\geq$ 48 h after mechanical ventilation. The final cohort included 631 patients. The profile of sedatives and analgesics administered within the first 48 h was summarized in Table S2. Dexmedetomidine was the most frequently used sedative (38.2%), followed by propofol (26.1%) and midazolam (19.2%). The most commonly used analgesic was remifentanil (73.5%).

A four-group model was chosen for the cohort based on specified selection criteria: trajectory 1 (persistent suboptimal; 13.2% of patients, RASS level  $\leq -3$  throughout the 30 days), trajectory 2 (delayed lightening; 13.9% of patients, RASS level  $\geq -2$  after the first 15 days), trajectory 3 (early lightening; 38.4% of patients, RASS level  $\geq -2$  after the first 7 days), trajectory 4 (persistent optimal: 34.6%, RASS level  $\geq -2$  during the first 30 days) (figure 1).

A large number of patients in the "persistent suboptimal" group were older, with 35.82% in the >80 age group (*p*-value = 0.002) (table 1). Conversely, 39.24% and 40.46% of patients in the "early lightening" and "persistent optimal" groups, respectively, were aged between 50–

Page 9 of 30

#### **BMJ** Open

69 years. Gender and body weight did not significantly differ between the trajectories. Considering the comorbidities, there was a significant difference in dementia between patients of different trajectories (p-value = 0.010). Although no significant difference was found, the "persistent suboptimal" group had the highest percentage of solid tumor and cerebrovascular disease (38.00%, p-value = 0.278; 28.00%, p-value = 0.101, respectively), whereas the "delayed lightening" group had the lowest percentage of moderate to severe chronic kidney disease (4.61%, p-value = 0.375). The "persistent suboptimal" and "delayed lightening" groups were more likely to be admitted to a medical ICU (52.24% and 48.81% versus 34.72% and 31.63%, respectively) with a medical illness (61.19% and 58.33% versus 46.79% and 43.26%, respectively) and less likely to be admitted to a surgical ICU (44.78% and 50.00% versus 59.25% and 66.05%, respectively; p-value = 0.023) for scheduled surgery (10.45% and 11.90% versus 23.77% and 23.72%, respectively; p-value = 0.001). The most common cause for ICU admission was respiratory (56.8%) in all the groups, and the "delayed lightening" group had the highest proportion for respiratory-related admissions (67.86%), whereas the "early lightening" group had the lowest (51.32%, p-value = 0.030). Cardiovascular-related ICU admissions were most common in the "early lightening" group (25.66%, p-value = 0.610), although there was no statistical significance. The APACHE I score was significantly different among the four trajectories (27.82, 25.28, 21.39, and 24.07 for "persistent suboptimal," "delayed lightening," "early lightening," and "persistent optimal" groups, respectively; p-value <0.001). As a part of ICU support within the first 48 h, the "delayed lightening" group received the largest number of vasopressor infusions (91.67%, p-value < 0.001), renal replacement therapy (26.19%, p-value = 0.078), and neuromuscular blockade use (46.43%, p-value < 0.001). In-hospital death occurred in 12.2% patients in the entire cohort. By trajectory, in-hospital mortality was 49.52% in the "persistent suboptimal" group, 21.43% in the "delayed lightening" group, 6.79% in the "early lightening" group, and 3.72% in the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

"persistent optimal" group (*p*-value < 0.001). Similarly, differences according to the trajectories were observed for ICU discharge and extubation. The proportion of ICU discharge was 67.16%, 79.76%, 92.45%, and 92.09%, respectively (*p*-value < 0.001); rate of extubation was 68.16%, 78.57%, 95.47%, and 95.81%, respectively (*p*-value < 0.001). Moreover, differences in time to extubation (*p*-value < 0.001), ICU discharge (*p*-value < 0.001), and inhospital mortality (*p*-value < 0.001) were observed among the four trajectories (figure 2). Table 2 summarizes the representative phenotypes of each trajectory.

In adjusted Cox proportional hazard analyses, the "persistent suboptimal" (HR 13.62, 95% CI 5.99–30.95, *p*-value < 0.001) and "delayed lightening" groups (HR 5.62, 95% CI 2.36–13.38, *p*-value < 0.001) had a significantly higher risk of death than the "persistent optimal" group (table 3). The "persistent suboptimal" (HR 0.23, 95% CI 0.16–0.32, *p*-value < 0.001), "delayed lightening" (HR 0.30, 95% CI 0.23–0.41, *p*-value < 0.001), and "early lightening" groups (HR 0.72, 95% CI 0.59–0.87, *p*-value < 0.001) showed a reduced probability of extubation and were less likely to discharge from the ICU (HR 0.36, 95% CI 0.26–0.51, *p*-value < 0.001; HR 0.44, 95% CI 0.33–0.59, *p*-value < 0.001; HR 0.80, 95% CI 0.65–0.97, *p*-value = 0.024, respectively) than the "persistent optimal" group. Patients undergoing scheduled surgery showed a higher probability of extubation (HR 2.13, 95% CI 1.64–2.78, *p*-value < 0.001) and ICU discharge (HR 2.10, 95% CI 1.59–2.78, *p*-value < 0.001) than outpatient admissions. Patients in the surgical ICU had a lower risk of death (HR 0.45, 95% CI 0.23–0.89, *p*-value = 0.021) than medical ICU patients. No additional significant differences were found with respect to age, gender, vasopressor infusions, or neuromuscular blockade.

## DISCUSSION

To the best of our knowledge, this is the first study to characterize the longitudinal pattern of sedation level over time in mechanically ventilated patients. We identified four

distinct trajectories of sedation depth over the first 30 days after mechanical ventilation in our subjects. Only 34.6% patients were in an optimal depth of sedation during this period, whereas 13.2% were in the suboptimal range of RASS for most of this time, and the remaining patients achieved adequate depth of sedation 7 (early lightening: 38.4%) or 15 (delayed lightening: 13.9%) days after initiation. Patients who were at suboptimal levels of sedation throughout this period had a higher risk of mortality and lower probabilities of extubation and ICU discharge than those who were in consistently optimal level of sedation.

Group-based trajectory modeling is useful for characterizing longitudinal courses over time to identify distinct subgroups.<sup>21 22</sup> This trajectory model is used in different domains of clinical research, such as nonadherence spectrum in newly-diagnosed juvenile epilepsy, health status in outpatients with heart failure, neurologic postinjury recovery, and symptom burden nuances of patients with metastatic cancer.<sup>20</sup> Therefore, group-based trajectory modeling is a specialized method for sorting individuals into meaningful subgroups that show statistically similar trajectories. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

There were several significant differences in characteristics between the four trajectory groups. Patients in trajectory 1 (persistent suboptimal) experienced deep sedation throughout the study period, with RASS ranging from -3 to -5. This group was mainly characterized by elderly patients with cognitive impairment, admitted to a medical ICU for treating illnesses, such as respiratory problems, with the worst condition at admission. Conversely, patients in trajectory 2 (delayed lightening) experienced initial deep sedation, which improved to a light depth of RASS -2 after 15 days. This group was characterized by elderly patients with dementia with respiratory failure, receiving vasopressors, neuromuscular blockade, and renal replacement therapy. Interestingly, although the two trajectories had relatively similar characteristics and the "delayed lightening" group even required more ICU support within the first 48 h, the "persistent suboptimal" group had worse time to extubation, ICU discharge, and

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### **BMJ** Open

hospital mortality. These findings suggest that the longitudinal course of sedation depth in our subjects was not associated with the severity of illness; the difference in sedation practice between the two trajectories might have resulted into different outcomes.

A prospective multicenter study, conducted across 42 international ICUs, demonstrated that the time to extubation and mortality increased with the sedation intensity.<sup>18</sup> In observational, matched-pair analyses based on the APACHE II score and the type of admission, early deep sedation during the first 48 h of ICU stay was associated with worse outcomes, including long-term mortality.<sup>7</sup> We report similar findings in our study upon comparing trajectories 3 and 4 with the earlier trajectories. Patients in trajectory 3 (early lightening) experienced early deep sedation, which became lighter after 7 days, whereas those in trajectory 4 (persistent optimal) experienced light sedation throughout. Patients in these groups were younger, had fewer medical conditions, and were mostly admitted to surgical ICUs than those in the other two groups. They also had lower APACHE I scores and needed lesser ICU support within the first 48 h. Patients in the "early lightening" group, especially, had the lowest APACHE score, the lowest proportion of renal replacement therapy, and the fewest respiratory problems. Nevertheless, multivariable Cox proportional hazard analysis showed that patients in this group had a lower probability of extubation and ICU discharge than those in the "persistent optimal" group. The early practice of inadequate sedation in the "early lightening" group might have induced this relatively worse prognosis in these patients. A recent meta-analysis assessing the literature on early sedation suggested that interventions targeting the depth of early sedation, starting with ICU admission, could improve patient outcomes.<sup>23</sup> Appropriate sedation is a critical aspect in the management of mechanically ventilated patients.

We observed that 65.9% patients in our study were deeply sedated for at least the first week after mechanical ventilation, whereas only 34.07% patients received consistent light sedation throughout the sedation period. This finding is consistent with previous data

Page 13 of 30

#### **BMJ** Open

describing the sedation depth. A multinational survey among intensivists reported that 74% patients monitored using a validated sedation tool were deeply sedated.<sup>24</sup> A survey in Germany found that the actual depth of sedation was significantly deeper (39.5%–62.4%) than the desired depth in all categories of sedation.<sup>25</sup> A Swedish study investigating the relationship between memory and sedation showed that only 39% of ventilated patients achieved their target sedation goal.<sup>26</sup> A previous systematic review estimated the incidence of over-sedation in ICUs at 40%–60%, despite the poor quality of epidemiologic data.<sup>2</sup> In a recent study conducted in the emergency department, the incidence of deep sedation was 52.8%.<sup>27</sup> These data suggest that deep sedation remains a common real-world ICU practice. To improve the quality of patient care, further research is warranted focusing on the longitudinal profile in addition to the binary concept of sedation, light versus deep.

Our study has a few limitations. First, information bias may exist because only patients visiting tertiary or university-affiliated hospitals were included in our study. Second, unmeasured confounders could have affected the trajectories, despite many relevant variables in our study. Moreover, nondifferential group of patients may have been misclassified. This restriction is inherent to group-based trajectory models with limited generalizability. Third, the causal relationship between trajectory and outcome could not be established in this study. For example, it is unclear whether a prolonged duration of extubation reflected the effects of sedative overdose, or whether more sedation was needed because of longer mechanical ventilation. Thus, prospective and randomized controlled studies are required to investigate the interaction of two parameters (depth and duration) of sedation to better define the optimal practice. Finally, we were unable to examine the long-term complications in the trajectory groups. Further nationwide studies should evaluate long-term complications after sedation to comprehensively understand its socioeconomic and clinical burden.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

In conclusion, this study captured the four trajectories of sedation level over time in

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

> mechanically ventilated patients. The patterns were significantly associated with time to extubation, ICU discharge, and hospital mortality. Our findings suggest sedation strategy in ICU patient needs to incorporate a longitudinal pattern of sedation level.

#### Acknowledgements

None

## **Contributors**

CML, HYG, JHA have contributed to the study conception and design. Material preparation was performed by HYG. Data collection was performed DH, JHA, CML. Statistical analysis were performed by CMN and CY. The first draft of the manuscript was written by DH and JHA, and all authors commented on previous versions of the manuscript. All authors have read and approved the final manuscript. erie

## Funding

This study was sponsored by Pfizer Korea Pharmaceuticals Ltd (Grant Number: N/A). The funding does not interfere with the analysis and interpretation of the data.

## **Competing Interests**

Ha-Yeong Gil is an employee of Pfizer Korea. The other authors declare that they have no competing interests.

#### Patient consent for publication

Not applicable.

## Ethic approval

The study protocol was approved by the Institutional Review Boards of all participating medical centers (B-1911/577-405, AJIRB-MED-OBS-19-372, AJIRB-MED-OBS-19-373, 1908-156-1058, 1908-157-1058, 1910-003-083, 2019-1624, 2019-1039, 2019-10-0321, 2019-09-040, 2019-10-162, GCIRB2019-366, DSMC 2019-08-018, HALLYM 2019-08-021, HALLYM 2019-08-022, 2019-09-010, 2019-08-082, DAUHIRB-19-166, 4-2019-0821, 4-2019-0820, 2019-09-011-002, 2019-07-038-002, CR-19-117-L, 2019AN0376, 2019AN0478, 20-2019-92, 20-2019-91, 2019GR0461, 2020GR0103, 2020AS0054). All patients (or patient representatives) provided their written informed consent. Some participating centers' local review boards waived the need for informed consent considering the observational nature of the study. This study was conducted per the amended Declaration of Helsinki. reliev

## Data Availability statement

Data are available on request

## References

Richards-Belle A, Canter RR, Power GS, et al. National survey and point prevalence 1. study of sedation practice in UK critical care. Crit Care 2016;20:355.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- 2. Jackson DL, Proudfoot CW, Cann KF, et al. The incidence of sub-optimal sedation in the ICU: a systematic review. Crit Care 2009;13:R204.
- 3. Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care sedation predicts longterm mortality in ventilated critically ill patients. Am J Respir Crit Care Med 2012;186:724-31.

 Shehabi Y, Chan L, Kadiman S, et al. Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study. *Intensive Care Med* 2013;39:910-8.

- Desai SV, Law TJ, Needham DM. Long-term complications of critical care. *Crit Care Med* 2011;39:371-9.
- 6. Burry L, Rose L, McCullagh IJ, et al. Daily sedation interruption versus no daily sedation interruption for critically ill adult patients requiring invasive mechanical ventilation. *Cochrane Database Syst Rev* 2014;2014:Cd009176.
- Balzer F, Weiß B, Kumpf O, et al. Early deep sedation is associated with decreased inhospital and two-year follow-up survival. *Crit Care* 2015;19:197.
- Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med* 2013;41:263-306.
- Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. *Crit Care Med* 2018;46:e825-e73.
- Pearson SD, Patel BK. Evolving targets for sedation during mechanical ventilation.
   *Curr Opin Crit Care* 2020;26:47-52.
- Guérin C. Calming Down about Sedation in Critically Ill Patients. N Engl J Med 2020;382:1162-4.
- Owen GD, Stollings JL, Rakhit S, et al. International Analgesia, Sedation, and Delirium Practices: a prospective cohort study. *J Intensive Care* 2019;7:25.
- 13. Yassin SM, Terblanche M, Yassin J, et al. A web-based survey of United Kingdom sedation practice in the intensive care unit. *J Crit Care* 2015;30:436.e1-6.

#### **BMJ** Open

| npairing  |  |
|-----------|--|
| ntensive  | -  |
|           |  |
| entilated | -  |
| 56:23-9.  |  |
| ement of  | Protec   |
| two-part  | ted by   |
|           | Enseignement Superieur (A<br>Protected by copyright, including for uses related to text and data |
| omes of   | ght, in  |
| rit Care  | cluding  |
|           | for us   |
| Hours of  | nseigr<br>es rela  |
| spective  | ited to  |
| ·         | Superi<br>text an  |
| in ICU    | ieur (A<br>d data  |
| (RASS).   | Ξœ   |
|           | g, Al tra  |
| • Metab   | aining,  |
| nnu Rev   | and sir  |
|           | nilar te   |
| ion, and  | E\$) .<br>ining, Al training, and similar technologies.  |
| nquency.  | gies.  |
| -         | C  |
|           |  |

| 14. | Sneyers B, Laterre PF, Perreault MM, et al. Current practices and barriers imp     |
|-----|--|
|     | physicians' and nurses' adherence to analgo-sedation recommendations in the inte   |
|     | care unita national survey. Crit Care 2014;18:655.                                 |
| 15. | Wøien H, Stubhaug A, Bjørk IT. Analgesia and sedation of mechanically vent         |
|     | patients - a national survey of clinical practice. Acta Anaesthesiol Scand 2012;56 |
| 16. | García-Sánchez M, Caballero-López J, Ceniceros-Rozalén I, et al. Manageme          |
|     | analgesia, sedation and delirium in Spanish Intensive Care Units: A national two   |
|     | survey. Med Intensiva (Engl Ed) 2019;43:225-33.                                    |
| 17. | Tanaka LM, Azevedo LC, Park M, et al. Early sedation and clinical outcom           |
|     | mechanically ventilated patients: a prospective multicenter cohort study. Crit     |
|     | 2014;18:R156.  |
| 18. | Shehabi Y, Bellomo R, Kadiman S, et al. Sedation Intensity in the First 48 Hor     |
|     | Mechanical Ventilation and 180-Day Mortality: A Multinational Prospe               |
|     | Longitudinal Cohort Study. Crit Care Med 2018;46:850-9.                            |
| 19. | Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time ir       |
|     | patients: reliability and validity of the Richmond Agitation-Sedation Scale (R.    |
|     | Jama 2003;289:2983-91.   |
| 20. | Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr N                 |
|     | 2014;65:205-10.  |
| 21. | Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Ann     |
|     | <i>Clin Psychol</i> 2010;6:109-38.   |
| 22. | Nagin D, Tremblay RE. Trajectories of boys' physical aggression, opposition        |
|     |  |

nn ion hyperactivity on the path to physically violent and nonviolent juvenile delinqu Child Dev 1999;70:1181-96.

 Stephens RJ, Dettmer MR, Roberts BW, et al. Practice Patterns and Outcomes Associated With Early Sedation Depth in Mechanically Ventilated Patients: A Systematic Review and Meta-Analysis. *Crit Care Med* 2018;46:471-9.

- Luetz A, Balzer F, Radtke FM, et al. Delirium, sedation and analgesia in the intensive care unit: a multinational, two-part survey among intensivists. *PLoS One* 2014;9:e110935.
- 25. Martin J, Franck M, Fischer M, et al. Sedation and analgesia in German intensive care units: how is it done in reality? Results of a patient-based survey of analgesia and sedation. *Intensive Care Med* 2006;32:1137-42.
- 26. Samuelson K, Lundberg D, Fridlund B. Memory in relation to depth of sedation in adult mechanically ventilated intensive care patients. *Intensive Care Med* 2006;32:660-7.
- 27. Fuller BM, Roberts BW, Mohr NM, et al. The ED-SED Study: A Multicenter, Prospective Cohort Study of Practice Patterns and Clinical Outcomes Associated With Emergency Department SEDation for Mechanically Ventilated Patients. *Crit Care Med* 2019;47:1539-48.

## **Figure Legends**

**Figure 1** Trajectories of longitudinal Richmond Agitation Sedation Scale in the first 30 days of sedation for mechanical ventilation. The percentage of patients included in each trajectory were presented in central illustration. Outcome of y-axis indicates the score of richmond agitation sedation scale and T of x-axis represents day after the initiation of sedation.

Figure 2 Kaplan-Meier of clinical outcomes from admission according to the trajectory groups. (a) time to extubation in the intensive care unit, (b) length of stay in the intensive care unit, (c) in-hospital mortality.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

3 4

| N = 631) $1.74%)$ $5.39%)$ $5.97%)$ $14.58%)$ $(22.19%)$ $(28.05%)$ $(21.08%)$ $(64.0)$ $(53.0-71.0)$ $(71.00)$ $4.31)$  | Total Cohort and for<br>1 (N = 67)<br>0 (0.00%)<br>0 (0.00%)<br>3 (4.48%)<br>6 (8.96%)<br>12 (17.91%)<br>22 (32.84%)<br>24 (35.82%)<br>44 (65.67)<br>62.25 $\pm$ 10.69<br>50 (74.62)<br>2 (4.00)   |  | $\begin{array}{c} \text{ory group} \\ \hline 3 \ (\text{N} = 265) \\ \hline \\ 6 \ (2.26\%) \\ \hline \\ 12 \ (4.53\%) \\ \hline \\ 13 \ (4.91\%) \\ \hline \\ 44 \ (16.60\%) \\ \hline \\ 60 \ (22.64\%) \\ \hline \\ 80 \ (30.19\%) \\ \hline \\ 80 \ (30.19\%) \\ \hline \\ 165 \ (62.26) \\ \hline \\ 62.51 \pm 13.01 \\ \hline \\ 183 \ (69.05) \\ \hline \\ \end{array}$ | <b>28</b> on $4 (N = 3 (1.4)$<br><b>20</b> of $27$ June 20 (9.3)<br><b>17</b> (7.5)<br><b>20</b> (9.3)<br><b>17</b> (7.5)<br><b>36</b> (16)<br><b>51</b> (23)<br><b>52</b> (24)<br><b>36</b> (16)<br><b>138</b> (6)<br><b>138</b> (6)<br><b>138</b> (6)<br><b>150</b> (6)<br><b>150</b> (6)<br><b>150</b> (6)   | = 215)<br>0%)<br>30%)<br>91%)<br>5.74%)<br>5.72%)<br>4.19%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.74%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.74%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.74%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72% | <i>p</i> -value<br>0.002<br>0.807<br>0.785<br>0.434  |
|--|--|--|--|---|--|--|
| N = 631) $1.74%)$ $5.39%)$ $5.97%)$ $14.58%)$ $(22.19%)$ $(28.05%)$ $(21.08%)$ $(64.0)$ $(53.0-71.0)$ $(71.00)$ $4.31)$  | $1 (N = 67)$ $0 (0.00\%)$ $0 (0.00\%)$ $3 (4.48\%)$ $6 (8.96\%)$ $12 (17.91\%)$ $22 (32.84\%)$ $24 (35.82\%)$ $44 (65.67)$ $62.25 \pm 10.69$ $50 (74.62)$ $2 (4.00)$   | Trajector2 (N = 84) 2 (2.38%)<br>2 (2.38%)<br>11 (13.10%)<br>6 (7.14%)<br>17 (20.24%)<br>23 (27.38%)<br>23 (27.38%)<br>57 (67.86)<br>62.81 $\pm$ 13.31<br>65 (77.38) | $\begin{array}{c} \text{ory group} \\ \hline 3 \ (\text{N} = 265) \\ \hline \\ 6 \ (2.26\%) \\ \hline \\ 12 \ (4.53\%) \\ \hline \\ 13 \ (4.91\%) \\ \hline \\ 44 \ (16.60\%) \\ \hline \\ 60 \ (22.64\%) \\ \hline \\ 80 \ (30.19\%) \\ \hline \\ 80 \ (30.19\%) \\ \hline \\ 165 \ (62.26) \\ \hline \\ 62.51 \pm 13.01 \\ \hline \\ 183 \ (69.05) \\ \hline \\ \end{array}$ | <b>28</b> on $4 (N = 3 (1.4)$<br><b>20</b> of $27$ June 20 (9.3)<br><b>17</b> (7.5)<br><b>20</b> (9.3)<br><b>17</b> (7.5)<br><b>36</b> (16)<br><b>51</b> (23)<br><b>52</b> (24)<br><b>36</b> (16)<br><b>138</b> (6)<br><b>138</b> (6)<br><b>138</b> (6)<br><b>150</b> (6)<br><b>150</b> (6)<br><b>150</b> (6)   | = 215)<br>0%)<br>30%)<br>91%)<br>5.74%)<br>5.72%)<br>4.19%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.74%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.74%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.74%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72% | 0.002  |
| 1.74%)         5.39%)         6.97%)         14.58%)         (22.19%)         (28.05%)         (21.08%)         (64.0)         (53.0-71.0)         (71.00)         4.31) | $\begin{array}{c} 0 \ (0.00\%) \\ \hline 0 \ (0.00\%) \\ \hline 3 \ (4.48\%) \\ \hline 6 \ (8.96\%) \\ \hline 12 \ (17.91\%) \\ \hline 22 \ (32.84\%) \\ \hline 24 \ (35.82\%) \\ \hline 44 \ (65.67) \\ \hline 62.25 \pm 10.69 \\ \hline 50 \ (74.62) \\ \hline 2 \ (4.00) \\ \hline \end{array}$ | 2 (N = 84)<br>2 (2.38%)<br>2 (2.38%)<br>11 (13.10%)<br>6 (7.14%)<br>17 (20.24%)<br>23 (27.38%)<br>23 (27.38%)<br>57 (67.86)<br>62.81 ± 13.31<br>65 (77.38)           | $\begin{array}{c} 3 \ (N=265) \\ \hline \\ 6 \ (2.26\%) \\ \hline \\ 12 \ (4.53\%) \\ \hline \\ 13 \ (4.91\%) \\ \hline \\ 44 \ (16.60\%) \\ \hline \\ 60 \ (22.64\%) \\ \hline \\ 80 \ (30.19\%) \\ \hline \\ 80 \ (30.19\%) \\ \hline \\ 165 \ (62.26) \\ \hline \\ 165 \ (62.26) \\ \hline \\ 183 \ (69.05) \\ \hline \\ \end{array}$                                       | June         3 (1.4)           20 (9.3)         17 (7.9)           36 (16)         36 (16)           52 (24)         36 (16)           36 (16)         138 (6)           63.79         150 (6)  | 0%)<br>30%)<br>91%)<br>5.74%)<br>5.72%)<br>4.19%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72% | 0.002  |
| 1.74%)         5.39%)         6.97%)         14.58%)         (22.19%)         (28.05%)         (21.08%)         (64.0)         (53.0-71.0)         (71.00)         4.31) | $\begin{array}{c} 0 \ (0.00\%) \\ \hline 0 \ (0.00\%) \\ \hline 3 \ (4.48\%) \\ \hline 6 \ (8.96\%) \\ \hline 12 \ (17.91\%) \\ \hline 22 \ (32.84\%) \\ \hline 24 \ (35.82\%) \\ \hline 44 \ (65.67) \\ \hline 62.25 \pm 10.69 \\ \hline 50 \ (74.62) \\ \hline 2 \ (4.00) \\ \hline \end{array}$ | 2 (2.38%)<br>2 (2.38%)<br>11 (13.10%)<br>6 (7.14%)<br>17 (20.24%)<br>23 (27.38%)<br>23 (27.38%)<br>57 (67.86)<br>62.81 ± 13.31<br>65 (77.38)                         | 6 (2.26%)<br>12 (4.53%)<br>13 (4.91%)<br>44 (16.60%)<br>60 (22.64%)<br>80 (30.19%)<br>165 (62.26)<br>165 (62.26)<br>183 (69.05)  | June         3 (1.4)           20 (9.3)         17 (7.9)           36 (16)         36 (16)           52 (24)         36 (16)           36 (16)         138 (6)           63.79         150 (6)  | 0%)<br>30%)<br>91%)<br>5.74%)<br>5.72%)<br>4.19%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72%)<br>5.72% | 0.002  |
| 5.39%)         6.97%)         14.58%)         (22.19%)         (28.05%)         (21.08%)         (64.0)         (53.0-71.0)         (71.00)         4.31)                | $\begin{array}{c} 0 \ (0.00\%) \\ \hline 3 \ (4.48\%) \\ \hline 6 \ (8.96\%) \\ \hline 12 \ (17.91\%) \\ \hline 22 \ (32.84\%) \\ \hline 24 \ (35.82\%) \\ \hline 44 \ (65.67) \\ \hline 62.25 \pm 10.69 \\ \hline 50 \ (74.62) \\ \hline 2 \ (4.00) \end{array}$                                  | 2 (2.38%)<br>11 (13.10%)<br>6 (7.14%)<br>17 (20.24%)<br>23 (27.38%)<br>23 (27.38%)<br>57 (67.86)<br>62.81 ± 13.31<br>65 (77.38)                                      | $\begin{array}{c} 12 \ (4.53\%) \\ 13 \ (4.91\%) \\ 44 \ (16.60\%) \\ 60 \ (22.64\%) \\ 80 \ (30.19\%) \\ 50 \ (18.87\%) \\ 165 \ (62.26) \\ 62.51 \pm 13.01 \\ 183 \ (69.05) \\ \end{array}$  | 20 (9.2)<br>17 (7.9)<br>36 (16)<br>51 (23)<br>52 (24)<br>36 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>138 (6)<br>138 (6)<br>138 (6)<br>150 (6)<br>150 (6)  | 0%)<br>30%)<br>91%)<br>5.74%)<br>5.72%)<br>5.72%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72%]<br>5.72% | 0.807<br>0.785   |
| 5.39%)         6.97%)         14.58%)         (22.19%)         (28.05%)         (21.08%)         (64.0)         (53.0-71.0)         (71.00)         4.31)                | $\begin{array}{c} 0 \ (0.00\%) \\ \hline 3 \ (4.48\%) \\ \hline 6 \ (8.96\%) \\ \hline 12 \ (17.91\%) \\ \hline 22 \ (32.84\%) \\ \hline 24 \ (35.82\%) \\ \hline 44 \ (65.67) \\ \hline 62.25 \pm 10.69 \\ \hline 50 \ (74.62) \\ \hline 2 \ (4.00) \end{array}$                                  | 2 (2.38%)<br>11 (13.10%)<br>6 (7.14%)<br>17 (20.24%)<br>23 (27.38%)<br>23 (27.38%)<br>57 (67.86)<br>62.81 ± 13.31<br>65 (77.38)                                      | $\begin{array}{c} 12 \ (4.53\%) \\ 13 \ (4.91\%) \\ 44 \ (16.60\%) \\ 60 \ (22.64\%) \\ 80 \ (30.19\%) \\ 50 \ (18.87\%) \\ 165 \ (62.26) \\ 62.51 \pm 13.01 \\ 183 \ (69.05) \\ \end{array}$  | 20 (9.2)<br>17 (7.9)<br>36 (16)<br>51 (23)<br>52 (24)<br>36 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>138 (6)<br>138 (6)<br>138 (6)<br>150 (6)<br>150 (6)  | 30%)<br>91%)<br>5.74%)<br>5.72%)<br>4.19%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.75%]<br>5.76%]   | 0.785  |
| 6.97%)         14.58%)         (22.19%)         (28.05%)         (21.08%)         (64.0)         (53.0-71.0)         (71.00)         4.31)                               | $3 (4.48\%)$ $6 (8.96\%)$ $12 (17.91\%)$ $22 (32.84\%)$ $24 (35.82\%)$ $44 (65.67)$ $62.25 \pm 10.69$ $50 (74.62)$ $2 (4.00)$  | 11 (13.10%)         6 (7.14%)         17 (20.24%)         23 (27.38%)         23 (27.38%)         57 (67.86)         62.81 ± 13.31         65 (77.38)                | $\begin{array}{c} 12 \ (4.53\%) \\ 13 \ (4.91\%) \\ 44 \ (16.60\%) \\ 60 \ (22.64\%) \\ 80 \ (30.19\%) \\ 50 \ (18.87\%) \\ 165 \ (62.26) \\ 62.51 \pm 13.01 \\ 183 \ (69.05) \\ \end{array}$  | 20 (9.2)<br>17 (7.9)<br>36 (16)<br>51 (23)<br>52 (24)<br>36 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>53 (16)<br>138 (6)<br>138 (6)<br>138 (6)<br>150 (6)<br>150 (6)  | 30%)<br>91%)<br>5.74%)<br>5.72%)<br>4.19%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.75%]<br>5.76%]   | 0.785  |
| 14.58%)         (22.19%)         (28.05%)         (21.08%)         (64.0)         (53.0-71.0)         (71.00)         4.31)  | $ \begin{array}{c} 6 (8.96\%) \\ 12 (17.91\%) \\ 22 (32.84\%) \\ 24 (35.82\%) \\ 44 (65.67) \\ 62.25 \pm 10.69 \\ 50 (74.62) \\ 2 (4.00) \\ \end{array} $  | 6 (7.14%)         17 (20.24%)         23 (27.38%)         23 (27.38%)         57 (67.86)         62.81 ± 13.31         65 (77.38)                                    | $\begin{array}{c} 13 (4.91\%) \\ 44 (16.60\%) \\ 60 (22.64\%) \\ 80 (30.19\%) \\ 50 (18.87\%) \\ 165 (62.26) \\ 62.51 \pm 13.01 \\ 183 (69.05) \\ \end{array}$   | 3.       17 (7.9)         36 (16)         51 (23)         52 (24)         36 (16)         52 (24)         36 (16)         138 (6)         63.79         150 (6)   | 91%)<br>5.74%)<br>5.72%)<br>5.72%)<br>5.74%)<br>5.74%)<br>5.74%)<br>5.4.19)<br>± 17.62<br>59.76)   | 0.785  |
| (22.19%)<br>(28.05%)<br>(21.08%)<br>(64.0)<br>(53.0-71.0)<br>(71.00)<br>(4.31)   | $12 (17.91\%)$ $22 (32.84\%)$ $24 (35.82\%)$ $44 (65.67)$ $62.25 \pm 10.69$ $50 (74.62)$ $2 (4.00)$  | 17 (20.24%)         23 (27.38%)         23 (27.38%)         57 (67.86)         62.81 ± 13.31         65 (77.38)  | 44 (16.60%)       60         60 (22.64%)       50         80 (30.19%)       60         50 (18.87%)       60         165 (62.26)       62.51 ± 13.01         183 (69.05)       60   | 36 (16)           51 (23)           52 (24)           36 (16)           36 (16)           138 (6)           63.79           150 (6)   | 5.74%)<br>5.72%)<br>5.72%)<br>5.74%)<br>5.74%)<br>54.19)<br>± 17.62<br>59.76)  | 0.785  |
| (28.05%)<br>(21.08%)<br>(64.0)<br>(53.0-71.0)<br>(71.00)<br>(4.31)   | $22 (32.84\%)$ $24 (35.82\%)$ $44 (65.67)$ $62.25 \pm 10.69$ $50 (74.62)$ $2 (4.00)$   | 23 (27.38%)<br>23 (27.38%)<br>57 (67.86)<br>62.81 ± 13.31<br>65 (77.38)  | 60 (22.64%)       60         80 (30.19%)       and         50 (18.87%)       and         165 (62.26)       and         62.51 ± 13.01       and         183 (69.05)       and   | Suborteur (ABES), 51 (23)<br>52 (24)<br>36 (16)<br>138 (6)<br>63.79<br>150 (6)  | 5.72%)<br>6.79%)<br>5.74%)<br>5.74%)<br>54.19)<br>± 17.62<br>59.76)  | 0.785  |
| (21.08%)<br>(64.0)<br>(53.0-71.0)<br>(71.00)<br>(4.31)   | 24 (35.82%)<br>44 (65.67)<br>62.25 ± 10.69<br>50 (74.62)<br>2 (4.00)   | 23 (27.38%)<br>57 (67.86)<br>62.81 ± 13.31<br>65 (77.38)   | 80 (30.19%)       and         50 (18.87%)       and         165 (62.26)       and         62.51 ± 13.01       and         183 (69.05)       and  | ad 52 (24<br>36 (16<br>138 (6<br>BES),<br>150 (6  | 19%)       5.74%)       54.19)       ± 17.62       59.76)  | 0.785  |
| (64.0)<br>(53.0-71.0)<br>(71.00)<br>(4.31)   | $44 (65.67) \\62.25 \pm 10.69 \\50 (74.62) \\2 (4.00)$   | 57 (67.86)<br>62.81 ± 13.31<br>65 (77.38)  | 50 (18.87%)         165 (62.26)         62.51 ± 13.01         183 (69.05)  | ABES:<br>150 (6   | 5.74%)<br>54.19)<br>± 17.62<br>59.76)  | 0.785  |
| (53.0-71.0)<br>(71.00)<br>4.31)  | 62.25 ± 10.69<br>50 (74.62)<br>2 (4.00)  | 62.81 ± 13.31<br>65 (77.38)  | 165 (62.26)         62.51 ± 13.01         183 (69.05)  | <b>ABE</b> 138 (6<br>63.79<br>150 (6  | 54.19)<br>± 17.62<br>59.76)  | 0.785  |
| (71.00)<br>(71.100)<br>(71.00)   | 50 (74.62)<br>2 (4.00)   | 65 (77.38)   | 183 (69.05) ing.   | 150 (6  | 69.76)   |  |
| 4.31)  | 2 (4.00)   |  |  |   |  | 0.434  |
| · · · · · · · · · · · · · · · · · · ·  | · /  | 2 (3.07)   |  |   |  |  |
| 8.6)   |  |  | 14 (7.65) <b>≥</b>   | <b>1</b> 2 (8.0   | 00)  | 0.573  |
|  | 7 (14.00)  | 8 (12.30)  | 25 (13.66) <b>fa</b>   | 20 (13  | 5.33)  | 0.994  |
| 7.0)   | 3 (6.00)   | 7 (10.76)  | 19 (10.38)         11           9 (4.91)         9   | 20 (13  | 5.33)  | 0.596  |
| 3.8)   | 3 (6.00)   | 3 (4.61)   | 9 (4.91) <sup>(C)</sup>  | 12 (8.0   | 00)  | 0.681  |
| 6.6)   | 5 (10.00)  | 3 (4.61)   | 18 (9.83) <b>d</b>   | <b>2</b> 0 (13  | 5.33)  | 0.375  |
| (18.2)   | 19 (38.00)   | 15 (23.07)   | 48 (26.22) <b>Sin</b>  | <b>o</b> 45 (30   | 0.00)  | 0.278  |
| 5.0)   | 6 (12.00)  | 9 (13.84)  | 16 (8.74) ar   | لم<br>ل 4 (3.00   | 0)   | 0.010  |
| 11.7)  | 14 (28.00)   | 14 (21.53)   |  | <b>De</b> 26 (17  | 7.33)  | 0.101  |
|  |  |  | hnc  | <b>1</b> 3,   |  | 0.023  |
| (48.6)   | 41 (61.19)   | 49 (58.33)   | 124 (46.79) <b>g</b>   | 8 93 (43  | 6.26)  |  |
| (30.5)   | 19 (28.36)   | 25 (29.76)   | 78 (29.43)   | a 71 (33  | 5.02)  |  |
| (20.7)   | 7 (10.45)  | 10 (11.90)   | 63 (23.77)   | <b>B</b> 51 (23   | 5.72)  |  |
|  |  |  |  | enc   |  | 0.001  |
| (37.4)   | 35 (52.24)   | 41 (48.81)   | 92 (34.72)   |   | .051   |  |
| (58.8)   | 30 (44.78)   | 42 (50.00)   | 157 (59.25)  | <b>b</b> 142 (6   | 66.05)   |  |
| 3.8)   | 2 (2.99)   | 1 (1.19)   | 16 (6.04)  | <b>6</b> 5 (2.3)  | 3)   |  |
| $\frac{6.0}{(1)}$  | 6)<br>8.2)<br>0)<br>.7)<br>8.6)<br>0.5)<br>0.7)<br>7.4)<br>8.8)  | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$  | 6) $5 (10.00)$ $3 (4.61)$ $8.2)$ $19 (38.00)$ $15 (23.07)$ $0)$ $6 (12.00)$ $9 (13.84)$ $.7)$ $14 (28.00)$ $14 (21.53)$ $88.6)$ $41 (61.19)$ $49 (58.33)$ $00.5)$ $19 (28.36)$ $25 (29.76)$ $20.7)$ $7 (10.45)$ $10 (11.90)$ $7.4)$ $35 (52.24)$ $41 (48.81)$ $88.8)$ $30 (44.78)$ $42 (50.00)$  | 6) $5 (10.00)$ $3 (4.61)$ $18 (9.83)$ $nd$ $8.2)$ $19 (38.00)$ $15 (23.07)$ $48 (26.22)$ $ni$ $0)$ $6 (12.00)$ $9 (13.84)$ $16 (8.74)$ $nd$ $.7)$ $14 (28.00)$ $14 (21.53)$ $28 (15.30)$ $nd$ $.8.6)$ $41 (61.19)$ $49 (58.33)$ $124 (46.79)$ $nd$ $.0.5)$ $19 (28.36)$ $25 (29.76)$ $78 (29.43)$ $nd$ $.0.7)$ $7 (10.45)$ $10 (11.90)$ $63 (23.77)$ $.7.4)$ $35 (52.24)$ $41 (48.81)$ $92 (34.72)$ $.8.8)$ $30 (44.78)$ $42 (50.00)$ $157 (59.25)$ $.8)$ $2 (2.99)$ $1 (1.19)$ $16 (6.04)$ | 6) $5 (10.00)$ $3 (4.61)$ $18 (9.83)$ $a$ $c$ $20 (13)$ $8.2)$ $19 (38.00)$ $15 (23.07)$ $48 (26.22)$ $a$ $45 (30)$ $0)$ $6 (12.00)$ $9 (13.84)$ $16 (8.74)$ $a$ $4 (3.00)$ $.7)$ $14 (28.00)$ $14 (21.53)$ $28 (15.30)$ $c$ $26 (17)$ $.8.6)$ $41 (61.19)$ $49 (58.33)$ $124 (46.79)$ $g$ $93 (43)$ $.0.5)$ $19 (28.36)$ $25 (29.76)$ $78 (29.43)$ $c$ $71 (33)$ $.0.7)$ $7 (10.45)$ $10 (11.90)$ $63 (23.77)$ $d$ $51 (23)$ $.7.4)$ $35 (52.24)$ $41 (48.81)$ $92 (34.72)$ $d$ $68 (31)$   | 6) $5 (10.00)$ $3 (4.61)$ $18 (9.83)$ $\mathbf{d}$ $\mathbf{o}$ $20 (13.33)$ $8.2)$ $19 (38.00)$ $15 (23.07)$ $48 (26.22)$ $\mathbf{s}$ $45 (30.00)$ $0)$ $6 (12.00)$ $9 (13.84)$ $16 (8.74)$ $\mathbf{s}$ $4 (3.00)$ $.7)$ $14 (28.00)$ $14 (21.53)$ $28 (15.30)$ $\mathbf{c}$ $26 (17.33)$ $.86.0$ $41 (61.19)$ $49 (58.33)$ $124 (46.79)$ $\mathbf{c}$ $93 (43.26)$ $.05.0$ $19 (28.36)$ $25 (29.76)$ $78 (29.43)$ $\mathbf{c}$ $71 (33.02)$ $.07.1$ $7 (10.45)$ $10 (11.90)$ $63 (23.77)$ $51 (23.72)$ $.7.4)$ $35 (52.24)$ $41 (48.81)$ $92 (34.72)$ $68 (31.63)$ $.8.8)$ $30 (44.78)$ $42 (50.00)$ $157 (59.25)$ $142 (66.05)$ $.8)$ $2 (2.99)$ $1 (1.19)$ $16 (6.04)$ $\mathbf{g}$ $5 (2.33)$ |

|                                    |                 |                  | J Open            |                  | / cop               | 2                |         |
|------------------------------------|-----------------|------------------|-------------------|------------------|---------------------|------------------|---------|
|                                    |                 |                  |                   |                  | copyright, ir       |                  |         |
| Reason for ICU admission***        |                 |                  |                   |                  |                     | 2202             |         |
| Renal                              | 16 (2.5)        | 1 (1.49)         | 0 (0.00)          | 7 (2.64)         | iding               | 8 (3.72)         | 0.294   |
| Digestive                          | 83 (13.1)       | 10 (14.93)       | 12 (14.29)        | 28 (10.57)       | a fo                | 33 (15.35)       | 0.434   |
| Cardiovascular                     | 147 (23.3)      | 15 (22.39)       | 16 (19.05)        | 68 (25.66)       | r us<br>E           | 48 (22.33)       | 0.610   |
| Hematologic                        | 14 (2.2)        | 2 (2.99%)        | 3 (3.57%)         | 4 (1.51%)        | es<br>nse           | 5 (2.33%)        | 0.679   |
| Respiratory                        | 359 (56.8)      | 43 (64.18%)      | 57 (67.86%)       | 136 (51.32%)     | ela                 | 123 (57.21%)     | 0.030   |
| Miscellaneous                      | 67 (10.6)       | 3 (4.48%)        | 11 (13.10%)       | 34 (12.83%)      |                     | 19 (8.84%)       | 0.152   |
| Neurologic                         | 12 (1.9)        | 3 (4.48%)        | 1 (1.19%)         | 4 (1.51%)        | to to               | 4 (1.86%)        | 0.418   |
| Others                             | 105 (16.6)      | 11 (16.42%)      | 13 (15.48%)       | 42 (15.85%)      | Sup                 | 39 (18.14%)      | 0.907   |
| APACHE II, score*                  | $23.4 \pm 10.0$ | $27.82 \pm 9.73$ | $25.28 \pm 11.45$ | $21.39 \pm 9.59$ | anc                 | $24.07 \pm 9.56$ | < 0.001 |
| ICU support within first 48 hours  |                 |                  |                   |                  |                     |                  |         |
| Vasopressor infusions              | 486 (77.02)     | 57 (85.07)       | 77 (91.67)        | 199 (75.09)      | eur (AB<br>I data n | 153 (71.16)      | < 0.001 |
| Renal replacement                  | 107 (16.9)      | 11 (16.42)       | 22 (26.19)        | 37 (13.96)       | nini                | 37 (17.21)       | 0.078   |
| Neuromuscular blockade             | 171 (27.1)      | 27 (40.30)       | 39 (46.43)        | 69 (26.04)       | ) .<br>ng,          | 36 (16.74)       | < 0.001 |
| Clinical outcomes                  |                 |                  |                   |                  | A                   | 3                |         |
| In-hospital mortality              | 77 (12.2)       | 33 (49.52)       | 18 (21.43)        | 18 (6.79)        | train               | 8 (3.72)         | < 0.001 |
| ICU discharge                      | 555 (87.9)      | 45 (67.16)       | 67 (79.76)        | 245 (92.45)      | ning                | 198 (92.09)      | < 0.001 |
| Extubation                         | 571 (90.4)      | 46 (68.66)       | 66 (78.57)        | 0.50 (0.5.15)    | ,<br>ຊ              | 206 (95.81)      | < 0.001 |
| Length of ventilator support, days | 5 (3–11)        | 11 (20–NE)       | 11.5 (7–23.5)     | 5 (3-8)          | nd s                | 3 (2–5)          | < 0.001 |
| ICU length of stay, days           | 10 (5-18)       | 20 (12–NE)       | 18 (10–26)        | 9 (6-14)         | in s                | 4 (6–10)         | < 0.001 |

**RMIOnen** 

bmj ý

Data are reported as mean ± standard deviation or median (interquartile range) for continuous variables and number (percenage) for categorical variables. \*Data on body weight are presented for all 605 patients, excluding 26 patients with missing data (4 in the light sedation group and 22 in the deep sedation group). Data on APACHE I are presented for all 577 patients, excluding 54 patients with missing data (15 in the light sedation group and 39 in the deep sedation group). \*\*Severe to moderate liver disease are defined as cirrhosis and portal hypertension with or without variceal bleeding histors. Severe to moderate CKD are defined as serum creatinine > 3 mg/dL or on dialysis or post-kidney transplant status or uremia status. ogies. \*\*\*172 patients had multiple reasons for ICU admission. at

ICU = intensive care unit; SMD = standardized mean difference; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; TIA = transient ischemic attack; APACHE II = acute physiology and chronic health evaluation II; NE = not estimated ence Bibliographique de l

| Table 2 Summary of the demogra   | aphics of the trajectories and the tr  | ajectory ranks for characteristics  |   | -0726;   |  |
|--|--|---|---|--|--|
|  | Trajectory 1   | Trajectory 2  | Trajectory 3  | omjopen-2023-072628 on<br>bv copyright, including  | Trajectory 4                                       |
| Demographics   |  |   |   | ずら   |  |
| Age  | 70–79 & ≥80  | 70–79 & ≥80   | 60–69 & 70–-79  |  | 60–69 & 70–-79                                     |
| Gender   | Male   | Male  | Male  | 27 June<br>Ens   | Male   |
| Comorbidity  | Solid tumor, CVD/TIA,<br>COPD  | Solid tumor, CVD/TIA, Dementia  | Solid tumor,<br>COPD<br>Surgical ICU<br>Respiratory & Ca                  | relate<br>SD/TIA,<br>10,23.  | Solid tumor, CVD/TIA,                              |
| Type of ICU  | Medical ICU  | Surgical ICU  | Surgical ICU  | id m D<br>to D   | Surgical ICU                                       |
| Reason for ICU admission   | Respiratory & Cardiovascular   | Respiratory & Cardiovascular  | Respiratory & Ca  | dio sascular   | Respiratory & Cardiovas                            |
| Ranks for characteristics  | U k  |   |   | loaded<br>Superie  |  |
| Medical admission  | lst  | 2nd   | 3rd   | led<br>nd  | 4th  |
| Scheduled surgery  | 4th  | 3rd   | 2nd   | l from ht<br>ur (ABE:<br>data mi   | 1st  |
| АРАСНЕ ІІ  | lst  | 2nd   | 4th   |  | 3rd  |
| Vasopressor infusions  | 2nd  | lst   | 3rd   |  | 4th  |
|  |  |   |   | Ā. N   |  |
| Renal replacement therapy  | 3rd  | 1st   | 4th   | //bn   | 2nd  |
| Neuromuscular blockade<br>Representative demographics with<br>determined by the comparison of<br>ICU = intensive care unit; APAC | 2nd<br>th more than half of the patients<br>proportion of variable within each<br>CHE $\mathbf{I}$ = acute physiology and cl | 1st         1st         on each trajectory, except age on trajectory. Trajectories are ordered pronic health evaluation II; CVD = | 3rd<br>ajectory 4, are sho<br>from lowest (4th) to<br>cardiovascular dise | The second secon | 4th<br>le. Rank-order of trajector<br>rank values. |
| Neuromuscular blockade<br>Representative demographics wit<br>determined by the comparison of                                     | 2nd<br>th more than half of the patients<br>proportion of variable within each<br>CHE $\mathbf{I}$ = acute physiology and cl | 1st<br>on each trajectory, except age on tra<br>n trajectory. Trajectories are ordered  | 3rd<br>ajectory 4, are sho<br>from lowest (4th) to<br>cardiovascular dise | The second secon | 4th<br>le. Rank-order of trajector<br>rank values. |

Page 23 of 30

## BMJ Open

|                               |   |                 | BMJ Open               |                 | d by copyright, including for | bmjopen-2023-072628<br>Time to in-hos                              |                 |
|-------------------------------|---|-----------------|------------------------|-----------------|-------------------------------|--|-----------------|
| Sable 3 Multivariable Cox Pro | portional Hazard regression<br>Time to extu |                 | event<br>Time to ICU d | ischarge        | includi                       | 726<br>726<br>726<br>726<br>726<br>726<br>726<br>726<br>726<br>726 | snital death    |
|                               | HR (95% CI)                                 | <i>p</i> -value | HR (95% CI)            | <i>p</i> -value | ng f                          | <b>9</b><br>HR (95% CI)  | <i>p</i> -value |
| Trajectory group              |   |                 |                        |                 | er u                          |  |                 |
| Group 1                       | 0.23 (0.16–0.32)                            | < 0.001         | 0.36 (0.26–0.51)       | < 0.001         | Ises                          | <b>2</b><br><b>3</b> .62 (5.99–30.95)                              | < 0.001         |
| Group 2                       | 0.30 (0.23–0.41)                            | < 0.001         | 0.44 (0.33–0.59)       | < 0.001         | relg                          | 8.62 (2.36–13.38)  | < 0.001         |
| Group 3                       | 0.72 (0.59–0.87)                            | < 0.001         | 0.80 (0.65–0.97)       | 0.024           | atec                          | <b>8</b> 62 (2.36–13.38)<br><b>1</b> .76 (0.76–4.08)               | 0.185           |
| Group 4                       | Reference                                   |                 | Reference              |                 | d to                          | Reference  |                 |
| Age                           |   |                 |                        |                 | tex                           | vnlo   |                 |
| 20–29                         | Reference                                   |                 | Reference              |                 | t an                          | <b>d</b> eference  |                 |
| 30–39                         | 1.08 (0.53–2.21)                            | 0.825           | 0.70 (0.35–1.42)       | 0.334           | d d                           | <b>1</b> .69 (0.06–7.72)   | 0.765           |
| 40–49                         | 0.89 (0.43–1.81)                            | 0.748           | 0.63 (0.31–1.25)       | 0.188           | ata                           | 9.59 (0.06-5.28)   | 0.641           |
| 50–59                         | 1.04 (0.53–2.03)                            | 0.893           | 0.65 (0.34–1.23)       | 0.192           | min                           | <b>4</b> .41 (0.04–3.46)   | 0.414           |
| 60–69                         | 1.00 (0.52–1.93)                            | 0.987           | 0.79 (0.42–1.48)       | 0.469           | ing                           | 88 (0.11–6.75)   | 0.905           |
| 70–79                         | 1.04 (0.54–1.99)                            | 0.893           | 0.64 (0.34–1.20)       | 0.170           | , AI                          | <b>9</b> .47 (0.06–3.65)   | 0.473           |
| ≥80                           | 0.85 (0.44–1.64)                            | 0.632           | 0.53 (0.28–1.00)       | 0.052           |                               | <b>8</b> .82 (0.10–6.26)   | 0.850           |
| Female                        | 0.85 (0.71–1.01)                            | 0.075           | 0.98 (0.81–1.17)       | 0.848           | ining, and                    | <b>3</b> .17 (0.73–1.89)   | 0.50            |
| Type of admission             |   |                 |                        |                 | g, a                          | mj   |                 |
| Medical                       | Reference                                   |                 | Reference              |                 |                               | Reference  |                 |
| Emergency surgery             | 1.02 (0.79–1.32)                            | 0.839           | 1.17 (0.90–1.53)       | 0.234           | sim                           | <b>d</b> .35 (0.62–2.91)   | 0.444           |
| Scheduled surgery             | 2.13 (1.64–2.78)                            | < 0.001         | 2.10 (1.59–2.78)       | < 0.001         | similar                       | <b>4</b> .91 (0.87–4.16)   | 0.102           |
| Type of ICU                   |   |                 |                        |                 | tec                           | Ine  |                 |
| Medical ICU                   | Reference                                   |                 | Reference              |                 | hnc                           | Reference  |                 |
| Surgical ICU                  | 1.05 (0.83–1.33)                            | 0.629           | 0.87 (0.68–1.12)       | 0.299           | hnologi                       | <b>8</b> .45 (0.23–0.89)   | 0.021           |
| Others                        | 1.53 (0.96–2.40)                            | 0.068           | 1.28 (0.80–2.06)       | 0.289           | ies.                          | <b>5</b> .55 (0.12–2.47)   | 0.441           |
| Vasopressor infusions         | 0.85 (0.69–1.04)                            | 0.116           | 0.85 (0.69–1.04)       | 0.122           |                               | ▶.25 (0.62–2.51)   | 0.529           |
| Neuromuscular blockade        | 1.05 (0.86–1.28)                            | 0.586           | 0.88 (0.72–1.07)       | 0.217           |                               | <b>8</b> .42 (0.88–2.29)   | 0.148           |

Hazard ratio > 1 indicates a higher probability of event than reference.

ICU = intensive care unit; HR hazard ratio = CI confidence interval.

Bibliographique de l

Outcome 100

0.00


-100

-2.00

-3.0

0.00

Group Percents



58 59

60

Figure 1 Trajectories of longitudinal Richmond Agitation Sedation Scale in the first 30 days of sedation for mechanical ventilation. The percentage of patients included in each trajectory were presented in central illustration. Outcome of y-axis indicates the score of richmond agitation sedation scale and T of x-axis represents day after the initiation of sedation.

т

222 13.9

10.00

+++ 13.2

20.00


\*\*\* 38.4 \*\*\* 34.6

30.00

338x190mm (200 x 200 DPI)

Figure 2 Kaplan-Meier of clinical outcomes from admission according to the trajectory groups. (a) time to extubation in the intensive care unit, (b) length of stay in the intensive care unit, (c) in-hospital mortality.

338x190mm (200 x 200 DPI)





Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Longitudinal trajectories of sedation level and clinical outcomes in mechanically ventilated patients: a prospective, multicenter, longitudinal, observational study

Dong-gon Hyun, M.D.<sup>1</sup>, Jee Hwan Ahn, M.D.<sup>1</sup>, Ha-Yeong Gil, M.S.<sup>2</sup>, Chung Mo Nam,

Ph.D.<sup>3</sup>, Choa Yun, M.S.<sup>4</sup>, Chae-Man Lim, M.D., Ph.D.<sup>1</sup>\*

<sup>1</sup>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>2</sup>Medical Research Project Team, IM Medical, Pfizer Korea Pharmaceuticals Ltd., Seoul, Republic of Korea

<sup>3</sup>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

<sup>4</sup>Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea

\*Corresponding author: Chae-Man Lim, M.D., Ph.D., FCCM

E-mail: <u>cmlim@amc.seoul.kr</u>

| City     | Participating hospitals                  | Investigators                |
|----------|--|------------------------------|
| Seoul    | Asan Medical Center                      | Dong-gon Hyun, Jee Hwan Ahn, |
|          |  | Suk-Kyung Hong, Chae-Man     |
|          |  | Lim                          |
| Seoul    | Seoul National University Hospital       | Sang-Min Lee, Ho-Geol Ryu    |
| Seoul    | Samsung Medical Center                   | Gee Young Suh, Chi Min Park  |
| Seoul    | Severance Hospital                       | Su Hwan Lee, Jeoung Min Kim  |
| Seoul    | Seoul St. Mary's Hospital                | Seok Chan Kim                |
| Seoul    | Korea University Anam Hospital           | Won Jai Jung, Jae-Myeong Lee |
| Seoul    | Korea University Guro Hospital           | Young-Seok Lee, Nak-Jun Choi |
| Seoul    | Seoul National University Boramae        | Taeyun Park                  |
|          | Medical Center                           |                              |
| Seongnam | Seoul National University Bundang        | Dong Jung Kim                |
| -        | Hospital                                 |                              |
| Suwon    | Ajou University School of Medicine       | Keu Sung Lee, Young-Gi Min   |
| Busan    | Pusan National University Hospital       | Jae Hun Kim                  |
| Busan    | Dong-A University Hospital               | Dong-Hyun Lee                |
| Busan    | Inje University Haeundae Paik Hospital   | Hang-Jea Jang, Ki Hoon Kim   |
| Wonju    | Yonsei University Wonju College of       | Seok Jeong Lee               |
| -        | Medicine                                 |                              |
| Incheon  | Gachon University Gil Medical Center     | Woo-Sung Choi                |
| Daegu    | Keimyung University School of Medicine   | Jae-Bum Kim                  |
| Daegu    | Yeungnam University Medical Center       | Eun Young Choi, Jong-Hyun    |
| -        |  | Baek                         |
| Daegu    | Daegu Catholic University Medical Center | Eun Jin Kim                  |
| Anyang   | Hallym University Sacred Heart Hospital  | Sunghoon Park, Hyung Won     |
|          |  | Kim                          |
| Ansan    | Korea University Ansan Hospital          | Je Hyeong Kim                |

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## Table S1. Participating intensive care units

| 2           |          |
|-------------|----------|
|             |          |
| 3<br>4<br>5 | Table S  |
| 6           | Type of  |
| 6<br>7      | Diaze    |
| 8           | Cun      |
| 9           | Mida     |
| 10<br>11    | Cun      |
| 12          | Loraz    |
| 13          | Cun      |
| 14          | Other    |
| 15          | Cun      |
| 16<br>17    | Propo    |
| 17<br>18    | Cun      |
| 19          | Ketar    |
| 20          | Cun      |
| 21          | Halop    |
| 22          | Cun      |
| 23          | Dexm     |
| 24<br>25    | Cun      |
| 26          | Other    |
| 27          | Cun      |
| 28          | Type of  |
| 29          | Fenta    |
| 30<br>21    | Cum      |
| 31<br>32    | Remi     |
| 33          | Cum      |
| 34          | Morp     |
| 35          | Cun      |
| 36          | Sufer    |
| 37<br>38    | Cun      |
| 38<br>39    | Data are |
| 40          | (percent |
| 41          | RASS =   |
| 42          |          |
| 43          |          |
| 44<br>45    |          |
| 45<br>46    |          |
| 47          |          |
| 48          |          |
| 49          |          |
| 50          |          |
| 51<br>52    |          |
| 52<br>53    |          |
| 55<br>54    |          |
| 55          |          |
| 56          |          |
| 57          |          |
| 50          |          |


1

Table S2. Profile of analgesic and sedative within the first 48 hours

| Type of Sedatives        | N = 662                   |
|--------------------------|---------------------------|
| Diazepam                 | 1 (0.2)                   |
| Cumulative dose (µg)     | 2000.0                    |
| Midazolam                | 127 (19.2)                |
| Cumulative dose (µg)     | $64253.9 \pm 133338.1$    |
| Lorazepam                | 14 (2.1)                  |
| Cumulative dose (µg)     | $2750 \pm 1868.3$         |
| Other benzodiazepine     | 19 (2.9)                  |
| Cumulative dose (µg)     | $34294.7 \pm 53960.7$     |
| Propofol                 | 173 (26.1)                |
| Cumulative dose (µg)     | $3444220.1 \pm 2752320.0$ |
| Ketamine                 | 53 (8.0)                  |
| Cumulative dose (µg)     | $1450147.2 \pm 1830958.4$ |
| Haloperidol              | 1 (0.2)                   |
| Cumulative dose (µg)     | 5000.0                    |
| Dexmedetomidine          | 253 (38.2)                |
| Cumulative dose (µg)     | $4080.2 \pm 38325.4$      |
| Other non-benzodiazepine | 21 (3.2)                  |
| Cumulative dose (µg)     | $75659.5 \pm 133078.2$    |
| Type of analgesics       | N = 528                   |
| Fentanyl                 | 119 (22.5)                |
| Cumulative dose (µg)     | $30861.1 \pm 315168.1$    |
| Remifentanil             | 388 (73.5)                |
| Cumulative dose (µg)     | 13227.8 ± 10971.7         |
| Morphine                 | 6 (1.1)                   |
| Cumulative dose (µg)     | 24000.0 ± 38740.2         |
| Sufentanil               | 15 (2.8)                  |
| Cumulative dose (µg)     | $285.4 \pm 280.6$         |

Data are reported as means ± standard deviation for continuous variables and numbers (percentage) for categorical variables.

RASS = Richmond agitation-sedation scale



**Figure S1.** Flow diagram of patients in the present study. MV = mechanical ventilation; RASS = Richmond agitation-sedation scale

|                        |           | BMJ Open by copyrig<br>g  | Page               |
|------------------------|-----------|---|--------------------|
|                        |           | 로 끊<br>STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cont studies                             |                    |
| Section/Topic          | ltem<br># | Recommendation  | Reported on page # |
| Title and abstract     | 1         | (a) Indicate the study's design with a commonly used term in the title or the abstract  | 1                  |
|                        |           | ៉េ ឆ្នាំ ឆ្នាំ ឆ្នាំ<br>(b) Provide in the abstract an informative and balanced summary of what was done and what was found         | 2                  |
| Introduction           |           |   |                    |
| Background/rationale   | 2         | Explain the scientific background and rationale for the investigation being reported 6 🚆 🖗  | 4                  |
| Objectives             | 3         | State specific objectives, including any prespecified hypotheses 유명 이 이 이 이 이 이 이 이 이 이 이 이 이 이 이 이 이 이                             | 4                  |
| Methods                | _         | aperied   |                    |
| Study design           | 4         | Present key elements of study design early in the paper   | 4                  |
| Setting                | 5         | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,                                    | 5                  |
| Participants           | 6         | ( <i>a</i> ) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 5                  |
|                        |           | (b) For matched studies, give matching criteria and number of exposed and unexposed   |                    |
| Variables              | 7         | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifier Give diagnostic criteria, if         | 5                  |
| Data sources/          | 8*        | For each variable of interest, give sources of data and details of methods of assessment (meas grentent). Describe                  | 5                  |
| measurement            |           | comparability of assessment methods if there is more than one group   |                    |
| Bias                   | 9         | Describe any efforts to address potential sources of bias   |                    |
| Study size             | 10        | Explain how the study size was arrived at   |                    |
| Quantitative variables | 11        | Explain how quantitative variables were handled in the analyses. If applicable, describe which gou bongs were chosen and why        | 5                  |
| Statistical methods    | 12        | (a) Describe all statistical methods, including those used to control for confounding   | 6                  |
|                        |           | (b) Describe any methods used to examine subgroups and interactions   | 6                  |
|                        |           | (c) Explain how missing data were addressed   | 6                  |
|                        |           | (d) If applicable, explain how loss to follow-up was addressed  | 6                  |
|                        |           | (e) Describe any sensitivity analyses   | 6                  |
| Results                |           |   |                    |

 bmjopen-202 1 by copyrigl

nphique de l

| Participants      | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, exanised for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 7  |
|-------------------|-----|---|----|
|                   |     | (b) Give reasons for non-participation at each stage  | 7  |
|                   |     | (c) Consider use of a flow diagram 호 것  | 7  |
| Descriptive data  | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information of the second potential confounders   | 7  |
|                   |     | (b) Indicate number of participants with missing data for each variable of interest   | 8  |
|                   |     | (c) Summarise follow-up time (eg, average and total amount)   |    |
| Outcome data      | 15* | Report numbers of outcome events or summary measures over time  | 8  |
| Main results      | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precising eg, 95% confidence  | 8  |
|                   |     | interval). Make clear which confounders were adjusted for and why they were included $\vec{a}$  |    |
|                   |     | (b) Report category boundaries when continuous variables were categorized   | 8  |
|                   |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful  |    |
| Other analyses    | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  | 9  |
| Discussion        |     |   |    |
| Key results       | 18  | Summarise key results with reference to study objectives 5  | 9  |
| Limitations       |     | ning by   |    |
| Interpretation    | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                        | 10 |
| Generalisability  | 21  | Discuss the generalisability (external validity) of the study results   | 10 |
| Other information |     | ar te   |    |
| Funding           | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, original study on which the present article is based   | 13 |

👾 හි \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in controls in case-control studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine@rg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.grobe-statement.org.

## Longitudinal trajectories of sedation level and clinical outcomes in mechanically ventilated patients based on a group-based trajectory model: a prospective, multicenter, longitudinal, observational study in Korea

| Journal:                             | BMJ Open   |
|--------------------------------------|--|
| Manuscript ID                        | bmjopen-2023-072628.R1   |
| Article Type:                        | Original research  |
| Date Submitted by the<br>Author:     | 12-Apr-2023  |
| Complete List of Authors:            | Hyun, Dong-gon; Asan Medical Center,<br>Ahn, Jee Hwan; University of Ulsan College of Medicine, Department of<br>Pulmonary and Critical Care Medicine<br>Gil, Ha-Yeong; pzfier<br>Nam, Chung Mo; Yonsei University College of Medicine, Preventive<br>Medicine<br>Yun, Choa; Department of Biostatistics & Computing, College of<br>Medicine, Yonsei University<br>Lim, Chae-Man; University of Ulsan College of Medicine, Department of<br>Pulmonary and Critical Care Medicine |
| <b>Primary Subject<br/>Heading</b> : | Intensive care   |
| Secondary Subject Heading:           | Epidemiology   |
| Keywords:                            | Adult anaesthesia < ANAESTHETICS, EPIDEMIOLOGY, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Thoracic medicine < INTERNAL MEDICINE   |
|                                      | ·  |

# SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**BMJ** Open

Longitudinal trajectories of sedation level and clinical outcomes in mechanically

| 2  | ventilated patients based on a group-based trajectory model: a prospective, multicenter,  |
|----|---|
| 3  | longitudinal, observational study in Korea  |
| 4  |   |
| 5  | Dong-gon Hyun <sup>1</sup> , Jee Hwan Ahn <sup>1</sup> , Ha-Yeong Gil <sup>2</sup> , Chung Mo Nam <sup>3</sup> , Choa Yun <sup>4</sup> , Chae-Man |
| 6  | Lim <sup>1</sup> *  |
| 7  | <sup>1</sup> Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of   |
| 8  | Ulsan College of Medicine, Seoul, Republic of Korea   |
| 9  | <sup>2</sup> Medical Research Project Team, IM Medical, Pfizer Korea Pharmaceuticals Ltd., Seoul,   |
| 10 | Republic of Korea   |
| 11 | <sup>3</sup> Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic  |
| 12 | of Korea  |
| 13 | <sup>4</sup> Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University   |
| 14 | College of Medicine, Seoul, Republic of Korea   |
| 15 |   |
| 16 | *Corresponding author: Chae-Man Lim, M.D., Ph.D., FCCM  |
| 17 | E-mail: <u>cmlim@amc.seoul.kr</u>   |
| 18 |   |
| 19 | Word Count: 2995  |
| 20 |   |
| 21 |   |
| 22 |   |
| 23 |   |
| 24 |   |
|    |   |

# 1 ABSTRACT

Objectives: Changes in sedation levels over long time in mechanically ventilated patients are
unknown. Therefore, we investigated long-term sedation levels of mechanically ventilated
patients by classifying them into different longitudinal patterns.

**Design:** This was a multicenter, prospective, longitudinal, observational study.

6 Setting: Twenty ICUs spanning several medical institutions in Korea.

Participants: Patients who received mechanical ventilation and sedatives in the ICU within 48
h of admission between April 2020 and July 2021.

9 Primary and secondary outcome measures: The primary objective of this study was to
10 identify the pattern of sedation practice. Also, we analyzed associations of trajectory groups
11 with clinical outcomes as the secondary outcome.

Results: Sedation depth was monitored using the Richmond agitation-sedation scale (RASS). A group-based trajectory model was used to classify 631 patients into four trajectories based on sedation depth: persistent suboptimal (13.2%, RASS  $\leq -3$  throughout the first 30 days), delayed lightening (13.9%, RASS  $\geq -2$  after the first 15 days), early lightening (38.4%, RASS  $\geq -2$  after the first 7 days), and persistent optimal (34.6%, RASS  $\geq -2$  during the first 30 days). The "persistent suboptimal" trajectory was associated with delayed extubation (hazard ratio [HR] 0.23, 95% confidence interval [CI] 0.16–0.32, *p* < 0.001), longer ICU stay (HR 0.36, 95%) CI 0.26–0.51, p < 0.001), and hospital mortality (HR 13.62, 95% CI 5.99–30.95, p < 0.001) compared with the "persistent optimal". The "delayed lightening" and "early lightening" trajectories showed lower extubation probability (HR 0.30, 95% CI 0.23–0.41, p < 0.001; HR 0.72, 95% CI 0.59–0.87, p < 0.001, respectively) and ICU discharge (HR 0.44, 95% CI 0.33– 0.59; p < 0.001 and HR 0.80, 95%CI 0.65–0.97; p = 0.024) compated to "persistently optimal". Conclusions: Among the four trajectories describing longitudinal sedation depth, "persistent 

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

| 2              |    |  |
|----------------|----|--|
| 3<br>4         | 1  | suboptimal" trajectory was associated with higher mortality.   |
| 5              | 2  |  |
| 6              | 2  |  |
| 7<br>8         | 3  | Keywords: deep sedation; intensive care units; mortality; critical care; mechanical ventilators            |
| 9<br>10        | 4  |  |
| 11             |    |  |
| 12<br>13       | 5  | STRENGTHS AND LIMITATIONS OF THIS STUDY  |
| 14<br>15<br>16 | 6  | $\Rightarrow$ Large national data from 20 ICUs in Korea representing real-world practice.                  |
| 17<br>18       | 7  | $\Rightarrow$ An investigation into the level of long-term sedation in mechanically ventilated patients.   |
| 19<br>20<br>21 | 8  | $\Rightarrow$ A group-based trajectory model identifying patterns of sedation over time.                   |
| 22<br>23       | 9  | $\Rightarrow$ Misclassification of nondifferential group as inherent restriction of group-based trajectory |
| 24<br>25<br>26 | 10 | models with limited generalizability.  |
| 27<br>28       | 11 | $\Rightarrow$ Unclear causal relationship between trajectory and outcome.                                  |
| 29<br>30<br>31 | 12 |  |
| 32<br>33       | 13 |  |
| 34<br>35<br>36 | 14 |  |
| 30<br>37<br>38 | 15 |  |
| 39<br>40       | 16 |  |
| 41<br>42       | 17 |  |
| 43             | 10 |  |
| 44<br>45       | 18 |  |
| 45<br>46       |    |  |
| 46<br>47       | 19 |  |
| 47<br>48       |    |  |
| 48<br>49       | 20 |  |
| 49<br>50       |    |  |
| 50<br>51       | 21 |  |
| 51<br>52       |    |  |
| 52<br>52       | 22 |  |
| 53<br>54       | 22 |  |
| 54<br>55       |    |  |
| 55<br>56       | 23 |  |
| 50<br>57       |    |  |
| 58             | 24 |  |
| 59             |    |  |
| 60             |    | 3  |
|                |    |  |

#### **BMJ** Open

## 1 INTRODUCTION

Sedation is cruical to promote tolerance in patients during mechanical ventilation in the intensive care unit (ICU).<sup>1</sup> Previously, ICU patients were considered unnecessarily over-sedated, and the tools to assess the depth of sedation varied widely.<sup>2</sup> Inappropriate sedation was associated with adverse outcomes, such as prolonged ventilation, longer ICU stay, and higher post-ICU psychological concerns.<sup>3-6</sup> Over-sedation also predicted long-term mortality in critically ill patients.<sup>7</sup> Considering its essential role in the care of mechanically ventilated patients, international guidelines guide to improve sedation practice for favorable outcomes in ICU patients.8-10 

Currently, sedation monitoring in the ICU is clinically recommended to achieve low levels of sedation,<sup>11</sup> though real-world implementation is debated.<sup>12</sup> Longitudinal studies on the level of sedation over long time are limited. Previous national surveys mainly focused on the type of sedatives and assessment tools.<sup>13-16</sup> Moreover, most studies are cross-sectional, evaluating the association between the sedation level for the first 2–3 days and clinical outcomes.<sup>17 18</sup> Therefore, we aimed to investigate long-term sedation levels in a national cohort of mechanically ventilated patients by classifying them into different longitudinal patterns. We further assessed the association between these patterns and clinical outcomes. 

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**METHODS** 

## 20 Study design

We conducted a multicenter, prospective, longitudinal, and observational, cohort study in 20 ICUs in Korea between April 2020 and July 2021, which was sponsored by Pfizer Korea Pharmaceuticals Ltd. and involved 30 investigators (table S1). We designed a harmonized electric case report form that was centrally managed and combined into one database for data

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

entry, day queries, and analysis. During the study period, patients were recruited according to the number of available patients at each ICU. Principal investigators, research staff, and nurses at each participating center were trained in the study procedures. The decisions regarding a patient's care were at the discretion of the attending medical staff. Our inclusion criteria were as follows: patients aged >19 years, who had undergone mechanical ventilation and sedation in the ICU within 48 h, and were expected to remain sedated and on mechanical ventilation for >48 h. We excluded patients with a disease that was likely to cause death within 90 days, those whose treatment had been discontinued due to imminent death or non-effective therapy, and who needed non-selective deep sedation due to medical conditions, including brain damage and hemorrhage, spinal cord injury, drug overdose, burns, and nerve root block.

# Monitoring of sedation and measurement of outcome

We monitored sedation depth using the Richmond agitation-sedation scale (RASS), ranging from -5 to +4 every 8 h until ICU discharge or day  $30.^{19}$  The daily depth of sedation was calculated as the median RASS value for 1 day. The primary objective of this study was to identify the pattern of sedation practice. Group-based trajectory models have been widely employed for analyzing developmental trajectories.<sup>20</sup> They can address the dynamic profile of sedation by classifying patients into different trajectories of sedation level over time. We used a group-based trajectory model analyzing a scale form of RASS over the first 30 days after enrollment. To characterize each trajectory group, an analysis between the trajectory groups and the patients' characteristics was also performed. The secondary objective included associations of trajectory groups with clinical outcomes by adjusting for covariates. 

24 Covariates

#### **BMJ** Open

Demographic, clinical, and laboratory data, including age, gender, reason for ICU admission, type of ICU admission, comorbidities, and illness severity (acute physiology and chronic health evaluation [APACHE] I score), were collected. Severe to moderate liver disease was defined as cirrhosis and portal hypertension with or without variceal bleeding history. Severe to moderate chronic kidney disease was defined as serum creatinine >3 mg/dL or on dialysis or post-kidney transplant status or uremia status. The need for vasopressors, renal replacement therapy, and neuromuscular blockade was also recorded. We collected and calculated the daily cumulative dose and the number of days prescribed for the sedatives and analgesics administered to patients during their ICU stay. Patients were followed up until hospital discharge, death, or day 30 in the ICU. Clinical outcomes, including ICU discharge, ventilator days, and survival status, were recorded. 

**Patient and public involvement** 

Patient and the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

## 17 Statistical analysis

The pattern of sedation over time was described using a group-based trajectory model, which identified differential patterns of individual change in the populations. The parameters of GBTM are generated by maximum likelihood estimation (MLE). The ultimate objective is to estimate a set of parameters,  $\Omega$ , that maximize the probability of  $Y_i = (y_{i1},...,y_{it})$ . The equation describing the likelihood of an individual's observed repeated measures is composed of two elements: (1) the probability of group membership and (2) the probability of the observed data given group membership. The finite mixture model is defined by

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

60

1

2

3

4

1

$$P(Y_i) = \sum_k \pi_k P^k(Y_i),$$

where *k*: trajectory group, i (= 1,...,N): subject, and j (= 1,...,T): measurement time. The group membership probabilities,

$$\pi_k = e^{\theta_k} / \sum_k e^{\theta_k}$$

, k = 1,...,K, are not observed, so estimated by a multinomial logit function. For given k, 5 conditional independence is assumed for the sequential realizations of the elements of  $Y_i$ ,  $y_{ij}$ , 6 7 over the T periods of measurement. This assumption implies that for each individual within a given trajectory group k, the distribution of  $y_{ij}$  for period T is independent of the realized 8 level of the outcome in prior periods. The likelihood function is  $L = \prod_{i=1}^{N} P(y_i | z_i, w_i)$  where 9  $p(y_i|z_i, w_i) = \sum_{k=1}^{K} p(C_i = k \mid Z_i = z_i) p(Y_i = y_i \mid C_i = k, W_i = w_i)$  that the first term is the 10 11 probability of group membership and second term is the probability of the observed data given  $Y_i = (Y_{i1}, ..., Y_{iT}), Z_i = (Z_{i1}, ..., Z_{iR}), W_i = (W_{i1}, ..., W_{iT}), p =$ group membership. 12  $\frac{\exp(\theta_k + \lambda'_k z_i)}{\sum_{i=1}^{K} \exp(\theta_k + \lambda'_k z_i)}, \text{ and } p(Y_i = y_i \mid C_i = k, W_i = w_i) \text{ which is specified by distribution of } Y_i. \text{ For } X_i = W_i + V_i + V$ 13 count data, it is specified as the zero-inflated Poisson distribution, for censored data, the 14 censored normal distribution and for binary data, it is specified as the binary logit distribution. 15 In this study, we use censored normal model. The final model was selected based on a 16 combination of the Bayesian information criterion and the estimated trajectory group 17 proportions that were sufficiently large. 18

Data are presented as numbers and proportions for categorical variables and as means  $\pm$  standard deviations or medians (interquartile range) for continuous variables. Differences between groups were analyzed using the  $\chi^2$  test or Fisher's exact test and the independent twosample t-test or Mann–Whitney *U* test with a normal or non-normal distribution, as appropriate.

#### **BMJ** Open

The normality of the data was assessed by inspecting histograms. For time-to-event analysis, the Kaplan–Meier method was used to estimate survival curves, whereas a log-rank test was used to test the significance of the differences. Univariable and multivariable Cox proportional hazards regression models were used to identify associations with clinical outcomes by adjusting known prognostic covariates, including age, gender, type of admission, type of ICU, vasopressor, and neuromuscular blockade. The results are presented as hazard ratios (HR) with 95% confidence interval (CI). Two-sided *p*-values <0.05 indicated significance. All analyses were performed using SAS (Statistical Analysis System) software version 9.4 (SAS Institute, Cary, NC).

**RESULTS** 

In 20 participating centers, 676 patients were recruited from April 2020 to July 2021 (figure S1). Of them, 45 were excluded because of missing data, an RASS date before mechanical ventilation, or were enrolled  $\geq$ 48 h after mechanical ventilation. The final cohort included 631 patients. In this study, four-group solutions that best characterized the cohort were identified. A four-group model was chosen for the cohort based on specified selection criteria: trajectory 1 (persistent suboptimal; 13.2% of patients, RASS level  $\leq -3$  throughout the 30 days), trajectory 2 (delayed lightening; 13.9% of patients, RASS level  $\geq -2$  after the first 15 days), trajectory 3 (early lightening; 38.4% of patients, RASS level  $\geq -2$  after the first 7 days), trajectory 4 (persistent optimal: 34.6%, RASS level  $\geq -2$  during the first 30 days) (figure 1). A large number of patients in the "persistent suboptimal" group were older, with 35.82% in the >80 age group (*p*-value = 0.002) (table 1). Conversely, 39.24% and 40.46% of patients in the "early lightening" and "persistent optimal" groups, respectively, were aged between 50-69 years. Gender and body weight did not significantly differ between the trajectories. 

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 1  | Considering the comorbidities, there was a significant difference in dementia between patients           |
|----|--|
| 2  | of different trajectories ( $p$ -value = 0.010). Although no significant difference was found, the       |
| 3  | "persistent suboptimal" group had the highest percentage of solid tumor and cerebrovascular              |
| 4  | disease (38.00%, p-value = $0.278$ ; 28.00%, p-value = $0.101$ , respectively), whereas the              |
| 5  | "delayed lightening" group had the lowest percentage of moderate to severe chronic kidney                |
| 6  | disease (4.61%, <i>p</i> -value = 0.375). The "persistent suboptimal" and "delayed lightening" groups    |
| 7  | were more likely to be admitted to a medical ICU (52.24% and 48.81% versus 34.72% and                    |
| 8  | 31.63%, respectively) with a medical illness (61.19% and 58.33% versus 46.79% and 43.26%,                |
| 9  | respectively) and less likely to be admitted to a surgical ICU (44.78% and 50.00% versus 59.25%          |
| 10 | and 66.05%, respectively; $p$ -value = 0.023) for scheduled surgery (10.45% and 11.90% versus            |
| 11 | 23.77% and 23.72%, respectively; $p$ -value = 0.001). The most common cause for ICU                      |
| 12 | admission was respiratory (56.8%) in all the groups, and the "delayed lightening" group had              |
| 13 | the highest proportion for respiratory-related admissions (67.86%), whereas the "early                   |
| 14 | lightening" group had the lowest (51.32%, $p$ -value = 0.030). Cardiovascular-related ICU                |
| 15 | admissions were most common in the "early lightening" group (25.66%, $p$ -value = 0.610),                |
| 16 | although there was no statistical significance. The APACHE I score was significantly                     |
| 17 | different among the four trajectories (27.82, 25.28, 21.39, and 24.07 for "persistent                    |
| 18 | suboptimal," "delayed lightening," "early lightening," and "persistent optimal" groups,                  |
| 19 | respectively; p-value <0.001). As a part of ICU support within the first 48 h, the "delayed              |
| 20 | lightening" group received the largest number of vasopressor infusions (91.67%, $p$ -value <             |
| 21 | 0.001), renal replacement therapy (26.19%, <i>p</i> -value = $0.078$ ), and neuromuscular blockade use   |
| 22 | (46.43%, <i>p</i> -value $< 0.001$ ). In-hospital death occurred in 12.2% patients in the entire cohort. |
| 23 | By trajectory, in-hospital mortality was 49.52% in the "persistent suboptimal" group, 21.43%             |
| 24 | in the "delayed lightening" group, 6.79% in the "early lightening" group, and 3.72% in the               |
|    |  |

Page 11 of 33

#### **BMJ** Open

"persistent optimal" group (*p*-value < 0.001). Similarly, differences according to the</li>
trajectories were observed for ICU discharge and extubation. The proportion of ICU discharge
was 67.16%, 79.76%, 92.45%, and 92.09%, respectively (*p*-value < 0.001); rate of extubation</li>
was 68.16%, 78.57%, 95.47%, and 95.81%, respectively (*p*-value < 0.001). Moreover,</li>
differences in time to extubation (*p*-value < 0.001), ICU discharge (*p*-value < 0.001), and in-</li>
hospital mortality (*p*-value < 0.001) were observed among the four trajectories (figure 2). Table</li>
2 summarizes the representative phenotypes of each trajectory.

In adjusted Cox proportional hazard analyses, the "persistent suboptimal" (HR 13.62, 95% CI 5.99–30.95, p-value < 0.001) and "delayed lightening" groups (HR 5.62, 95% CI 2.36– 13.38, *p*-value < 0.001) had a significantly higher risk of death than the "persistent optimal" group (table 3). The "persistent suboptimal" (HR 0.23, 95% CI 0.16–0.32, p-value < 0.001), "delayed lightening" (HR 0.30, 95% CI 0.23–0.41, *p*-value < 0.001), and "early lightening" groups (HR 0.72, 95% CI 0.59–0.87, p-value < 0.001) showed a reduced probability of extubation and were less likely to discharge from the ICU (HR 0.36, 95% CI 0.26–0.51, p-value < 0.001; HR 0.44, 95% CI 0.33–0.59, p-value < 0.001; HR 0.80, 95% CI 0.65–0.97, p-value = 0.024, respectively) than the "persistent optimal" group. Patients undergoing scheduled surgery showed a higher probability of extubation (HR 2.13, 95% CI 1.64–2.78, p-value < 0.001) and ICU discharge (HR 2.10, 95% CI 1.59–2.78, *p*-value < 0.001) than outpatient admissions. Patients in the surgical ICU had a lower risk of death (HR 0.45, 95% CI 0.23–0.89, p-value = 0.021) than medical ICU patients. No additional significant differences were found with respect to age, gender, vasopressor infusions, or neuromuscular blockade. 

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

# **DISCUSSION**

To the best of our knowledge, this is the first study to characterize the longitudinal

#### Page 12 of 33

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### **BMJ** Open

pattern of sedation level over time in mechanically ventilated patients. We identified four distinct trajectories of sedation depth over the first 30 days after mechanical ventilation in our subjects. Only 34.6% patients were in an optimal depth of sedation during this period, whereas 13.2% were in the suboptimal range of RASS for most of this time, and the remaining patients achieved adequate depth of sedation 7 (early lightening: 38.4%) or 15 (delayed lightening: 13.9%) days after initiation. Patients who were at suboptimal levels of sedation throughout this period had a higher risk of mortality and lower probabilities of extubation and ICU discharge than those who were in consistently optimal level of sedation.

9 Group-based trajectory modeling is useful for characterizing longitudinal courses over 10 time to identify distinct subgroups.<sup>21 22</sup> This trajectory model is used in different domains of 11 clinical research, such as nonadherence spectrum in newly-diagnosed juvenile epilepsy, health 12 status in outpatients with heart failure, neurologic postinjury recovery, and symptom burden 13 nuances of patients with metastatic cancer.<sup>20</sup> Therefore, group-based trajectory modeling is a 14 specialized method for sorting individuals into meaningful subgroups that show statistically 15 similar trajectories.

There were several significant differences in characteristics between the four trajectory groups. Patients in trajectory 1 (persistent suboptimal) experienced deep sedation throughout the study period, with RASS ranging from -3 to -5. This group was mainly characterized by elderly patients with cognitive impairment, admitted to a medical ICU for treating illnesses, such as respiratory problems, with the worst condition at admission. Conversely, patients in trajectory 2 (delayed lightening) experienced initial deep sedation, which improved to a light depth of RASS -2 after 15 days. This group was characterized by elderly patients with dementia with respiratory failure, receiving vasopressors, neuromuscular blockade, and renal replacement therapy. Interestingly, although the two trajectories had relatively similar 

Page 13 of 33

#### **BMJ** Open

characteristics and the "delayed lightening" group even required more ICU support within the first 48 h, the "persistent suboptimal" group had worse time to extubation, ICU discharge, and hospital mortality. These findings suggest that the longitudinal course of sedation depth in our subjects was not associated with the severity of illness; the difference in sedation practice between the two trajectories might have resulted into different outcomes.

A prospective multicenter study, conducted across 42 international ICUs, demonstrated that the time to extubation and mortality increased with the sedation intensity.<sup>18</sup> In observational, matched-pair analyses based on the APACHE II score and the type of admission, early deep sedation during the first 48 h of ICU stay was associated with worse outcomes, including long-term mortality.<sup>7</sup> We report similar findings in our study upon comparing trajectories 3 and 4 with the earlier trajectories. Patients in trajectory 3 (early lightening) experienced early deep sedation, which became lighter after 7 days, whereas those in trajectory 4 (persistent optimal) experienced light sedation throughout. Patients in these groups were younger, had fewer medical conditions, and were mostly admitted to surgical ICUs than those in the other two groups. They also had lower APACHE I scores and needed lesser ICU support within the first 48 h. Patients in the "early lightening" group, especially, had the lowest APACHE score, the lowest proportion of renal replacement therapy, and the fewest respiratory problems. Nevertheless, multivariable Cox proportional hazard analysis showed that patients in this group had a lower probability of extubation and ICU discharge than those in the "persistent optimal" group. The early practice of inadequate sedation in the "early lightening" group might have induced this relatively worse prognosis in these patients. A recent meta-analysis assessing the literature on early sedation suggested that interventions targeting the depth of early sedation, starting with ICU admission, could improve patient outcomes.<sup>23</sup> Appropriate sedation is a critical aspect in the management of mechanically ventilated patients. 

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

We observed that 65.9% patients in our study were deeply sedated for at least the first week after mechanical ventilation, whereas only 34.07% patients received consistent light sedation throughout the sedation period. This finding is consistent with previous data describing the sedation depth. A multinational survey among intensivists reported that 74% patients monitored using a validated sedation tool were deeply sedated.<sup>24</sup> A survey in Germany found that the actual depth of sedation was significantly deeper (39.5%-62.4%) than the desired depth in all categories of sedation.<sup>25</sup> A Swedish study investigating the relationship between memory and sedation showed that only 39% of ventilated patients achieved their target sedation goal.<sup>26</sup> A previous systematic review estimated the incidence of over-sedation in ICUs at 40%–60%, despite the poor quality of epidemiologic data.<sup>2</sup> In a recent study conducted in the emergency department, the incidence of deep sedation was 52.8%.<sup>27</sup> These data suggest that deep sedation remains a common real-world ICU practice. To improve the quality of patient care, further research is warranted focusing on the longitudinal profile in addition to the binary concept of sedation, light versus deep. 

Our study has a few limitations. First, information bias may exist because only patients visiting tertiary or university-affiliated hospitals were included in our study. Second, unmeasured confounders could have affected the trajectories, despite many relevant variables in our study. Moreover, nondifferential group of patients may have been misclassified. This restriction is inherent to group-based trajectory models with limited generalizability. Third, the causal relationship between trajectory and outcome could not be established in this study. For example, it is unclear whether a prolonged duration of extubation reflected the effects of sedative overdose, or whether more sedation was needed because of longer mechanical ventilation. However, the strength, consistency, temporal precedence of the association and agreement with existing evidence of this study suggested the possibility of causal 

#### **BMJ** Open

relationship.<sup>28</sup> Thus, prospective and randomized controlled studies are required to investigate the interaction of two parameters (depth and duration) of sedation to better define the optimal practice. Fourth, there was a restriction on recruiting patients due to corona-19 crisis. Although the number of patients with mechanical ventilation increased in the corona-19 era, the lack of man-power in the ICU led to a low rate of registration. Finally, we were unable to examine the long-term complications in the trajectory groups. Further nationwide studies should evaluate long-term complications after sedation to comprehensively understand its socioeconomic and clinical burden. 

9 In conclusion, this study captured the four trajectories of sedation level over time in 10 mechanically ventilated patients. The patterns were significantly associated with time to 11 extubation, ICU discharge, and hospital mortality. Our findings suggest sedation strategy in 12 ICU patient needs to incorporate a longitudinal pattern of sedation level.

elien

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

14 Acknowledgements

15 None

**Contributors** 

18 CML, HYG, JHA have contributed to the study conception and design. Material preparation 19 was performed by HYG. Data collection was performed DH, JHA, CML. Statistical analysis 20 were performed by CMN and CY. The first draft of the manuscript was written by DH and 21 JHA, and all authors commented on previous versions of the manuscript. All authors have read 22 and approved the final manuscript.

24 Funding

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

This study was sponsored by Pfizer Korea Pharmaceuticals Ltd (Grant Number: N/A). The funding does not interfere with the analysis and interpretation of the data. 

# **Competing Interests**

Ha-Yeong Gil is an employee of Pfizer Korea. The other authors declare that they have no competing interests. The Pfizer Korea, sponsor of the present study, made no influence on study design, data collection and analysis, and writing.

#### Patient consent for publication

- Not applicable.

#### Ethic approval

The study protocol was approved by the Institutional Review Boards of all participating medical centers (B-1911/577-405, AJIRB-MED-OBS-19-372, AJIRB-MED-OBS-19-373, 1908-156-1058, 1908-157-1058, 1910-003-083, 2019-1624, 2019-1039, 2019-10-0321, 2019-09-040, 2019-10-162, GCIRB2019-366, DSMC 2019-08-018, HALLYM 2019-08-021, HALLYM 2019-08-022, 2019-09-010, 2019-08-082, DAUHIRB-19-166, 4-2019-0821, 4-2019-0820, 2019-09-011-002, 2019-07-038-002, CR-19-117-L, 2019AN0376, 2019AN0478, 20-2019-92, 20-2019-91, 2019GR0461, 2020GR0103, 2020AS0054). All patients (or patient representatives) provided their written informed consent. Some participating centers' local review boards waived the need for informed consent considering the observational nature of the study. This study was conducted per the amended Declaration of Helsinki. 

| 2<br>3         | 1  | Data                        | Availability statement  |  |  |  |  |  |
|----------------|----|-----------------------------|---|--|--|--|--|--|
| 4              | 1  | Data Availability statement |   |  |  |  |  |  |
| 5<br>6<br>7    | 2  | Data a                      | Data are available on request   |  |  |  |  |  |
| 7<br>8<br>9    | 3  |                             |   |  |  |  |  |  |
| 9<br>10<br>11  | 4  | References                  |   |  |  |  |  |  |
| 12<br>13       | 5  | 1.                          | Richards-Belle A, Canter RR, Power GS, et al. National survey and point prevalence        |  |  |  |  |  |
| 14<br>15       | 6  |                             | study of sedation practice in UK critical care. Crit Care 2016;20:355.                    |  |  |  |  |  |
| 16<br>17<br>18 | 7  | 2.                          | Jackson DL, Proudfoot CW, Cann KF, et al. The incidence of sub-optimal sedation in        |  |  |  |  |  |
| 19<br>20       | 8  |                             | the ICU: a systematic review. Crit Care 2009;13:R204.                                     |  |  |  |  |  |
| 21<br>22       | 9  | 3.                          | Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care sedation predicts long-       |  |  |  |  |  |
| 23<br>24<br>25 | 10 |                             | term mortality in ventilated critically ill patients. Am J Respir Crit Care Med           |  |  |  |  |  |
| 25<br>26<br>27 | 11 |                             | 2012;186:724-31.  |  |  |  |  |  |
| 28<br>29       | 12 | 4.                          | Shehabi Y, Chan L, Kadiman S, et al. Sedation depth and long-term mortality in            |  |  |  |  |  |
| 30<br>31       | 13 |                             | mechanically ventilated critically ill adults: a prospective longitudinal multicentre     |  |  |  |  |  |
| 32<br>33<br>34 | 14 |                             | cohort study. Intensive Care Med 2013;39:910-8.   |  |  |  |  |  |
| 35<br>36       | 15 | 5.                          | Desai SV, Law TJ, Needham DM. Long-term complications of critical care. Crit Care         |  |  |  |  |  |
| 37<br>38       | 16 |                             | Med 2011;39:371-9.  |  |  |  |  |  |
| 39<br>40       | 17 | 6.                          | Burry L, Rose L, McCullagh IJ, et al. Daily sedation interruption versus no daily         |  |  |  |  |  |
| 41<br>42<br>43 | 18 |                             | sedation interruption for critically ill adult patients requiring invasive mechanical     |  |  |  |  |  |
| 44<br>45       | 19 |                             | ventilation. Cochrane Database Syst Rev 2014;2014:Cd009176.                               |  |  |  |  |  |
| 46<br>47       | 20 | 7.                          | Balzer F, Weiß B, Kumpf O, et al. Early deep sedation is associated with decreased in-    |  |  |  |  |  |
| 48<br>49<br>50 | 21 |                             | hospital and two-year follow-up survival. Crit Care 2015;19:197.                          |  |  |  |  |  |
| 50<br>51<br>52 | 22 | 8.                          | Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of  |  |  |  |  |  |
| 53<br>54       | 23 |                             | pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med |  |  |  |  |  |
| 55<br>56       | 24 |                             | 2013;41:263-306.  |  |  |  |  |  |
| 57<br>58       |    |                             |   |  |  |  |  |  |
| 59<br>60       |    |                             | 16  |  |  |  |  |  |

Page 18 of 33

### BMJ Open

| 3<br>4               | 1  | 9.  | Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention  |  |  |  |  |  |
|----------------------|----|-----|--|--|--|--|--|--|
| 5<br>6<br>7          | 2  |     | and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep              |  |  |  |  |  |
| 7<br>8<br>9          | 3  |     | Disruption in Adult Patients in the ICU. Crit Care Med 2018;46:e825-e73.                 |  |  |  |  |  |
| 10<br>11             | 4  | 10. | Pearson SD, Patel BK. Evolving targets for sedation during mechanical ventilation.       |  |  |  |  |  |
| 12<br>13             | 5  |     | <i>Curr Opin Crit Care</i> 2020;26:47-52.  |  |  |  |  |  |
| 14<br>15<br>16       | 6  | 11. | Guérin C. Calming Down about Sedation in Critically Ill Patients. N Engl J Med           |  |  |  |  |  |
| 17<br>18             | 7  |     | 2020;382:1162-4.   |  |  |  |  |  |
| 19<br>20             | 8  | 12. | Owen GD, Stollings JL, Rakhit S, et al. International Analgesia, Sedation, and Delirium  |  |  |  |  |  |
| 21<br>22<br>23       | 9  |     | Practices: a prospective cohort study. J Intensive Care 2019;7:25.                       |  |  |  |  |  |
| 24<br>25             | 10 | 13. | Yassin SM, Terblanche M, Yassin J, et al. A web-based survey of United Kingdom           |  |  |  |  |  |
| 26<br>27             | 11 |     | sedation practice in the intensive care unit. J Crit Care 2015;30:436.e1-6.              |  |  |  |  |  |
| 28<br>29<br>30       | 12 | 14. | Sneyers B, Laterre PF, Perreault MM, et al. Current practices and barriers impairing     |  |  |  |  |  |
| 31<br>32             | 13 |     | physicians' and nurses' adherence to analgo-sedation recommendations in the intensive    |  |  |  |  |  |
| 33<br>34             | 14 |     | care unita national survey. Crit Care 2014;18:655.                                       |  |  |  |  |  |
| 35<br>36<br>27       | 15 | 15. | Wøien H, Stubhaug A, Bjørk IT. Analgesia and sedation of mechanically ventilated         |  |  |  |  |  |
| 37<br>38<br>39       | 16 |     | patients - a national survey of clinical practice. Acta Anaesthesiol Scand 2012;56:23-9. |  |  |  |  |  |
| 40<br>41             | 17 | 16. | García-Sánchez M, Caballero-López J, Ceniceros-Rozalén I, et al. Management of           |  |  |  |  |  |
| 42<br>43             | 18 |     | analgesia, sedation and delirium in Spanish Intensive Care Units: A national two-part    |  |  |  |  |  |
| 44<br>45<br>46       | 19 |     | survey. Med Intensiva (Engl Ed) 2019;43:225-33.  |  |  |  |  |  |
| 40<br>47<br>48       | 20 | 17. | Tanaka LM, Azevedo LC, Park M, et al. Early sedation and clinical outcomes of            |  |  |  |  |  |
| 49<br>50             | 21 |     | mechanically ventilated patients: a prospective multicenter cohort study. Crit Care      |  |  |  |  |  |
| 51<br>52<br>53<br>54 | 22 |     | 2014;18:R156.  |  |  |  |  |  |

# BMJ Open

| - 6 |  |
|-----|--|
| of  |  |
| ive | -  |
|     |  |
| CU  | -  |
| S). |  |
|     |  |
| tab | tecter   |
| uo  | d by c   |
|     | Enseignement Superieur (ABES<br>Protected by copyright, including for uses related to text and data mini |
| Rev | yht, in  |
|     | cludir   |
| ind | ng for   |
| cy. | Ense<br>uses   |
|     | relate   |
| nes | nent S<br>d to te  |
| A   | ext and  |
| А   | eur (A<br>d data   |
|     | BES) .<br>mining   |
| ive | ng, Al   |
| Dne | trainii  |
|     | ng, an   |
| are | d sim  |
| ind | ilar te  |
|     | ining, Al training, and similar technologies.  |
|     | ogies.   |
| ult | Ċ  |
|     |  |
|     | c  |
|     | -  |

| 2<br>3<br>4          | 1  | 18. | Shehabi Y, Bellomo R, Kadiman S, et al. Sedation Intensity in the First 48 Hours of    |
|----------------------|----|-----|--|
| 5<br>6               | 2  |     | Mechanical Ventilation and 180-Day Mortality: A Multinational Prospective              |
| 7<br>8               | 3  |     | Longitudinal Cohort Study. Crit Care Med 2018;46:850-9.                                |
| 9<br>10<br>11        | 4  | 19. | Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU       |
| 12<br>13             | 5  |     | patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS).    |
| 14<br>15             | 6  |     | Jama 2003;289:2983-91.   |
| 16<br>17<br>18       | 7  | 20. | Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab                 |
| 19<br>20             | 8  |     | 2014;65:205-10.  |
| 21<br>22             | 9  | 21. | Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev    |
| 23<br>24<br>25       | 10 |     | <i>Clin Psychol</i> 2010;6:109-38.   |
| 25<br>26<br>27       | 11 | 22. | Nagin D, Tremblay RE. Trajectories of boys' physical aggression, opposition, and       |
| 28<br>29             | 12 |     | hyperactivity on the path to physically violent and nonviolent juvenile delinquency.   |
| 30<br>31             | 13 |     | <i>Child Dev</i> 1999;70:1181-96.  |
| 32<br>33<br>34       | 14 | 23. | Stephens RJ, Dettmer MR, Roberts BW, et al. Practice Patterns and Outcomes             |
| 35<br>36             | 15 |     | Associated With Early Sedation Depth in Mechanically Ventilated Patients: A            |
| 37<br>38             | 16 |     | Systematic Review and Meta-Analysis. Crit Care Med 2018;46:471-9.                      |
| 39<br>40<br>41       | 17 | 24. | Luetz A, Balzer F, Radtke FM, et al. Delirium, sedation and analgesia in the intensive |
| 41<br>42<br>43       | 18 |     | care unit: a multinational, two-part survey among intensivists. PLoS One               |
| 44<br>45             | 19 |     | 2014;9:e110935.  |
| 46<br>47             | 20 | 25. | Martin J, Franck M, Fischer M, et al. Sedation and analgesia in German intensive care  |
| 48<br>49<br>50       | 21 |     | units: how is it done in reality? Results of a patient-based survey of analgesia and   |
| 50<br>51<br>52       | 22 |     | sedation. Intensive Care Med 2006;32:1137-42.  |
| 53<br>54             | 23 | 26. | Samuelson K, Lundberg D, Fridlund B. Memory in relation to depth of sedation in adult  |
| 55<br>56             | 24 |     | mechanically ventilated intensive care patients. Intensive Care Med 2006;32:660-7.     |
| 57<br>58<br>59<br>60 |    |     | 18   |

| 3<br>4         | 1  | 27. | Fuller BM, Roberts BW, Mohr NM, et al. The ED-SED Study: A Multicenter,              |
|----------------|----|-----|--|
| 5<br>6         | 2  |     | Prospective Cohort Study of Practice Patterns and Clinical Outcomes Associated With  |
| 7<br>8         | 3  |     | Emergency Department SEDation for Mechanically Ventilated Patients. Crit Care Med    |
| 9<br>10<br>11  | 4  |     | 2019;47:1539-48.   |
| 12<br>13       | 5  | 28. | Austin Bradford Hill. The environment and disease: association or causation? J R Soc |
| 14<br>15       | 6  |     | Med 2015;108:32-7.   |
| 16<br>17<br>18 | 7  |     |  |
| 19<br>20       | 8  |     |  |
| 21<br>22       | 9  |     |  |
| 23<br>24<br>25 | 10 |     |  |
| 26<br>27       | 11 |     |  |
| 28<br>29       | 12 |     |  |
| 30<br>31<br>32 | 13 |     |  |
| 33<br>34       | 14 |     |  |
| 35<br>36       | 15 |     |  |
| 37<br>38<br>39 | 16 |     |  |
| 40<br>41       | 17 |     |  |
| 42<br>43       | 18 |     |  |
| 44<br>45<br>46 | 19 |     |  |
| 47<br>48       | 20 |     |  |
| 49<br>50       | 21 |     |  |
| 51<br>52<br>53 | 22 |     |  |
| 54<br>55       | 23 |     |  |
| 56<br>57       | 24 |     |  |
| 58<br>59<br>60 |    |     | 19   |
|                |    |     |  |

| 1<br>2         |    |   |
|----------------|----|---|
| -<br>3<br>4    | 1  | Figure Legends  |
| 5<br>6         | 2  | Figure 1 Trajectories of longitudinal Richmond Agitation Sedation Scale in the first 30 days        |
| 7<br>8<br>9    | 3  | of sedation for mechanical ventilation. The percentage of patients included in each trajectory      |
| 10<br>11       | 4  | were presented in central illustration. Outcome of y-axis indicates the score of richmond           |
| 12<br>13       | 5  | agitation sedation scale and T of x-axis represents day after the initiation of sedation.           |
| 14<br>15<br>16 | 6  |   |
| 17<br>18       | 7  | Figure 2 Kaplan-Meier of clinical outcomes from admission according to the trajectory               |
| 19<br>20       | 8  | groups. (a) time to extubation in the intensive care unit, (b) length of stay in the intensive care |
| 21<br>22       | 9  | unit, (c) in-hospital mortality.  |
| 23<br>24<br>25 | 10 |   |
| 26<br>27       | 11 |   |
| 28<br>29       | 12 |   |
| 30<br>31<br>32 | 13 |   |
| 33<br>34       | 14 |   |
| 35<br>36       | 15 |   |
| 37<br>38       | 16 |   |
| 39<br>40<br>41 | 17 |   |
| 42<br>43       | 18 |   |
| 44<br>45       | 19 |   |
| 46<br>47<br>48 | 20 |   |
| 48<br>49<br>50 | 21 |   |
| 51<br>52       | 22 |   |
| 53<br>54       | 23 |   |
| 55<br>56<br>57 | 24 |   |
| 58<br>59       |    |   |
| 60             |    | 20  |

| Table 1 Baseline Characteristics and Clin | nical Outcomes for th | e Total Cohort and for | Each Trajectory of | the Richmond Agient   | io Sedation Scale                          |                 |
|---|-----------------------|------------------------|--------------------|---|--|-----------------|
|   |                       |                        |                    | tory group  | No   |                 |
| Characteristic                            | All (N = 631)         | 1 (N = 67)             | 2 (N = 84)         | 3 (N = 265)   | <b>9</b> 4 (N = 215)                       | <i>p</i> -value |
| Age                                       |                       |                        |                    |   |  | 0.002           |
| 20–29                                     | 11 (1.74%)            | 0 (0.00%)              | 2 (2.38%)          | 6 (2.26%)   | 3 (1.40%)                                  |                 |
| 30–39                                     | 34 (5.39%)            | 0 (0.00%)              | 2 (2.38%)          | 12 (4.53%) <b>đ</b>   | 20 (9.30%)                                 |                 |
| 40–49                                     | 44 (6.97%)            | 3 (4.48%)              | 11 (13.10%)        | 13 (4.91%)  | <b>3</b> 17 (7.91%)                        |                 |
| 50–59                                     | 92 (14.58%)           | 6 (8.96%)              | 6 (7.14%)          | 44 (16.60%) <b>5</b>  | 36 (16.74%)                                |                 |
| 60–69                                     | 140 (22.19%)          | 12 (17.91%)            | 17 (20.24%)        | 60 (22.64%) <b>§</b>  |  |                 |
| 70–79                                     | 177 (28.05%)          | 22 (32.84%)            | 23 (27.38%)        | 80 (30.19%) and   | <b>52</b> (24.19%)                         |                 |
| ≥80                                       | 133 (21.08%)          | 24 (35.82%)            | 23 (27.38%)        | 50 (18.87%) d   |  |                 |
| Male gender                               | 404 (64.0)            | 44 (65.67)             | 57 (67.86)         | 165 (62.26) at 5  | 138 (64.19)                                | 0.807           |
| Body weight, kg*                          | 62.0 (53.0-71.0)      | $62.25 \pm 10.69$      | 62.81 ± 13.31      | 62.51 ± 13.01   | 63.79 ± 17.62                              | 0.785           |
| Comorbidity                               | 448 (71.00)           | 50 (74.62)             | 65 (77.38)         |   | 150 (69.76)                                | 0.434           |
| Diabetes with end-organ damage            | 30 (4.31)             | 2 (4.00)               | 2 (3.07)           | 14 (7.65)   | 12 (8.00)                                  | 0.573           |
| COPD                                      | 60 (8.6)              | 7 (14.00)              | 8 (12.30)          | 25 (13.66) <b>fa</b>  | 20 (13.33)                                 | 0.994           |
| Congestive heart failure                  | 49 (7.0)              | 3 (6.00)               | 7 (10.76)          | 19 (10.38) <b>D</b> i   | 20 (13.33)                                 | 0.596           |
| Moderate-to-severe liver disease**        | 27 (3.8)              | 3 (6.00)               | 3 (4.61)           | 19 (10.38)     ni       9 (4.91)     g       18 (9.83)     nd | 12 (8.00)                                  | 0.681           |
| Moderate-to-severe CKD**                  | 46 (6.6)              | 5 (10.00)              | 3 (4.61)           | 18 (9.83) <b>d</b>  | <b>2</b> 0 (13.33)                         | 0.375           |
| Solid tumor                               | 127 (18.2)            | 19 (38.00)             | 15 (23.07)         | 48 (26.22) <b>S</b>   | <b>o</b> 45 (30.00)                        | 0.278           |
| Dementia                                  | 35 (5.0)              | 6 (12.00)              | 9 (13.84)          | 16 (8.74) ar  | <b>د</b> 4 (3.00)                          | 0.010           |
| Cerebrovascular disease/TIA               | 82 (11.7)             | 14 (28.00)             | 14 (21.53)         | 28 (15.30) <b>ह</b>   | <b>De</b> 26 (17.33)                       | 0.101           |
| Type of admission                         |                       |                        |                    | hnc   | 13,  | 0.023           |
| Medical                                   | 307 (48.6)            | 41 (61.19)             | 49 (58.33)         | 124 (46.79) <b>og</b>   | 8 93 (43.26)                               |                 |
| Emergency surgery                         | 193 (30.5)            | 19 (28.36)             | 25 (29.76)         | 78 (29.43)  | a) 71 (33.02)                              |                 |
| Scheduled surgery                         | 131 (20.7)            | 7 (10.45)              | 10 (11.90)         | 63 (23.77)  | <b>b</b> 51 (23.72)                        |                 |
| Type of ICU                               |                       |                        |                    |   | <b>b</b> 51 (23.72)<br><b>c</b> 68 (31.63) | 0.001           |
| Medical ICU                               | 236 (37.4)            | 35 (52.24)             | 41 (48.81)         | 92 (34.72)  | <b>68</b> (31.63)                          |                 |
| Surgical ICU                              | 371 (58.8)            | 30 (44.78)             | 42 (50.00)         | 157 (59.25)   | bi<br>ographique de                        |                 |

| Page | 23 | of | 33 |
|------|----|----|----|
|------|----|----|----|

#### **BMJ** Open

d by copyri bmjopen-2(

|                                    |                 |                  |                   | ight,                     | 023-                  |         |
|------------------------------------|-----------------|------------------|-------------------|---------------------------|-----------------------|---------|
| Others                             | 24 (3.8)        | 2 (2.99)         | 1 (1.19)          | in<br>16 (6.04)<br>16 min | <b>5</b> (2.33)       |         |
| Reason for ICU admission***        |                 |                  |                   | ding                      | 8                     |         |
| Renal                              | 16 (2.5)        | 1 (1.49)         | 0 (0.00)          | 7 (2.64) 5                | 8 (3.72)              | 0.294   |
| Digestive                          | 83 (13.1)       | 10 (14.93)       | 12 (14.29)        | 28 (10.57)                | <b>2</b> 33 (15.35)   | 0.434   |
| Cardiovascular                     | 147 (23.3)      | 15 (22.39)       | 16 (19.05)        | 68 (25.66) <b>8</b> 3     | <b>e</b> 48 (22.33)   | 0.610   |
| Hematologic                        | 14 (2.2)        | 2 (2.99%)        | 3 (3.57%)         | 4 (1.51%) reign           | <b>NO</b> 5 (2.33%)   | 0.679   |
| Respiratory                        | 359 (56.8)      | 43 (64.18%)      | 57 (67.86%)       | 136 (51.32%) <b>É</b>     | <b>3</b> 123 (57.21%) | 0.030   |
| Miscellaneous                      | 67 (10.6)       | 3 (4.48%)        | 11 (13.10%)       |                           | <b>8</b> 19 (8.84%)   | 0.152   |
| Neurologic                         | 12 (1.9)        | 3 (4.48%)        | 1 (1.19%)         | 4 (1.51%) <b>e u</b>      | <b>1</b> 4 (1.86%)    | 0.418   |
| Others                             | 105 (16.6)      | 11 (16.42%)      | 13 (15.48%)       | 42 (15.85%) and           | <b>3</b> 9 (18.14%)   | 0.907   |
| APACHE II, score*                  | $23.4 \pm 10.0$ | $27.82 \pm 9.73$ | $25.28 \pm 11.45$ |                           |                       | < 0.001 |
| ICU support within first 48 hours  |                 | 0                |                   | ta r                      | 24.07 ± 9.56          |         |
| Vasopressor infusions              | 486 (77.02)     | 57 (85.07)       | 77 (91.67)        | 199 (75.09) <b>ni 5</b>   | 153 (71.16)           | < 0.001 |
| Renal replacement                  | 107 (16.9)      | 11 (16.42)       | 22 (26.19)        | 37 (13.96) <b>g</b> ·     | 37 (17.21)            | 0.078   |
| Neuromuscular blockade             | 171 (27.1)      | 27 (40.30)       | 39 (46.43)        | 69 (26.04) <b>≥</b>       | 36 (16.74)            | < 0.001 |
| Clinical outcomes                  |                 |                  |                   | traii                     | pe                    |         |
| In-hospital mortality              | 77 (12.2)       | 33 (49.52)       | 18 (21.43)        | 18 (6.79) <b>n</b>        | 8 (3.72)              | < 0.001 |
| ICU discharge                      | 555 (87.9)      | 45 (67.16)       | 67 (79.76)        | 245 (92.45) <b>a</b>      | 198 (92.09)           | < 0.001 |
| Extubation                         | 571 (90.4)      | 46 (68.66)       | 66 (78.57)        | 253 (95.47) d             | 206 (95.81)           | < 0.001 |
| Length of ventilator support, days | 5 (3-11)        | 11 (20–NE)       | 11.5 (7–23.5)     | 5 (3-8) <b>B</b>          | <b>9</b> 3 (2–5)      | < 0.001 |
| ICU length of stay, days           | 10 (5-18)       | 20 (12–NE)       | 18 (10-26)        | 9 (6–14)                  | <b>L</b> 4 (6–10)     | < 0.001 |

Data are reported as mean  $\pm$  standard deviation or median (interguartile range) for continuous variables and number (perce  $\frac{1}{2}$  age) for categorical variables. \*Data on body weight are presented for all 605 patients, excluding 26 patients with missing data (4 in the light sedation group and 22 in the deep sedation group). Data on APACHE I are presented for all 577 patients, excluding 54 patients with missing data (15 in the light sedation group and  $\frac{2}{9}$  in the deep sedation group). \*\*Severe to moderate liver disease are defined as cirrhosis and portal hypertension with or without variceal bleeding histor Severe to moderate CKD are defined as at serum creatinine > 3 mg/dL or on dialysis or post-kidney transplant status or uremia status. õ \*\*\*172 patients had multiple reasons for ICU admission. ICU = intensive care unit; SMD = standardized mean difference; COPD = chronic obstructive pulmonary disease; CKD = chroneck kidney disease; TIA = transient

ischemic attack; APACHE II = acute physiology and chronic health evaluation II; NE = not estimated Bibliographique de l

d by copyrig bmjopen-20

| Page | 24 | of | 33 |
|------|----|----|----|
| ruge | 27 | U, | 55 |

|                                |                                       |                                    | 923-0<br>ght, i  |                              |
|--------------------------------|---------------------------------------|------------------------------------|--|------------------------------|
| Table 2 Summary of the demogra | aphics of the trajectories and the tr | ajectory ranks for characteristics | ncludii  |                              |
|                                | Trajectory 1                          | Trajectory 2                       | Trajectory 3 G S   | Trajectory 4                 |
| Demographics                   |                                       |                                    | or u   |                              |
| Age                            | 70–79 & ≥80                           | 70–79 & ≥80                        | 60–69 & 70–-79 g Hun   | 60–69 & 70–-79               |
| Gender                         | Male                                  | Male                               | Male R. 2  | Male                         |
| Comorbidity                    | Solid tumor, CVD/TIA,<br>COPD         | Solid tumor, CVD/TIA, Dementia     | Solid tumor, COPD  | Solid tumor, CVD/TIA, COPD   |
| Type of ICU                    | Medical ICU                           | Surgical ICU                       |  | Surgical ICU                 |
| Reason for ICU admission       | Respiratory & Cardiovascular          | Respiratory & Cardiovascular       | Respiratory & Catol Respiratory                              | Respiratory & Cardiovascular |
| Ranks for characteristics      |                                       |                                    | aded   |                              |
| Medical admission              | 1st                                   | 2nd                                | 3rd     data from       2nd     AB from       4th     nicson | 4th                          |
| Scheduled surgery              | 4th                                   | 3rd                                | 2nd  | 1st                          |
| АРАСНЕ 🛙                       | 1st                                   | 2nd                                | 4th  | 3rd                          |
| Vasopressor infusions          | 2nd                                   | 1st                                | 3rd 🙇 👼  | 4th                          |
| Renal replacement therapy      | 3rd                                   | 1st                                | 4th Art Jo   | 2nd                          |
| Neuromuscular blockade         | 2nd                                   | 1st                                | 3rd  | 4th                          |

 Neuromuscular blockade
 Int
 Int
 Int
 Int

 Neuromuscular blockade
 2nd
 1st
 3rd
 Int
 I


| Page | 25 of | 33 |
|------|-------|----|
|------|-------|----|

### BMJ Open

|                        | portional Hazard regression<br>Time to extu | 1               | Time to ICU discharge |                 | d by copyright, including | bmjopen-2023-072628<br>on Time to in-hos | Time to in-hospital death |  |
|------------------------|---|-----------------|-----------------------|-----------------|---------------------------|--|---------------------------|--|
|                        | HR (95% CI)                                 | <i>p</i> -value | HR (95% CI)           | <i>p</i> -value | ę                         | NR (95% CI)                              | <i>p</i> -value           |  |
| Trajectory group       |   |                 |                       | 1               | Ens<br>uses               |  |                           |  |
| Group 1                | 0.23 (0.16–0.32)                            | < 0.001         | 0.36 (0.26–0.51)      | < 0.001         | 문                         | ₩3.62 (5.99–30.95)                       | < 0.001                   |  |
| Group 2                | 0.30 (0.23–0.41)                            | < 0.001         | 0.44 (0.33–0.59)      | < 0.001         | ne                        | <b>6</b> .62 (2.36–13.38)                | < 0.001                   |  |
| Group 3                | 0.72 (0.59–0.87)                            | < 0.001         | 0.80 (0.65–0.97)      | 0.024           | nnei<br>d t               | <b>8</b> .76 (0.76–4.08)                 | 0.185                     |  |
| Group 4                | Reference                                   |                 | Reference             |                 | o te                      | Reference                                |                           |  |
| Age                    |   |                 |                       |                 | t a                       | Reference<br>Ogg                         |                           |  |
| 20–29                  | Reference                                   |                 | Reference             |                 | nd u                      | eference                                 |                           |  |
| 30–39                  | 1.08 (0.53–2.21)                            | 0.825           | 0.70 (0.35–1.42)      | 0.334           | Jr (7<br>Jata             | <b>ğ</b> .69 (0.06–7.72)                 | 0.765                     |  |
| 40–49                  | 0.89 (0.43–1.81)                            | 0.748           | 0.63 (0.31–1.25)      | 0.188           |                           | <b>9</b> .59 (0.06–5.28)                 | 0.641                     |  |
| 50–59                  | 1.04 (0.53–2.03)                            | 0.893           | 0.65 (0.34–1.23)      | 0.192           |                           | 2.41 (0.04–3.46)                         | 0.414                     |  |
| 60–69                  | 1.00 (0.52–1.93)                            | 0.987           | 0.79 (0.42–1.48)      | 0.469           | 9, A                      | 8.88 (0.11-6.75)                         | 0.905                     |  |
| 70–79                  | 1.04 (0.54–1.99)                            | 0.893           | 0.64 (0.34–1.20)      | 0.170           |                           | <b>9</b> .47 (0.06–3.65)                 | 0.473                     |  |
| ≥80                    | 0.85 (0.44–1.64)                            | 0.632           | 0.53 (0.28–1.00)      | 0.052           | ni.                       | 82 (0.10-6.26)                           | 0.850                     |  |
| Female                 | 0.85 (0.71–1.01)                            | 0.075           | 0.98 (0.81–1.17)      | 0.848           | ng,                       | <b>1</b> .17 (0.73–1.89)                 | 0.50                      |  |
| Type of admission      |   |                 | N                     |                 | and                       | G  |                           |  |
| Medical                | Reference                                   |                 | Reference             |                 | sin                       | Reference                                |                           |  |
| Emergency surgery      | 1.02 (0.79–1.32)                            | 0.839           | 1.17 (0.90–1.53)      | 0.234           | simila                    | <b>J</b> .35 (0.62–2.91)                 | 0.444                     |  |
| Scheduled surgery      | 2.13 (1.64–2.78)                            | < 0.001         | 2.10 (1.59–2.78)      | < 0.001         | r teo                     | <b>5</b> .91 (0.87–4.16)                 | 0.102                     |  |
| Type of ICU            |   |                 |                       |                 | chn                       | 13                                       |                           |  |
| Medical ICU            | Reference                                   |                 | Reference             |                 | olog                      | Beference                                |                           |  |
| Surgical ICU           | 1.05 (0.83–1.33)                            | 0.629           | 0.87 (0.68–1.12)      | 0.299           |                           | <b>9</b> .45 (0.23–0.89)                 | 0.021                     |  |
| Others                 | 1.53 (0.96–2.40)                            | 0.068           | 1.28 (0.80–2.06)      | 0.289           |                           | 55 (0.12–2.47)                           | 0.441                     |  |
| Vasopressor infusions  | 0.85 (0.69–1.04)                            | 0.116           | 0.85 (0.69–1.04)      | 0.122           |                           | <b>g</b> .25 (0.62–2.51)                 | 0.529                     |  |
| Neuromuscular blockade | 1.05 (0.86–1.28)                            | 0.586           | 0.88 (0.72–1.07)      | 0.217           |                           | <b>8</b> .42 (0.88–2.29)                 | 0.148                     |  |

bmjopen-2023-072628 on 27 June 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . by copyright, including for uses related to text and data mining, Al training, and similar technologies. 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml








Figure 2 Kaplan-Meier of clinical outcomes from admission according to the trajectory groups. (a) time to extubation in the intensive care unit, (b) length of stay in the intensive care unit, (c) in-hospital mortality.

338x190mm (200 x 200 DPI)

#### **BMJ** Open

Longitudinal trajectories of sedation level and clinical outcomes in mechanically ventilated patients: a prospective, multicenter, longitudinal, observational study

Dong-gon Hyun, M.D.<sup>1</sup>, Jee Hwan Ahn, M.D.<sup>1</sup>, Ha-Yeong Gil, M.S.<sup>2</sup>, Chung Mo Nam, Ph.D.<sup>3</sup>, Choa Yun, M.S.<sup>4</sup>, Chae-Man Lim, M.D., Ph.D.<sup>1</sup>\*

<sup>1</sup>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>2</sup>Medical Research Project Team, IM Medical, Pfizer Korea Pharmaceuticals Ltd., Seoul, Republic of Korea

<sup>3</sup>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

<sup>4</sup>Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea

\*Corresponding author: Chae-Man Lim, M.D., Ph.D., FCCM

E-mail: <u>cmlim@amc.seoul.kr</u>

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 1        |
|----------|
| 2        |
| 3        |
| 4        |
| 5        |
| 6        |
| 7        |
| 8        |
| 9        |
| 10       |
| 11       |
| 12       |
| 13       |
| 14       |
| 15<br>16 |
| 17       |
| 18       |
| 19       |
| 20       |
| 21       |
| 22       |
| 23       |
| 24       |
| 25       |
| 26       |
| 27       |
| 28       |
| 29       |
| 30       |
| 31       |
| 32<br>33 |
| 33<br>34 |
| 35       |
| 36       |
| 37       |
| 38       |
| 39       |
| 40       |
| 41       |
| 42       |
| 43       |
| 44       |
| 45       |
| 46<br>47 |
| 47<br>48 |
| 48<br>49 |
| 49<br>50 |
| 50       |
| 52       |
| 53       |
| 54       |
| 55       |
| 56       |
| 57       |
| 58       |
| 59       |
| 60       |

60

| City     | Participating hospitals                  | Investigators                |  |
|----------|--|------------------------------|--|
| Seoul    | Asan Medical Center                      | Dong-gon Hyun, Jee Hwan Ahn, |  |
|          |  | Suk-Kyung Hong, Chae-Man     |  |
|          |  | Lim                          |  |
| Seoul    | Seoul National University Hospital       | Sang-Min Lee, Ho-Geol Ryu    |  |
| Seoul    | Samsung Medical Center                   | Gee Young Suh, Chi Min Park  |  |
| Seoul    | Severance Hospital                       | Su Hwan Lee, Jeoung Min Kim  |  |
| Seoul    | Seoul St. Mary's Hospital                | Seok Chan Kim                |  |
| Seoul    | Korea University Anam Hospital           | Won Jai Jung, Jae-Myeong Lee |  |
| Seoul    | Korea University Guro Hospital           | Young-Seok Lee, Nak-Jun Choi |  |
| Seoul    | Seoul National University Boramae        | Taeyun Park                  |  |
|          | Medical Center                           |                              |  |
| Seongnam | Seoul National University Bundang        | Dong Jung Kim                |  |
| _        | Hospital                                 |                              |  |
| Suwon    | Ajou University School of Medicine       | Keu Sung Lee, Young-Gi Min   |  |
| Busan    | Pusan National University Hospital       | Jae Hun Kim                  |  |
| Busan    | Dong-A University Hospital               | Dong-Hyun Lee                |  |
| Busan    | Inje University Haeundae Paik Hospital   | Hang-Jea Jang, Ki Hoon Kim   |  |
| Wonju    | Yonsei University Wonju College of       | Seok Jeong Lee               |  |
|          | Medicine                                 |                              |  |
| Incheon  | Gachon University Gil Medical Center     | Woo-Sung Choi                |  |
| Daegu    | Keimyung University School of Medicine   | Jae-Bum Kim                  |  |
| Daegu    | Yeungnam University Medical Center       | Eun Young Choi, Jong-Hyun    |  |
|          |  | Baek                         |  |
| Daegu    | Daegu Catholic University Medical Center | Eun Jin Kim                  |  |
| Anyang   | Hallym University Sacred Heart Hospital  | Sunghoon Park, Hyung Won     |  |
| _        |  | Kim                          |  |
| Ansan    | Korea University Ansan Hospital          | Je Hyeong Kim                |  |

# Table S1. Participating intensive care units


| 1<br>2         |  |
|----------------|--|
| 3<br>4         |  |
| 5<br>6         |  |
| 7<br>8<br>9    |  |
| 10<br>11       |  |
| 12<br>13       |  |
| 14<br>15       |  |
| 16<br>17<br>18 |  |
| 19<br>20       |  |
| 21<br>22       |  |
| 23<br>24<br>25 |  |
| 26<br>27       |  |
| 28<br>29       |  |
| 30<br>31<br>32 |  |
| 33<br>34       |  |
| 35<br>36<br>37 |  |
| 37<br>38<br>39 |  |
| 40<br>41       |  |
| 42<br>43<br>44 |  |
| 44<br>45<br>46 |  |
| 47<br>48       |  |
| 49<br>50<br>51 |  |
| 52<br>53       |  |
| 54<br>55       |  |
| 56<br>57       |  |
| 58<br>59       |  |

| Table S2. | Profile    | of analgesi | c and sedativ | ve within th | ne first 48 hours |
|-----------|------------|-------------|---------------|--------------|-------------------|
|           | I I OI IIC | or unungeon | e una seaun   |              | to mound          |

| Type of Sedatives        | N = 662                   |
|--------------------------|---------------------------|
| Diazepam                 | 1 (0.2)                   |
| Cumulative dose (µg)     | 2000.0                    |
| Midazolam                | 127 (19.2)                |
| Cumulative dose (µg)     | $64253.9 \pm 133338.1$    |
| Lorazepam                | 14 (2.1)                  |
| Cumulative dose (µg)     | $2750 \pm 1868.3$         |
| Other benzodiazepine     | 19 (2.9)                  |
| Cumulative dose (µg)     | $34294.7 \pm 53960.7$     |
| Propofol                 | 173 (26.1)                |
| Cumulative dose (µg)     | $3444220.1 \pm 2752320.0$ |
| Ketamine                 | 53 (8.0)                  |
| Cumulative dose (µg)     | $1450147.2 \pm 1830958.4$ |
| Haloperidol              | 1 (0.2)                   |
| Cumulative dose (µg)     | 5000.0                    |
| Dexmedetomidine          | 253 (38.2)                |
| Cumulative dose (µg)     | $4080.2 \pm 38325.4$      |
| Other non-benzodiazepine | 21 (3.2)                  |
| Cumulative dose (µg)     | $75659.5 \pm 133078.2$    |
| Type of analgesics       | N = 528                   |
| Fentanyl                 | 119 (22.5)                |
| Cumulative dose (µg)     | $30861.1 \pm 315168.1$    |
| Remifentanil             | 388 (73.5)                |
| Cumulative dose (µg)     | • 13227.8 ± 10971.7       |
| Morphine                 | 6 (1.1)                   |
| Cumulative dose (µg)     | 24000.0 ± 38740.2         |
| Sufentanil               | 15 (2.8)                  |
| Cumulative dose (µg)     | $285.4 \pm 280.6$         |

Data are reported as means  $\pm$  standard deviation for continuous variables and numbers (percentage) for categorical variables.

RASS = Richmond agitation-sedation scale



**Figure S1.** Flow diagram of patients in the present study. MV = mechanical ventilation; RASS = Richmond agitation-sedation scale

|                              |           | BMJ Open by copyright  |                  |
|------------------------------|-----------|--|------------------|
|                              |           | STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of content studies  |                  |
| Section/Topic                | ltem<br># | Recommendation   | Reported on page |
| Title and abstract           | 1         | ( <i>a</i> ) Indicate the study's design with a commonly used term in the title or the abstract  | 1                |
|                              |           | ័រ ភូតិ<br>(b) Provide in the abstract an informative and balanced summary of what was done and what was found   | 2                |
| Introduction                 |           |  |                  |
| Background/rationale         | 2         | Explain the scientific background and rationale for the investigation being reported 6 g   | 4                |
| Objectives                   | 3         | State specific objectives, including any prespecified hypotheses   | 4                |
| Methods                      | 1         | and a seried   |                  |
| Study design                 | 4         | Present key elements of study design early in the paper  | 4                |
| Setting                      | 5         | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,   | 5                |
| Participants                 | 6         | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up   | 5                |
|                              |           | (b) For matched studies, give matching criteria and number of exposed and unexposed  |                  |
| Variables                    | 7         | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifier Give diagnostic criteria, if  | 5                |
| Data sources/<br>measurement | 8*        | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group   | 5                |
| Bias                         | 9         | Describe any efforts to address potential sources of bias  |                  |
| Study size                   | 10        | Explain how the study size was arrived at  |                  |
| Quantitative variables       | 11        | Explain how quantitative variables were handled in the analyses. If applicable, describe which gou bongs were chosen and why   | 5                |
| Statistical methods          | 12        | ( <i>a</i> ) Describe all statistical methods, including those used to control for confounding   | 6                |
|                              |           | (b) Describe any methods used to examine subgroups and interactions  | 6                |
|                              |           | (c) Explain how missing data were addressed  | 6                |
|                              |           | (c) Explain how missing data were addressed     Image: Comparison of the second s | 6                |
|                              |           | (e) Describe any sensitivity analyses  | 6                |

 phique de l

|                   |     | BMJ Open<br>BMJ Open-202   | Page |
|-------------------|-----|--|------|
| Participants      | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, exangine of the stage of study and the study and the study and the stu | 7    |
|                   |     | eligible, included in the study, completing follow-up, and analysed  | 7    |
|                   |     |  | 7    |
| Descriptive data  | 14* | (c) Consider use of a flow diagram<br>(a) Give characteristics of study participants (eg demographic, clinical, social) and information 중 하는 Constant of Confounders   | 7    |
|                   |     | (b) Indicate number of participants with missing data for each variable of interest  | 8    |
|                   |     | (b) Indicate number of participants with missing data for each variable of interest <b>a b b b c </b>  |      |
| Outcome data      | 15* | Report numbers of outcome events or summary measures over time   | 8    |
| Main results      | 16  | ( <i>a</i> ) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precedence interval). Make clear which confounders were adjusted for and why they were included   | 8    |
|                   |     | (b) Report category boundaries when continuous variables were categorized  | 8    |
|                   |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful   |      |
| Other analyses    | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | 9    |
| Discussion        |     | a, bmj   |      |
| Key results       | 18  | Summarise key results with reference to study objectives   | 9    |
| Limitations       |     |  |      |
| Interpretation    | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence   | 10   |
| Generalisability  | 21  | Discuss the generalisability (external validity) of the study results  | 10   |
| Other information |     | ar te un   |      |
| Funding           | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, by the original study on which the present article is based   | 13   |

👋 مې \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in coss-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published exan bless of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine 👼 rg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www. Bobe-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# Longitudinal trajectories of sedation level and clinical outcomes in patients who are mechanically ventilated based on a group-based trajectory model: a prospective, multicenter, longitudinal, and observational study in Korea

| Journal:                             | BMJ Open   |
|--------------------------------------|--|
| Manuscript ID                        | bmjopen-2023-072628.R2   |
| Article Type:                        | Original research  |
| Date Submitted by the<br>Author:     | 09-Jun-2023  |
| Complete List of Authors:            | Hyun, Dong-gon; Asan Medical Center,<br>Ahn, Jee Hwan; University of Ulsan College of Medicine, Department of<br>Pulmonary and Critical Care Medicine<br>Gil, Ha-Yeong; pzfier<br>Nam, Chung Mo; Yonsei University College of Medicine, Preventive<br>Medicine<br>Yun, Choa; Department of Biostatistics & Computing, College of<br>Medicine, Yonsei University<br>Lim, Chae-Man; University of Ulsan College of Medicine, Department of<br>Pulmonary and Critical Care Medicine |
| <b>Primary Subject<br/>Heading</b> : | Intensive care   |
| Secondary Subject Heading:           | Epidemiology   |
| Keywords:                            | Adult anaesthesia < ANAESTHETICS, EPIDEMIOLOGY, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Thoracic medicine < INTERNAL MEDICINE   |
|                                      | 1  |

# SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Page 2 of 33

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**BMJ** Open

Longitudinal trajectories of sedation level and clinical outcomes in patients who are

| 2  | mechanically ventilated based on a group-based trajectory model: a prospective,   |
|----|---|
| 3  | multicenter, longitudinal, and observational study in Korea   |
| 4  |   |
| 5  | Dong-gon Hyun <sup>1</sup> , Jee Hwan Ahn <sup>1</sup> , Ha-Yeong Gil <sup>2</sup> , Chung Mo Nam <sup>3</sup> , Choa Yun <sup>4</sup> , Chae-Man |
| 6  | Lim <sup>1</sup> *  |
| 7  | <sup>1</sup> Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of   |
| 8  | Ulsan College of Medicine, Seoul, Republic of Korea   |
| 9  | <sup>2</sup> Medical Research Project Team, IM Medical, Pfizer Korea Pharmaceuticals Ltd., Seoul,   |
| 10 | Republic of Korea   |
| 11 | <sup>3</sup> Department of Preventive Medicine, Yonsei University College of Medicine, Seoul,   |
| 12 | Republic of Korea   |
| 13 | <sup>4</sup> Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University   |
| 14 | College of Medicine, Seoul, Republic of Korea   |
| 15 |   |
| 16 | *Corresponding author: Chae-Man Lim, M.D., Ph.D., FCCM  |
| 17 | E-mail: <u>cmlim@amc.seoul.kr</u>   |
| 18 |   |
| 19 | Word Count: 3201  |
| 20 |   |
| 21 |   |
| 22 |   |
| 23 |   |
| 24 |   |
|    |   |

#### ABSTRACT

**Objectives:** Changes in sedation levels over a long time in patients who are mechanically ventilated are unknown. Therefore, we investigated the long-term sedation levels of these patients by classifying them into different longitudinal patterns.

**Design:** This was a multicenter, prospective, longitudinal, and observational study.

Setting: Twenty intensive care units (ICUs) spanning several medical institutions in Korea.

Participants: Patients who received mechanical ventilation and sedatives in ICU within 48 h of admission between April 2020 and July 2021.

**Primary and secondary outcome measures:** The primary objective of this study was to identify the pattern of sedation practice. Additionally, we analyzed the associations of trajectory groups with clinical outcomes as the secondary outcome.

Results: Sedation depth was monitored using Richmond agitation-sedation scale (RASS). A group-based trajectory model was used to classify 631 patients into four trajectories based on sedation depth: persistent suboptimal (13.2%, RASS  $\leq -3$  throughout the first 30 days), delayed lightening (13.9%, RASS  $\geq -2$  after the first 15 days), early lightening (38.4%, RASS  $\geq -2$  after the first 7 days), and persistent optimal (34.6%, RASS  $\geq -2$  during the first 30 days). "Persistent suboptimal" trajectory was associated with delayed extubation (hazard ratio [HR] 0.23, 95% confidence interval [CI] 0.16–0.32, p < 0.001), longer ICU stay (HR 0.36, 95% CI 0.26–0.51, p < 0.001), and hospital mortality (HR 13.62, 95% CI 5.99–30.95, p< 0.001) compared with "persistent optimal". The "delayed lightening" and "early lightening" trajectories showed lower extubation probability (HR 0.30, 95% CI 0.23–0.41, p < 0.001; HR 0.72, 95% CI 0.59–0.87, p < 0.001, respectively) and ICU discharge (HR 0.44, 95% CI 0.33–0.59; p < 0.001 and HR 0.80, 95%CI 0.65–0.97; p = 0.024) compared with "persistently optimal."

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

| 2        |            |  |
|----------|------------|--|
| 3<br>4   | 1          | Conclusions: Among the four trajectories, "persistent suboptimal" trajectory was associated                |
| 4<br>5   |            |  |
| 6        | 2          | with higher mortality.   |
| 7        | 2          |  |
| 8<br>9   | 3          |  |
| 9<br>10  | 4          | Keywords: deep sedation; intensive care units; mortality; critical care; mechanical ventilators            |
| 11       | 4          | <b>Reywords.</b> deep sedation, intensive care units, mortanty, entical care, incenanical ventilators      |
| 12       | 5          |  |
| 13<br>14 | C          |  |
| 15       | 6          | STRENGTHS AND LIMITATIONS OF THIS STUDY  |
| 16       |            |  |
| 17       | 7          | $\Rightarrow$ Large national data from 20 ICUs in Korea representing real-world practice                   |
| 18<br>19 |            |  |
| 20       | 8          | $\Rightarrow$ An investigation into the long-term sedation level in patients who are mechanically          |
| 21       |            |  |
| 22       | 9          | ventilated   |
| 23<br>24 |            |  |
| 25       | 10         | $\Rightarrow$ A group-based trajectory model identifying patterns of sedation over time                    |
| 26       |            |  |
| 27<br>29 | 11         | $\Rightarrow$ Misclassification of nondifferential group as inherent restriction of group-based trajectory |
| 28<br>29 |            |  |
| 30       | 12         | models with limited generalizability   |
| 31       |            |  |
| 32<br>33 | 13         | $\Rightarrow$ Unclear causal relationship between trajectory and outcome                                   |
| 33<br>34 |            |  |
| 35       | 14         |  |
| 36       | 1.7        |  |
| 37<br>38 | 15         |  |
| 39       | 16         |  |
| 40       | 10         |  |
| 41<br>42 | 17         |  |
| 42<br>43 |            |  |
| 44       | 18         |  |
| 45       |            |  |
| 46<br>47 | 19         |  |
| 48       | 20         |  |
| 49       | 20         |  |
| 50       | 21         |  |
| 51<br>52 | 21         |  |
| 53       | 22         |  |
| 54       |            |  |
| 55<br>56 | 23         |  |
| 50<br>57 | <i>.</i> . |  |
| 58       | 24         |  |
| 59<br>60 |            | 3  |
| 60       |            |  |

### **BMJ** Open

## 1 INTRODUCTION

Sedation is crucial to promote tolerance in patients during mechanical ventilation in the intensive care unit (ICU).<sup>1</sup> Previously, ICU patients were considered unnecessarily oversedated, and the tools to assess the depth of sedation varied widely.<sup>2</sup> Inappropriate sedation was associated with adverse outcomes, such as prolonged ventilation, longer ICU stay, and higher post-ICU psychological concerns.<sup>3-6</sup> Over-sedation also predicted long-term mortality in critically ill patients.<sup>7</sup> Considering its essential role in the care of patients who were mechanically ventilated, international guidelines guide to improve sedation practice for favorable outcomes in ICU patients.<sup>8-10</sup> 

Currently, sedation monitoring in the ICU is clinically recommended to achieve low levels of sedation,<sup>11</sup> though real-world implementation is debated.<sup>12</sup> Longitudinal studies on the level of sedation over a long time are limited. Previous national surveys mainly focused on the type of sedatives and assessment tools.<sup>13-16</sup> Moreover, most studies are cross-sectional, evaluating the association between the sedation levels for the first 2–3 days and clinical outcomes.<sup>17</sup> <sup>18</sup> Therefore, we aimed to investigate long-term sedation levels in a national cohort of patients who were mechanically ventilated by classifying them into different longitudinal patterns. We further assessed the association between these patterns and clinical outcomes.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

# 20 METHODS AND ANALYSIS

21 Study design

We conducted a multicenter, prospective, longitudinal, and observational cohort study in 20 ICUs in Korea between April 2020 and July 2021, sponsored by Pfizer Korea Pharmaceuticals Ltd. and involved 30 investigators (Table S1). We designed a harmonized

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

electric case report form that was centrally managed and combined into one database for data entry, day queries, and analysis. During the study period, patients were recruited according to the number of available patients at each ICU. Principal investigators, research staff, and nurses at each participating center were trained in the study procedures. The decisions regarding a patient's care were at the discretion of the attending medical staff. Our inclusion criteria were as follows: patients >19 years of age, who had undergone mechanical ventilation and sedation in the ICU within 48 h and were expected to remain sedated and on mechanical ventilation for >48 h. We excluded patients with a disease that was likely to cause death within 90 days, those whose treatment had been discontinued owing to imminent death or noneffective therapy, and those who needed nonselective deep sedation owing to medical conditions, including brain damage and hemorrhage, spinal cord injury, drug overdose, burns, and nerve root block.

## 14 Monitoring of sedation and measurement of outcome

We monitored sedation depth using the Richmond agitation-sedation scale (RASS), ranging from -5 to +4 every 8 h until ICU discharge or day 30.<sup>19</sup> The daily depth of sedation was calculated as the median RASS value for 1 day. The primary objective of this study was to identify the pattern of sedation practice. Group-based trajectory models have been widely used for analyzing developmental trajectories.<sup>20</sup> They can address the dynamic profile of sedation by classifying patients into different trajectories of sedation level over time. We used a group-based trajectory model analyzing a scale form of RASS over the first 30 days after enrollment. To characterize each trajectory group, an analysis between the trajectory groups and the patients' characteristics was also performed. The secondary objective included associations of trajectory groups with clinical outcomes by adjusting for covariates.

1

| 2  |  |
|--|--|
| 3  |  |
| 4  |  |
| 5  |  |
| 6  |  |
| 7  |  |
| γ<br>Q   |  |
| 0  |  |
| 6<br>7<br>8<br>9<br>10                                   |  |
| 10   |  |
| 11   |  |
| 12   |  |
| 13   |  |
| 12<br>13<br>14<br>15                                     |  |
| 12<br>13<br>14<br>15                                     |  |
| 16   |  |
| 17   |  |
| 18   |  |
| 19   |  |
| 20   |  |
| 21   |  |
| 22   |  |
| 23   |  |
| 16<br>17<br>18<br>19<br>20<br>21<br>22<br>23<br>24<br>25 |  |
| 25   |  |
| 26   |  |
| 27   |  |
| 26<br>27<br>28<br>29<br>30                               |  |
| 20   |  |
| 20   |  |
| 21   |  |
| 31<br>32   |  |
| 32   |  |
| 33   |  |
| 33<br>34<br>35   |  |
| 35   |  |
| 36   |  |
| 36<br>37   |  |
| 38   |  |
| 39   |  |
| 40   |  |
| 41   |  |
| 42   |  |
| 43   |  |
| 44   |  |
| 45   |  |
| 46   |  |
| 47   |  |
| 48   |  |
| 49   |  |
| 50   |  |
| 51   |  |
| 52   |  |
| 53   |  |
| 55<br>54   |  |
| 54<br>55   |  |
| 55<br>56   |  |
|  |  |
| 57   |  |
| 58   |  |
| 59   |  |
| 60   |  |
|  |  |

# 2 Covariates

3 Demographic, clinical, and laboratory data, including age, gender, reason for ICU 4 admission, type of ICU admission, comorbidities, and illness severity (acute physiology and 5 chronic health evaluation [APACHE] I score), were collected. Moderate-to-severe liver 6 disease was defined as cirrhosis and portal hypertension with or without variceal bleeding 7 history. Moderate-to-severe chronic kidney disease was defined as serum creatinine >3 8 mg/dL or on dialysis or post-kidney transplant status or uremia status. The need for 9 vasopressors, renal replacement therapy, and neuromuscular blockade was also recorded. We 10 collected and calculated the daily cumulative dose and the number of days prescribed for the 11 sedatives and analgesics administered to patients during their ICU stay. Patients were 12 followed-up until hospital discharge, death, or day 30 in the ICU. Clinical outcomes, 13 including ICU discharge, ventilator days, and survival status, were recorded.

14

# 15 **Patient and public involvement**

16 The patient and public were not involved in the design, conduct, reporting, or 17 dissemination plans of this research. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

18

## 19 Sample size

The sample size was initially calculated for the study to evaluate the difference in ICU lengths of stay between patients with early deep sedation and with early light sedation.<sup>21</sup> Considering previous results reporting that the hazard ratio (HR) of ICU length between the sedation group (n = 70) and non-sedation group (n =70) was 1.86 (95% CI 1.05–3.23), the following values were required to calculate the number of subjects: $S_{Deep Sedation} = e^{-\lambda_{Deep} * t}$ 

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

 $= e^{-0.03 * 28} = 0.43$ ,  $S_{Light Sedation} = e^{-\lambda_{Light} * t} = e^{-0.02 * 28} = 0.57$ , and HR = 1.5.<sup>22</sup> The importance of the two-sided test was set at 5%, the power was 80%, and the ratio between the light and deep sedation groups was set at 3:7. The sample size was inflated by approximately 30% to account for attrition. No interim efficacy analyses were planned. Finally, 660 patients were planned. Thereafter, this study to classify the pattern of sedation over time was conducted by using this sample.

Statistical analysis

9 The pattern of sedation over time was described using a group-based trajectory model 10 that identified differential patterns of individual change in the population. The parameters of 11 GBTM are generated by maximum likelihood estimation. The ultimate objective is to 12 estimate a set of parameters,  $\Omega$ , that maximize the probability of  $Y_i = (y_{i1},...,y_{it})$ . The 13 equation describing the likelihood of an individual's observed repeated measures comprises 14 two elements: (1) the probability of group membership and (2) the probability of the observed 15 data given group membership. The finite mixture model is defined by

$$P(Y_i) = \sum_k \pi_k P^k(Y_i),$$

17 where *k*: trajectory group, i (= 1,...,N): subject, and j (= 1,...,T): measurement time. The 18 group membership probabilities,

$$\pi_k = e^{ heta_k} / \sum_k e^{ heta_k}$$

k = 1,...,K, are not observed, so estimated by a multinomial logit function. For a given k, conditional independence is assumed for the sequential realizations of the elements of  $Y_i$ ,  $y_{ij}$ , over the *T* periods of measurement. This assumption implies that for each individual within a given trajectory group k, the distribution of  $y_{ij}$  for period *T* is independent of the realized Page 9 of 33

#### **BMJ** Open

level of the outcome in prior periods. The likelihood function is  $L = \prod_{i=1}^{N} P(y_i | z_i, w_i)$  where  $p(y_i|z_i, w_i) = \sum_{k=1}^{K} p(C_i = k | Z_i = z_i) p(Y_i = y_i | C_i = k, W_i = w_i)$ ; the first term is the probability of group membership and the second term is the probability of the observed data membership.  $Y_i = (Y_{i1}, ..., Y_{iT}), Z_i = (Z_{i1}, ..., Z_{iR}), W_i = (W_{i1}, ..., W_{iT}), p =$ given group  $\frac{\exp(\theta_k + \lambda'_k z_i)}{\sum_{k=1}^{K} \exp(\theta_k + \lambda'_k z_i)}, \text{ and } p(Y_i = y_i \mid C_i = k, W_i = w_i), \text{ which is specified by the distribution of } Y_i.$ For count data, it is specified as the zero-inflated Poisson distribution, for censored data, the censored normal distribution and for binary data, it is specified as the binary logit distribution for binary data. In this study, we use a censored normal model. The final model was selected based on a combination of the Bayesian information criterion and the estimated trajectory group proportions that were sufficiently large.

Data are presented as numbers and proportions for categorical variables and as means ± standard deviations or medians (interquartile range) for continuous variables. Differences between groups were analyzed using the  $\chi^2$  test or Fisher's exact test and the independent two-sample t-test or Mann-Whitney U test with a normal or non-normal distribution, as appropriate. The normality of the data was assessed by inspecting histograms. For time-to-event analysis, the Kaplan-Meier method was used to estimate survival curves, whereas a log-rank test was used to test the importance of the differences. Univariable and multivariable Cox proportional hazards regression models were used to identify associations with clinical outcomes by adjusting known prognostic covariates, including age, gender, type of admission, type of ICU, vasopressor, and neuromuscular blockade. The results are presented as HR with 95% confidence interval (CI). Two-sided *p*-values <0.05 indicated significance. All analyses were performed using Statistical Analysis System (SAS) software version 9.4 (SAS Institute, Cary, NC).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**RESULTS** 

In 20 participating centers, 676 patients were recruited from April 2020 to July 2021 (Figure S1). Of them, 45 patients were excluded because of missing data, an RASS date before mechanical ventilation, or were enrolled  $\geq 48$  h after mechanical ventilation. The final cohort included 631 patients. In this study, four-group solutions that best characterized the cohort were identified. A four-group model was chosen for the cohort based on specified selection criteria: trajectory 1 (persistent suboptimal; 13.2% of patients, RASS level  $\leq -3$ throughout the 30 days), trajectory 2 (delayed lightening; 13.9% of patients, RASS level  $\geq -2$ after the first 15 days), trajectory 3 (early lightening; 38.4% of patients, RASS level  $\geq -2$ after the first 7 days), and trajectory 4 (persistent optimal: 34.6%, RASS level  $\geq -2$  during the first 30 days) (Figure 1). The majority of patients in "persistent suboptimal" group were older, with 35.82% in the >80 age group (p-value = 0.002) (Table 1). Conversely, 39.24% and 40.46% of patients in the "early lightening" and "persistent optimal" groups, respectively, were aged between 50 and 69 years. Gender and body weight did not considerably differ between the trajectories. Considering the comorbidities, there was a significant difference in dementia between patients of different trajectories (p-value = 0.010). Although no significant difference was found, the "persistent suboptimal" group had the highest percentage of solid tumor and cerebrovascular disease (38.00%, *p*-value = 0.278; 28.00%, *p*-value = 0.101, respectively), whereas the "delayed lightening" group had the lowest percentage of moderate-to-severe chronic kidney disease (4.61%, p-value = 0.375). The "persistent suboptimal" and "delayed lightening" groups were more likely to be admitted to medical ICU (52.24% and 48.81% versus 34.72% and 31.63%, respectively) with a medical illness (61.19% and 58.33% versus 46.79% and 43.26%, respectively) and less likely

### **BMJ** Open

| 1  | to be admitted to surgical ICU (44.78% and 50.00% versus 59.25% and 66.05%, respectively;                           |
|----|---|
| 2  | p-value = 0.023) for a scheduled surgery (10.45% and 11.90% versus 23.77% and 23.72%,                               |
| 3  | respectively; $p$ -value = 0.001). The most common cause of ICU admission was respiratory                           |
| 4  | (56.8%) in all groups, and the "delayed lightening" group had the highest proportion of                             |
| 5  | respiratory-related admissions (67.86%), whereas the "early lightening" group had the lowest                        |
| 6  | proportion (51.32%, $p$ -value = 0.030). Cardiovascular-related ICU admissions were most                            |
| 7  | common in the "early lightening" group (25.66%, $p$ -value = 0.610), although there was no                          |
| 8  | statistical significance. The APACHE I score was significantly different among the four                             |
| 9  | trajectories (27.82, 25.28, 21.39, and 24.07 for "persistent suboptimal," "delayed lightening,"                     |
| 10 | "early lightening," and "persistent optimal" groups, respectively; $p$ -value < 0.001). As a part                   |
| 11 | of ICU support within the first 48 h, the "delayed lightening" group received the largest                           |
| 12 | number of vasopressor infusions (91.67%, $p$ -value < 0.001), renal replacement therapy                             |
| 13 | (26.19%, p-value = 0.078), and neuromuscular blockade use (46.43%, p-value < 0.001). In-                            |
| 14 | hospital death occurred in 12.2% of patients in the entire cohort. By trajectory, in-hospital                       |
| 15 | mortality was 49.52% in the "persistent suboptimal" group, 21.43% in the "delayed                                   |
| 16 | lightening" group, 6.79% in the "early lightening" group, and 3.72% in the "persistent                              |
| 17 | optimal" group ( $p$ -value < 0.001). Similarly, differences according to the trajectories were                     |
| 18 | observed for ICU discharge and extubation. The proportion of ICU discharge was 67.16%,                              |
| 19 | 79.76%, 92.45%, and 92.09%, respectively ( <i>p</i> -value < 0.001); rate of extubation was 68.16%,                 |
| 20 | 78.57%, 95.47%, and 95.81%, respectively ( $p$ -value < 0.001). Moreover, differences in time                       |
| 21 | to extubation ( <i>p</i> -value $< 0.001$ ), ICU discharge ( <i>p</i> -value $< 0.001$ ), and in-hospital mortality |
| 22 | (p-value < 0.001) were observed among the four trajectories (Figure 2). Table 2 summarizes                          |
| 23 | the representative phenotypes of each trajectory.   |
| 24 | In adjusted Cox proportional hazard analyses, the "persistent suboptimal" (HR =                                     |

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 1  | 13.62, 95% CI 5.99–30.95, <i>p</i> -value $< 0.001$ ) and "delayed lightening" groups (HR = 5.62,          |
|----|--|
| 2  | 95% CI 2.36–13.38, p-value < 0.001) had a significantly higher risk of death than the                      |
| 3  | "persistent optimal" group (Table 3). The "persistent suboptimal" (HR = $0.23$ , 95% CI $0.16$ –           |
| 4  | 0.32, p-value < 0.001), "delayed lightening" (HR = 0.30, 95% CI 0.23–0.41, p-value <                       |
| 5  | 0.001), and "early lightening" groups (HR = 0.72, 95% CI 0.59–0.87, p-value < 0.001)                       |
| 6  | showed a reduced probability of extubation and were less likely to discharge from the ICU                  |
| 7  | (HR = 0.36, 95% CI 0.26–0.51, <i>p</i> -value < 0.001; HR = 0.44, 95% CI 0.33–0.59, <i>p</i> -value <      |
| 8  | 0.001; HR = 0.80, 95% CI 0.65–0.97, $p$ -value = 0.024, respectively) than the "persistent                 |
| 9  | optimal" group. Patients undergoing scheduled surgery showed a higher probability of                       |
| 10 | extubation (HR = 2.13, 95% CI 1.64–2.78, <i>p</i> -value < 0.001) and ICU discharge (HR = 2.10,            |
| 11 | 95% CI 1.59–2.78, <i>p</i> -value $<$ 0.001) than outpatient admissions. Patients in the surgical ICU      |
| 12 | had a lower risk of death (HR = $0.45$ , 95% CI $0.23-0.89$ , <i>p</i> -value = $0.021$ ) than medical ICU |
| 13 | patients. No additional considerable differences were found with respect to age, gender,                   |
| 14 | vasopressor infusions, or neuromuscular blockade.  |

# **DISCUSSION**

To the best of our knowledge, this is the first study to characterize the longitudinal pattern of sedation level over time in patients who are mechanically ventilated. We identified four distinct trajectories of sedation depth in the first 30 days after mechanical ventilation in our patients. Only 34.6% patients were in an optimal depth of sedation during this period, whereas 13.2% were in the suboptimal range of RASS for most of this time, and the remaining patients achieved adequate depth of sedation 7 (early lightening: 38.4%) or 15 (delayed lightening: 13.9%) days after initiation. Patients who were at suboptimal levels of sedation throughout this period had a higher risk of mortality and lower probabilities of

### **BMJ** Open

extubation and ICU discharge than those who were at consistently optimal levels of sedation. Group-based trajectory modeling is useful for characterizing longitudinal courses over time to identify distinct subgroups.<sup>23 24</sup> This trajectory model is used in different domains of clinical research, such as nonadherence spectrum in newly-diagnosed juvenile epilepsy, health status in outpatients with heart failure, neurologic postinjury recovery, and symptom burden nuances of patients with metastatic cancer.<sup>20</sup> Therefore, group-based trajectory modeling is a specialized method for sorting individuals into meaningful subgroups that show statistically similar trajectories.

There were several considerable differences in characteristics between the four trajectory groups. Patients in trajectory 1 (persistent suboptimal) experienced deep sedation throughout the study period, with RASS ranging from -3 to -5. This group was mainly characterized by elderly patients with cognitive impairment, admitted to a medical ICU for treating illnesses, such as respiratory problems, with the worst condition at admission. Conversely, patients in trajectory 2 (delayed lightening) experienced initial deep sedation, which improved to a light depth of RASS -2 after 15 days. This group was characterized by elderly patients with dementia with respiratory failure, receiving vasopressors, neuromuscular blockade, and renal replacement therapy. Interestingly, although the two trajectories had relatively similar characteristics and the "delayed lightening" group even required more ICU support within the first 48 h, the "persistent suboptimal" group had worse time to extubation, ICU discharge, and hospital mortality. These findings suggest that the longitudinal course of sedation depth in our subjects was not associated with the severity of illness; the difference in sedation practice between the two trajectories might have resulted into different outcomes.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

A prospective multicenter study, conducted across 42 international ICUs,
 demonstrated that the time to extubation and mortality increased with sedation intensity.<sup>18</sup> In

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

observational and matched-pair analyses based on the APACHE II score and the type of admission, early deep sedation during the first 48 h of ICU stay was associated with worse outcomes, including long-term mortality.<sup>7</sup> We report similar findings in our study by comparing trajectories 3 and 4 with the earlier trajectories 1 and 2. Patients in trajectory 3 (early lightening) experienced early deep sedation, which became lighter after 7 days, whereas those in trajectory 4 (persistent optimal) experienced light sedation throughout. Patients in these groups (trajectories 3 and 4) were younger, had fewer medical conditions, and were mostly admitted to surgical ICUs than those in the other two groups (trajectories 1 and 2). They also had lower APACHE I scores and needed less ICU support within the first 48 h. The patients in "early lightening" group, especially, had the lowest APACHE score, the lowest proportion of renal replacement therapy, and the fewest respiratory problems. Nevertheless, multivariable Cox proportional hazard analysis showed that patients in this group had a lower probability of extubation and ICU discharge than those in the "persistent optimal" group. The early practice of inadequate sedation in "early lightening" group might have induced this relatively worse prognosis in these patients. A recent meta-analysis assessing the literature on early sedation suggested that interventions targeting the depth of early sedation, starting with ICU admission, could improve patient outcomes.<sup>25</sup> Appropriate sedation is a critical aspect in the management of patients who are mechanically ventilated.

We observed that 65.9% patients in our study were deeply sedated for at least the first week after mechanical ventilation, whereas only 34.07% patients received consistent light sedation throughout the sedation period. This finding is consistent with previous data describing the sedation depth. A multinational survey among intensivists reported that 74% patients monitored using a validated sedation tool were deeply sedated.<sup>26</sup> A survey in Germany found that the actual depth of sedation was considerably deeper (39.5%–62.4%) Page 15 of 33

### **BMJ** Open

than the desired depth in all categories of sedation.<sup>27</sup> A Swedish study investigating the relationship between memory and sedation showed that only 39% of patients who were ventilated achieved their target sedation goal.<sup>28</sup> A previous systematic review estimated the incidence of oversedation in ICUs at 40%-60%, despite the poor quality of epidemiologic data.<sup>2</sup> In a recent study conducted in the emergency department, the incidence of deep sedation was 52.8%.<sup>29</sup> These data suggest that deep sedation remains a common real-world ICU practice. To improve the quality of patient care, further research is warranted focusing on the longitudinal profile in addition to the binary concept of sedation, light versus deep.

Our study has a few limitations. First, information bias may exist because only patients visiting tertiary or university-affiliated hospitals were included in our study. Second, unmeasured confounders could have affected the trajectories, despite many relevant variables in our study. Moreover, the nondifferential group of patients may have been misclassified. This restriction is inherent to group-based trajectory models with limited generalizability. Third, the causal relationship between trajectory and outcome could not be established in this study. For example, it is unclear whether a prolonged duration of extubation reflected the effects of sedative overdose or whether more sedation was needed because of longer mechanical ventilation. However, the strength, consistency, and temporal precedence of the association and agreement with existing evidence of this study suggested the possibility of a causal relationship.<sup>30</sup> Thus, prospective and randomized controlled studies are required to investigate the interaction of the two parameters (depth and duration) of sedation to better define the optimal practice. Fourth, there was a restriction on recruiting patients owing to the COVID-19 crisis. Although the number of patients with mechanical ventilation increased in the COVID-19 era, the lack of staff in the ICU led to a low rate of patient registration. Finally, we were unable to examine the long-term complications in the trajectory groups.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **BMJ** Open

Furthermore, nationwide studies should evaluate long-term complications after sedation to
 comprehensively understand its socioeconomic and clinical burden.

In conclusion, this study captured the four trajectories of sedation level over time in patients who were mechanically ventilated. These patterns were considerably associated with time to extubation, ICU discharge, and hospital mortality. Our findings suggest that the sedation strategy in ICU patients should incorporate a longitudinal pattern of sedation level.

Acknowledgments

9 None

### **Contributors**

12 CML, HYG, and JHA have equally contributed to the study conception and design. Material 13 preparation was performed by HYG. Data collection was performed DH, JHA, and CML. 14 Statistical analysis were performed by CMN and CY. The first draft of the manuscript was 15 written by DH and JHA, and all authors commented on the previous versions of the 16 manuscript. All authors have read and approved the final manuscript.

18 Funding

This study was sponsored by Pfizer Korea Pharmaceuticals Ltd (Grant Number: N/A). The
funding does not interfere with the analysis and interpretation of the data.

**Competing interests** 

Ha-Yeong Gil is an employee of Pfizer Korea. The other authors declare that they have no
competing interests. Pfizer Korea, sponsor of this study, made no influence on study design,

| 2              |    |  |
|----------------|----|--|
| 3<br>4         | 1  | data collection and analysis, and writing.   |
| 5<br>6<br>7    | 2  |  |
| 7<br>8<br>9    | 3  | Patient consent for publication  |
| 10<br>11       | 4  | Not applicable.  |
| 12<br>13       | 5  |  |
| 14<br>15<br>16 | 6  | Ethic approval   |
| 17<br>18       | 7  | The study protocol was approved by the Institutional Review Boards of all                    |
| 19<br>20       | 8  | participating medical centers (B-1911/577-405, AJIRB-MED-OBS-19-372, AJIRB-MED-              |
| 21<br>22<br>22 | 9  | OBS-19-373, 1908-156-1058, 1908-157-1058, 1910-003-083, 2019-1624, 2019-1039, 2019-          |
| 23<br>24<br>25 | 10 | 10-0321, 2019-09-040, 2019-10-162, GCIRB2019-366, DSMC 2019-08-018, HALLYM                   |
| 26<br>27       | 11 | 2019-08-021, HALLYM 2019-08-022, 2019-09-010, 2019-08-082, DAUHIRB-19-166, 4-                |
| 28<br>29       | 12 | 2019-0821, 4-2019-0820, 2019-09-011-002, 2019-07-038-002, CR-19-117-L, 2019AN0376,           |
| 30<br>31<br>32 | 13 | 2019AN0478, 20-2019-92, 20-2019-91, 2019GR0461, 2020GR0103, 2020AS0054). All                 |
| 32<br>33<br>34 | 14 | patients (or patient representatives) provided their written informed consent. Some          |
| 35<br>36       | 15 | participating centers' local review boards waived the need for informed consent considering  |
| 37<br>38       | 16 | the observational nature of this study. This study was conducted per the amended Declaration |
| 39<br>40<br>41 | 17 | of Helsinki.   |
| 42<br>43       | 18 |  |
| 44<br>45       | 19 | Data availability statement  |
| 46<br>47<br>48 | 20 | Data are available on request.   |
| 40<br>49<br>50 | 21 |  |
| 51<br>52       | 22 | References   |
| 53<br>54       | 23 | 1. Richards-Belle A, Canter RR, Power GS, et al. National survey and point prevalence        |
| 55<br>56<br>57 | 24 | study of sedation practice in UK critical care. Crit Care 2016;20:355.                       |
| 57<br>58<br>59 |    | 16   |

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

| 1<br>2         |    |     |   |
|----------------|----|-----|---|
| 2<br>3<br>4    | 1  | 2.  | Jackson DL, Proudfoot CW, Cann KF, Walsh TS. The incidence of sub-optimal                 |
| 5<br>6         | 2  |     | sedation in the ICU: a systematic review. Crit Care 2009;13:R204.                         |
| 7<br>8         | 3  | 3.  | Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care sedation predicts long-       |
| 9<br>10<br>11  | 4  |     | term mortality in ventilated critically ill patients. Am J Respir Crit Care Med           |
| 12<br>13       | 5  |     | 2012;186:724–31.  |
| 14<br>15       | 6  | 4.  | Shehabi Y, Chan L, Kadiman S, et al. Sedation depth and long-term mortality in            |
| 16<br>17<br>18 | 7  |     | mechanically ventilated critically ill adults: a prospective longitudinal multicentre     |
| 19<br>20       | 8  |     | cohort study. Intensive Care Med 2013;39:910-8.   |
| 21<br>22       | 9  | 5.  | Desai SV, Law TJ, Needham DM. Long-term complications of critical care. Crit Care         |
| 23<br>24       | 10 |     | Med 2011;39:371–9.  |
| 25<br>26<br>27 | 11 | 6.  | Burry L, Rose L, McCullagh IJ, Fergusson DA, Ferguson ND, Mehta S. Daily                  |
| 28<br>29       | 12 |     | sedation interruption versus no daily sedation interruption for critically ill adult      |
| 30<br>31       | 13 |     | patients requiring invasive mechanical ventilation. Cochrane Database Syst Rev            |
| 32<br>33<br>34 | 14 |     | 2014;2014:CD009176.   |
| 35<br>36       | 15 | 7.  | Balzer F, Weiß B, Kumpf O, et al. Early deep sedation is associated with decreased        |
| 37<br>38       | 16 |     | in-hospital and two-year follow-up survival. Crit Care 2015;19:197.                       |
| 39<br>40<br>41 | 17 | 8.  | Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of  |
| 41<br>42<br>43 | 18 |     | pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med |
| 44<br>45       | 19 |     | 2013;41:263–306.  |
| 46<br>47       | 20 | 9.  | Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention   |
| 48<br>49<br>50 | 21 |     | and management of pain, agitation/sedation, delirium, immobility, and sleep               |
| 51<br>52       | 22 |     | disruption in adult patients in the ICU. Crit Care Med 2018;46:e825-73.                   |
| 53<br>54       | 23 | 10. | Pearson SD, Patel BK. Evolving targets for sedation during mechanical ventilation.        |
| 55<br>56<br>57 | 24 |     | Curr Opin Crit Care 2020;26:47–52.  |
| 58<br>59       |    |     |   |
| 60             |    |     | 17  |

# BMJ Open

| 2<br>3         |    |     |   |
|----------------|----|-----|---|
| 4              | 1  | 11. | Guérin C. Calming down about sedation in critically ill patients. N Engl J Med          |
| 5<br>6         | 2  |     | 2020;382:1162–4.  |
| 7<br>8<br>9    | 3  | 12. | Owen GD, Stollings JL, Rakhit S, et al. International analgesia, sedation, and delirium |
| 10<br>11       | 4  |     | practices: a prospective cohort study. J Intensive Care 2019;7:25.                      |
| 12<br>13       | 5  | 13. | Yassin SM, Terblanche M, Yassin J, McKenzie CA. A web-based survey of United            |
| 14<br>15<br>16 | 6  |     | Kingdom sedation practice in the intensive care unit. J Crit Care 2015;30:436.e1-       |
| 16<br>17<br>18 | 7  |     | 436.e6.   |
| 19<br>20       | 8  | 14. | Sneyers B, Laterre PF, Perreault MM, Wouters D, Spinewine A. Current practices and      |
| 21<br>22       | 9  |     | barriers impairing physicians' and nurses' adherence to analgo-sedation                 |
| 23<br>24<br>25 | 10 |     | recommendations in the intensive care unita national survey. Crit Care 2014;18:655.     |
| 26<br>27       | 11 | 15. | Wøien H, Stubhaug A, Bjørk IT. Analgesia and sedation of mechanically ventilated        |
| 28<br>29       | 12 |     | patients - a national survey of clinical practice. Acta Anaesthesiol Scand 2012;56:23-  |
| 30<br>31<br>22 | 13 |     | 9.  |
| 32<br>33<br>34 | 14 | 16. | García-Sánchez M, Caballero-López J, Ceniceros-Rozalén I, et al. Management of          |
| 35<br>36       | 15 |     | analgesia, sedation and delirium in Spanish Intensive Care Units: A national two-part   |
| 37<br>38       | 16 |     | survey. Med Intensiva (Engl Ed) 2019;43:225-33.   |
| 39<br>40<br>41 | 17 | 17. | Tanaka LM, Azevedo LC, Park M, et al. Early sedation and clinical outcomes of           |
| 42<br>43       | 18 |     | mechanically ventilated patients: a prospective multicenter cohort study. Crit Care     |
| 44<br>45       | 19 |     | 2014;18:R156.   |
| 46<br>47<br>48 | 20 | 18. | Shehabi Y, Bellomo R, Kadiman S, et al. Sedation intensity in the first 48 hours of     |
| 49<br>50       | 21 |     | mechanical ventilation and 180-day mortality: A multinational prospective               |
| 51<br>52       | 22 |     | longitudinal cohort study. Crit Care Med 2018;46:850–9.                                 |
| 53<br>54       |    |     |   |
| 55<br>56       |    |     |   |
| 57<br>58       |    |     |   |

| 1<br>2         |    |     |   |
|----------------|----|-----|---|
| -<br>3<br>4    | 1  | 19. | Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU          |
| 5<br>6         | 2  |     | patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS).       |
| 7<br>8<br>9    | 3  |     | JAMA 2003;289:2983–91.  |
| 9<br>10<br>11  | 4  | 20. | Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab                    |
| 12<br>13       | 5  |     | 2014;65:205–10.   |
| 14<br>15       | 6  | 21. | Hyun DG, Ahn JH, Gil HY, et al. The profile of early sedation depth and clinical          |
| 16<br>17<br>18 | 7  |     | outcomes of mechanically ventilated patients in Korea. J Korean Med Sci                   |
| 19<br>20       | 8  |     | 2023;38:e141.   |
| 21<br>22       | 9  | 22. | Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients     |
| 23<br>24<br>25 | 10 |     | receiving mechanical ventilation: a randomised trial. Lancet 2010;375:475-80.             |
| 25<br>26<br>27 | 11 | 23. | Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu           |
| 28<br>29       | 12 |     | Rev Clin Psychol 2010;6:109–38.   |
| 30<br>31       | 13 | 24. | Nagin D, Tremblay RE. Trajectories of boys' physical aggression, opposition, and          |
| 32<br>33<br>34 | 14 |     | hyperactivity on the path to physically violent and nonviolent juvenile delinquency.      |
| 35<br>36       | 15 |     | Child Dev 1999;70:1181–96.  |
| 37<br>38       | 16 | 25. | Stephens RJ, Dettmer MR, Roberts BW, et al. Practice patterns and outcomes                |
| 39<br>40<br>41 | 17 |     | associated with early sedation depth in mechanically ventilated patients: A systematic    |
| 42<br>43       | 18 |     | review and meta-analysis. Crit Care Med 2018;46:471–9.                                    |
| 44<br>45       | 19 | 26. | Luetz A, Balzer F, Radtke FM, et al. Delirium, sedation and analgesia in the intensive    |
| 46<br>47<br>48 | 20 |     | care unit: a multinational, two-part survey among intensivists. PLOS ONE                  |
| 48<br>49<br>50 | 21 |     | 2014;9:e110935.   |
| 51<br>52       | 22 | 27. | Martin J, Franck M, Fischer M, Spies C. Sedation and analgesia in German intensive        |
| 53<br>54       | 23 |     | care units: how is it done in reality? Results of a patient-based survey of analgesia and |
| 55<br>56<br>57 | 24 |     | sedation. Intensive Care Med 2006;32:1137-42.   |
| 58<br>59       |    |     | 10  |
| 60             |    |     | 19  |

| 3<br>4         | 1  | 28. | Samuelson K, Lundberg D, Fridlund B. Memory in relation to depth of sedation in     |
|----------------|----|-----|---|
| 5<br>6         | 2  |     | adult mechanically ventilated intensive care patients. Intensive Care Med           |
| 7<br>8         | 3  |     | 2006;32:660–7.  |
| 9<br>10<br>11  | 4  | 29. | Fuller BM, Roberts BW, Mohr NM, et al. The ED-SED Study: a Multicenter,             |
| 12<br>13       | 5  |     | Prospective Cohort Study of Practice Patterns and Clinical Outcomes Associated With |
| 14<br>15       | 6  |     | Emergency Department SEDation for Mechanically Ventilated Patients. Crit Care       |
| 16<br>17<br>18 | 7  |     | Med 2019;47:1539–48.  |
| 19<br>20       | 8  | 30. | Hill AB. The environment and disease: association or causation? 1965. J R Soc Med   |
| 21<br>22       | 9  |     | 2015;108:32–7.  |
| 23<br>24<br>25 | 10 |     |   |
| 26<br>27       | 11 |     |   |
| 28<br>29       | 12 |     |   |
| 30<br>31<br>32 | 13 |     |   |
| 33<br>34       | 14 |     |   |
| 35<br>36       | 15 |     |   |
| 37<br>38<br>39 | 16 |     | 2015;108:32–7.  |
| 40<br>41       | 17 |     |   |
| 42<br>43       | 18 |     |   |
| 44<br>45<br>46 | 19 |     |   |
| 47<br>48       | 20 |     |   |
| 49<br>50       | 21 |     |   |
| 51<br>52<br>53 | 22 |     |   |
| 54<br>55       | 23 |     |   |
| 56<br>57       | 24 |     |   |
| 58<br>59<br>60 |    |     | 20  |
|                |    |     |   |

| 2              |    |   |
|----------------|----|---|
| -<br>3<br>4    | 1  |   |
| 5<br>6         | 2  |   |
| 7<br>8         | 3  |   |
| 9<br>10        | 4  | Figure legends  |
| 11<br>12<br>13 | 5  | Figure 1 Trajectories of longitudinal Richmond Agitation-Sedation Scale in the first 30 days        |
| 14<br>15       | 6  | of sedation for mechanical ventilation. The percentage of patients included in each trajectory      |
| 16<br>17       | 7  | was presented in central illustration. Outcome of y-axis indicates the score of Richmond            |
| 18<br>19<br>20 | 8  | Agitation-Sedation Scale and T of x-axis represents day after the initiation of sedation.           |
| 20<br>21<br>22 | 9  |   |
| 23<br>24       | 10 | Figure 2 Kaplan–Meier of clinical outcomes from admission according to the trajectory               |
| 25<br>26<br>27 | 11 | groups. (a) time to extubation in the intensive care unit, (b) length of stay in the intensive care |
| 27<br>28<br>29 | 12 | unit, and (c) in-hospital mortality.  |
| 30             |    | unit, and (c) in-hospital mortality.  |
| 31<br>32       |    |   |
| 33             |    |   |
| 34             |    |   |
| 35             |    |   |
| 36<br>37       |    |   |
| 38             |    |   |
| 39             |    |   |
| 40             |    |   |
| 41             |    |   |
| 42<br>43       |    |   |
| 44             |    |   |
| 45             |    |   |
| 46             |    |   |
| 47<br>48       |    |   |
| 40<br>49       |    |   |
| 50             |    |   |
| 51             |    |   |
| 52             |    |   |
| 53<br>54       |    |   |
| 54<br>55       |    |   |
| 56             |    |   |
| 57             |    |   |
| 58<br>59       |    |   |
| 59<br>60       |    | 21  |
| 50             |    |   |

Page 23 of 33

# BMJ Open

| Table 1 Baseline Characteristics and C | linical Outcomes for t | he Total Cohort and for | · Fach Trajectory of th | e Richmond Agietio  | Sedation Scale                        |                 |
|--|------------------------|-------------------------|-------------------------|---|---------------------------------------|-----------------|
| Tuble T Busenne Characteristics and C  |                        |                         |                         | ory group   |                                       |                 |
| Characteristic                         | All (N = $631$ )       | 1 (N = 67)              | 2 (N = 84)              | 3 (N = 265)   | 4 (N = 215)                           | <i>p</i> -value |
| Age                                    |                        |                         |                         |   | X                                     | 0.002           |
| 20–29                                  | 11 (1.74%)             | 0 (0.00%)               | 2 (2.38%)               | 6 (2.26%) <b>S II S</b>   | 3 (1.40%)                             |                 |
| 30–39                                  | 34 (5.39%)             | 0 (0.00%)               | 2 (2.38%)               |   | <b>3</b> 20 (9.30%)                   |                 |
| 40–49                                  | 44 (6.97%)             | 3 (4.48%)               | 11 (13.10%)             | 13 (4.91%) tem  | 3<br>17 (7.91%)                       |                 |
| 50–59                                  | 92 (14.58%)            | 6 (8.96%)               | 6 (7.14%)               | 44 (16.60%) 6 1 4   |                                       |                 |
| 60–69                                  | 140 (22.19%)           | 12 (17.91%)             | 17 (20.24%)             | 60 (22.64%) <b>t</b>  |                                       |                 |
| 70–79                                  | 177 (28.05%)           | 22 (32.84%)             | 23 (27.38%)             | 80 (30.19%) an er   |                                       |                 |
| ≥80                                    | 133 (21.08%)           | 24 (35.82%)             | 23 (27.38%)             | 50 (18.87%) d eu  | 36 (16.74%)                           |                 |
| Male gender                            | 404 (64.0)             | 44 (65.67)              | 57 (67.86)              | 165 (62.26)   |                                       | 0.807           |
| Body weight, kg*                       | 62.0 (53.0-71.0)       | $62.25 \pm 10.69$       | 62.81 ± 13.31           | 62.51 ± 13.01   |                                       | 0.785           |
| Comorbidity                            | 448 (71.00)            | 50 (74.62)              | 65 (77.38)              | 183 (69.05) in .  |                                       | 0.434           |
| Diabetes with end-organ damage         | 30 (4.31)              | 2 (4.00)                | 2 (3.07)                | 14 (7.65) <b>&gt;</b>   | 2                                     | 0.573           |
| COPD                                   | 60 (8.6)               | 7 (14.00)               | 8 (12.30)               |   | 20 (13.33)                            | 0.994           |
| Congestive heart failure               | 49 (7.0)               | 3 (6.00)                | 7 (10.76)               | 25 (13.66) <b>trained</b><br>19 (10.38) <b>n</b><br>9 (4.91) <b>g</b><br>18 (9.83) <b>n</b> | 20 (13.33)                            | 0.596           |
| Moderate-to-severe liver disease**     | 27 (3.8)               | 3 (6.00)                | 3 (4.61)                | 9 (4.91)  | 12 (8.00)                             | 0.681           |
| Moderate-to-severe CKD**               | 46 (6.6)               | 5 (10.00)               | 3 (4.61)                | 18 (9.83) <b>D</b>  | 20 (13.33)                            | 0.375           |
| Solid tumor                            | 127 (18.2)             | 19 (38.00)              | 15 (23.07)              | 48 (26.22) <b>S</b>   | 45 (30.00)                            | 0.278           |
| Dementia                               | 35 (5.0)               | 6 (12.00)               | 9 (13.84)               | 16 (8.74) <b>a</b>  | 4 (3.00)                              | 0.010           |
| Cerebrovascular disease/TIA            | 82 (11.7)              | 14 (28.00)              | 14 (21.53)              | 28 (15.30) <b>g</b>   | 26 (17.33)                            | 0.101           |
| Type of admission                      |                        |                         |                         | hno   |                                       | 0.023           |
| Medical                                | 307 (48.6)             | 41 (61.19)              | 49 (58.33)              | 124 (46.79) <b>g</b>  | 93 (43.26)                            |                 |
| Emergency surgery                      | 193 (30.5)             | 19 (28.36)              | 25 (29.76)              | 78 (29.43)  | ה ה ה ה ה ה ה ה ה ה ה ה ה ה ה ה ה ה ה |                 |
| Scheduled surgery                      | 131 (20.7)             | 7 (10.45)               | 10 (11.90)              | 63 (23.77)  | 51 (23.72)                            |                 |
| Type of ICU                            |                        |                         |                         | 63 (23.77)<br>92 (34.72)  |                                       | 0.001           |
| Medical ICU                            | 236 (37.4)             | 35 (52.24)              | 41 (48.81)              | 92 (34.72)  | 68 (31.63)                            |                 |
| Surgical ICU                           | 371 (58.8)             | 30 (44.78)              | 42 (50.00)              | 157 (59.25)   |                                       |                 |

d by copyrig bmjopen-202

| Others                             | 24 (3.8)        | 2 (2.99)     | 1 (1.19)          | 16 (6.04) C              | 5 (2.33)            |         |
|------------------------------------|-----------------|--------------|-------------------|--------------------------|---------------------|---------|
| Reason for ICU admission***        |                 |              |                   |                          |                     |         |
| Renal                              | 16 (2.5)        | 1 (1.49)     | 0 (0.00)          | 7 (2.64) <b>5</b>        | 8 (3.72)            | 0.294   |
| Digestive                          | 83 (13.1)       | 10 (14.93)   | 12 (14.29)        | 28 (10.57) <b>5</b> m    | N                   | 0.434   |
| Cardiovascular                     | 147 (23.3)      | 15 (22.39)   | 16 (19.05)        | 68 (25.66) <b>B S</b>    | <b>e</b> 48 (22.33) | 0.610   |
| Hematologic                        | 14 (2.2)        | 2 (2.99%)    | 3 (3.57%)         | 4 (1.51%) reign          | <b>5</b> (2.33%)    | 0.679   |
| Respiratory                        | 359 (56.8)      | 43 (64.18%)  | 57 (67.86%)       | 136 (51.32%)             | μ 123 (57.21%)      | 0.030   |
| Miscellaneous                      | 67 (10.6)       | 3 (4.48%)    | 11 (13.10%)       | 34 (12.83%) <b>6 ht</b>  | <b>Q</b> 19 (8.84%) | 0.152   |
| Neurologic                         | 12 (1.9)        | 3 (4.48%)    | 1 (1.19%)         | 4 (1.51%) <b>X</b>       | <b>4</b> (1.86%)    | 0.418   |
| Others                             | 105 (16.6)      | 11 (16.42%)  | 13 (15.48%)       | 42 (15.85%) an er.       |                     | 0.907   |
| APACHE II, score*                  | $23.4 \pm 10.0$ | 27.82 ± 9.73 | $25.28 \pm 11.45$ | 21.39 ± 9.59 a           | 24.07 ± 9.56        | < 0.001 |
| ICU support within first 48 hours  |                 |              |                   | (AB                      | 0<br>m              |         |
| Vasopressor infusions              | 486 (77.02)     | 57 (85.07)   | 77 (91.67)        | 199 (75.09) <b>ni ES</b> | 153 (71.16)         | < 0.001 |
| Renal replacement                  | 107 (16.9)      | 11 (16.42)   | 22 (26.19)        | 37 (13.96) g.            | 37 (17.21)          | 0.078   |
| Neuromuscular blockade             | 171 (27.1)      | 27 (40.30)   | 39 (46.43)        | 69 (26.04) <b>≥</b>      | 36 (16.74)          | < 0.001 |
| Clinical outcomes                  |                 | L C          |                   | trai                     | pe                  |         |
| In-hospital mortality              | 77 (12.2)       | 33 (49.52)   | 18 (21.43)        | 18 (6.79) <b>ni</b>      | 8 (3.72)            | < 0.001 |
| ICU discharge                      | 555 (87.9)      | 45 (67.16)   | 67 (79.76)        | 245 (92.45) ق            | 198 (92.09)         | < 0.001 |
| Extubation                         | 571 (90.4)      | 46 (68.66)   | 66 (78.57)        | 253 (95.47) d            | 206 (95.81)         | < 0.001 |
| Length of ventilator support, days | 5 (3-11)        | 11 (20–NE)   | 11.5 (7–23.5)     | <u> </u>                 | <b>g</b> 3 (2–5)    | < 0.001 |
| ICU length of stay, days           | 10 (5-18)       | 20 (12–NE)   | 18 (10-26)        |                          |                     | < 0.001 |

Data are reported as mean  $\pm$  standard deviation or median (interquartile range) for continuous variables and number (perce  $\frac{1}{2}$  as  $\frac{1}{2}$  or categorical variables. \*Data on body weight are presented for all 605 patients, excluding 26 patients with missing data (4 in the light sedation group and 22 in the deep sedation group). Data on APACHE I are presented for all 577 patients, excluding 54 patients with missing data (15 in the light sedation group and  $\frac{2}{9}$  in the deep sedation group). \*\* Moderate-to-severe liver disease is defined as cirrhosis and portal hypertension with or without variceal bleeding histor & Moderate-to-severe CKD is defined as serum at creatinine > 3 mg/dL or on dialysis or post-kidney transplant status or uremia status. õ

 \*\*\*172 patients had multiple reasons for ICU admission. ICU = intensive care unit; SMD = standardized mean difference; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; TIA = transient ischemic attack; APACHE II = acute physiology and chronic health evaluation II; NE = not estimated Bibliographique de l


| Page | 25 | of | 33 |
|------|----|----|----|
|------|----|----|----|

### **BMJ** Open

d by copyrigh bmjopen-202

|  | Trajectory 1  | Trajectory 2  | Trajectory 3   | 23-072628 or                    | Trajectory 4                                 |
|--|---|---|--|---------------------------------|--|
| Demographics   |   |   |  |                                 |  |
| Age  | 70–79 & ≥80   | 70–79 <b>&amp;</b> ≥80  | 60–69 & 70–-79<br>Male   | 9 7<br>L_L                      | 60–69 & 70–-79                               |
| Gender   | Male  | Male  | Male   | ses<br>ses                      | Male   |
| Comorbidity  | Solid tumor, CVD/TIA,<br>COPD   | Solid tumor, CVD/TIA, Dementia  | Solid tumor,<br>COPD<br>Surgical ICU<br>Respiratory & Ca<br>3rd<br>2nd | reignen<br>2020/TIA,<br>reignen | Solid tumor, CVD/TIA, C                      |
| Type of ICU  | Medical ICU   | Surgical ICU  | Surgical ICU   |                                 | Surgical ICU                                 |
| Reason for ICU admission   | Respiratory & Cardiovascular  | Respiratory & Cardiovascular  | Respiratory & Ca   | ascular                         | Respiratory & Cardiovas                      |
| Ranks for characteristics  | Ur  | ·   |  |                                 |  |
| Medical admission  | 1st   | 2nd   | 3rd  | led<br>pried                    | 4th  |
| Scheduled surgery  | 4th   | 3rd   | 2nd  | l from ht<br>ur (ABE            | 1st  |
| АРАСНЕ П   | 1st   | 2nd   | 4th  |                                 | 3rd  |
| Vasopressor infusions  | 2nd   | lst   | 3rd  | nin<br>S)                       | 4th  |
| Renal replacement therapy  | 3rd   | 1st   | 4th  |                                 | 2nd  |
|  | 2nd   | 1st   | 3rd  |                                 | 4th  |
| Neuromuscular blockade<br>Representative demographics w<br>determined by the comparison o<br>ICU = intensive care unit; APA<br>chronic obstructive pulmonary d | ith more than half of the patients<br>f proportion of variable within each<br>CHE $II$ = acute physiology and c | on each trajectory, except age on trajectory. Trajectories are ordered thronic health evaluation $II$ ; CVD = | ajectory 4, are sho<br>from lowest (4th) to<br>cardiovascular dis      | highest (1st)<br>ase, TIA = tr  | e. Rank-order of trajectoric<br>rank values. |
| Representative demographics w<br>determined by the comparison o<br>ICU = intensive care unit; APA  | ith more than half of the patients<br>f proportion of variable within each<br>CHE $II$ = acute physiology and c | on each trajectory, except age on tr<br>h trajectory. Trajectories are ordered                                | ajectory 4, are sho<br>from lowest (4th) to<br>cardiovascular dis      | ind similar technologie         | e. Rank-order of trajectoric rank values.    |
| Representative demographics w<br>determined by the comparison o<br>ICU = intensive care unit; APA  | ith more than half of the patients<br>f proportion of variable within each<br>CHE $II$ = acute physiology and c | on each trajectory, except age on tr<br>h trajectory. Trajectories are ordered                                | ajectory 4, are sho<br>from lowest (4th) to<br>cardiovascular dis      | highest (1st)<br>ase, TIA = tr  | e. Rank-order of trajector rank values.      |

|                        | Time to extu     | bation          | Time to ICU d    | ischarge        | di                            | bmjopen-2023-072628<br>Time to in-hos                 | pital death     |
|------------------------|------------------|-----------------|------------------|-----------------|-------------------------------|---|-----------------|
|                        | HR (95% CI)      | <i>p</i> -value | HR (95% CI)      | <i>p</i> -value | d by copyright, including for | <del>2</del><br>HR (95% CI)                           | <i>p</i> -value |
| Trajectory group       |                  |                 |                  |                 | or us                         | 27<br>  |                 |
| Group 1                | 0.23 (0.16-0.32) | < 0.001         | 0.36 (0.26–0.51) | < 0.001         | Ises                          | <b>5</b> 13.62 (5.99–30.95)                           | < 0.001         |
| Group 2                | 0.30 (0.23–0.41) | < 0.001         | 0.44 (0.33–0.59) | < 0.001         | rel                           | 8.62 (2.36–13.38)                                     | < 0.001         |
| Group 3                | 0.72 (0.59–0.87) | < 0.001         | 0.80 (0.65–0.97) | 0.024           | atec                          | <b>5</b> .62 (2.36–13.38)<br><b>5</b> .76 (0.76–4.08) | 0.185           |
| Group 4                | Reference        |                 | Reference        |                 | l t 🖁                         | Reference   |                 |
| Age                    |                  |                 |                  |                 | tex                           | a<br>Reference  |                 |
| 20–29                  | Reference        |                 | Reference        |                 | t an                          | Reference   |                 |
| 30–39                  | 1.08 (0.53–2.21) | 0.825           | 0.70 (0.35-1.42) | 0.334           | d d                           | <b>1</b> .69 (0.06–7.72)                              | 0.765           |
| 40–49                  | 0.89 (0.43–1.81) | 0.748           | 0.63 (0.31–1.25) | 0.188           | ata                           | <b>9</b> 0.59 (0.06–5.28)                             | 0.641           |
| 50–59                  | 1.04 (0.53–2.03) | 0.893           | 0.65 (0.34–1.23) | 0.192           | mir                           | 0.41 (0.04–3.46)                                      | 0.414           |
| 60–69                  | 1.00 (0.52–1.93) | 0.987           | 0.79 (0.42–1.48) | 0.469           |                               | 0.88 (0.11-6.75)                                      | 0.905           |
| 70–79                  | 1.04 (0.54–1.99) | 0.893           | 0.64 (0.34–1.20) | 0.170           | , AI                          | <b>3</b> .47 (0.06–3.65)                              | 0.473           |
| ≥80                    | 0.85 (0.44–1.64) | 0.632           | 0.53 (0.28–1.00) | 0.052           | tra                           | 0.82 (0.10-6.26)                                      | 0.850           |
| Female                 | 0.85 (0.71–1.01) | 0.075           | 0.98 (0.81-1.17) | 0.848           | ining,                        | <b>2</b> .17 (0.73–1.89)                              | 0.50            |
| Type of admission      |                  |                 |                  |                 | 6                             | mj.   |                 |
| Medical                | Reference        |                 | Reference        |                 | nd                            | Reference   |                 |
| Emergency surgery      | 1.02 (0.79–1.32) | 0.839           | 1.17 (0.90–1.53) | 0.234           | sim                           | <b>o</b> l.35 (0.62–2.91)                             | 0.444           |
| Scheduled surgery      | 2.13 (1.64–2.78) | < 0.001         | 2.10 (1.59–2.78) | < 0.001         |                               | <b>2</b> 1.91 (0.87–4.16)                             | 0.102           |
| Type of ICU            |                  |                 |                  |                 | tec                           | Ine   |                 |
| Medical ICU            | Reference        |                 | Reference        |                 | hnc                           | Reference   |                 |
| Surgical ICU           | 1.05 (0.83–1.33) | 0.629           | 0.87 (0.68–1.12) | 0.299           | hnolog                        | <b>2</b> .45 (0.23–0.89)                              | 0.021           |
| Others                 | 1.53 (0.96–2.40) | 0.068           | 1.28 (0.80–2.06) | 0.289           | ies.                          | <b>a</b> 0.55 (0.12–2.47)                             | 0.441           |
| Vasopressor infusions  | 0.85 (0.69–1.04) | 0.116           | 0.85 (0.69–1.04) | 0.122           |                               | A.25 (0.62–2.51)<br>1.42 (0.88–2.29)                  | 0.529           |
| Neuromuscular blockade | 1.05 (0.86–1.28) | 0.586           | 0.88 (0.72–1.07) | 0.217           |                               | <b>9</b> 42 (0 88–2 29)                               | 0.148           |








Figure 2. Kaplan–Meier of clinical outcomes from admission according to the trajectory groups. (a) time to extubation in the intensive care unit, (b) length of stay in the intensive care unit, and (c) in-hospital mortality.

199x112mm (600 x 600 DPI)

#### **BMJ** Open

Longitudinal trajectories of sedation level and clinical outcomes in mechanically ventilated patients: a prospective, multicenter, longitudinal, observational study

Dong-gon Hyun, M.D.<sup>1</sup>, Jee Hwan Ahn, M.D.<sup>1</sup>, Ha-Yeong Gil, M.S.<sup>2</sup>, Chung Mo Nam, Ph.D.<sup>3</sup>, Choa Yun, M.S.<sup>4</sup>, Chae-Man Lim, M.D., Ph.D.<sup>1</sup>\*

<sup>1</sup>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>2</sup>Medical Research Project Team, IM Medical, Pfizer Korea Pharmaceuticals Ltd., Seoul, Republic of Korea

<sup>3</sup>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

<sup>4</sup>Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea

\*Corresponding author: Chae-Man Lim, M.D., Ph.D., FCCM

E-mail: <u>cmlim@amc.seoul.kr</u>

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 1        |
|----------|
| 2        |
| 3        |
| 4        |
| 5        |
| 6        |
| 7        |
| 8        |
| 9        |
| 10       |
| 11       |
| 12       |
| 13       |
| 14       |
| 15<br>16 |
| 17       |
| 18       |
| 19       |
| 20       |
| 21       |
| 22       |
| 23       |
| 24       |
| 25       |
| 26       |
| 27       |
| 28       |
| 29       |
| 30       |
| 31       |
| 32<br>33 |
| 33<br>34 |
| 35       |
| 36       |
| 37       |
| 38       |
| 39       |
| 40       |
| 41       |
| 42       |
| 43       |
| 44       |
| 45       |
| 46<br>47 |
| 47<br>48 |
| 48<br>49 |
| 49<br>50 |
| 50       |
| 52       |
| 53       |
| 54       |
| 55       |
| 56       |
| 57       |
| 58       |
| 59       |
| 60       |

60

| City     | Participating hospitals                  | Investigators                |
|----------|--|------------------------------|
| Seoul    | Asan Medical Center                      | Dong-gon Hyun, Jee Hwan Ahn, |
|          |  | Suk-Kyung Hong, Chae-Man     |
|          |  | Lim                          |
| Seoul    | Seoul National University Hospital       | Sang-Min Lee, Ho-Geol Ryu    |
| Seoul    | Samsung Medical Center                   | Gee Young Suh, Chi Min Park  |
| Seoul    | Severance Hospital                       | Su Hwan Lee, Jeoung Min Kim  |
| Seoul    | Seoul St. Mary's Hospital                | Seok Chan Kim                |
| Seoul    | Korea University Anam Hospital           | Won Jai Jung, Jae-Myeong Lee |
| Seoul    | Korea University Guro Hospital           | Young-Seok Lee, Nak-Jun Choi |
| Seoul    | Seoul National University Boramae        | Taeyun Park                  |
|          | Medical Center                           |                              |
| Seongnam | Seoul National University Bundang        | Dong Jung Kim                |
| _        | Hospital                                 |                              |
| Suwon    | Ajou University School of Medicine       | Keu Sung Lee, Young-Gi Min   |
| Busan    | Pusan National University Hospital       | Jae Hun Kim                  |
| Busan    | Dong-A University Hospital               | Dong-Hyun Lee                |
| Busan    | Inje University Haeundae Paik Hospital   | Hang-Jea Jang, Ki Hoon Kim   |
| Wonju    | Yonsei University Wonju College of       | Seok Jeong Lee               |
|          | Medicine                                 |                              |
| Incheon  | Gachon University Gil Medical Center     | Woo-Sung Choi                |
| Daegu    | Keimyung University School of Medicine   | Jae-Bum Kim                  |
| Daegu    | Yeungnam University Medical Center       | Eun Young Choi, Jong-Hyun    |
|          |  | Baek                         |
| Daegu    | Daegu Catholic University Medical Center | Eun Jin Kim                  |
| Anyang   | Hallym University Sacred Heart Hospital  | Sunghoon Park, Hyung Won     |
| _        |  | Kim                          |
| Ansan    | Korea University Ansan Hospital          | Je Hyeong Kim                |

# Table S1. Participating intensive care units


| 1<br>2   |  |
|----------|--|
| 3        |  |
| 4<br>5   |  |
| 6<br>7   |  |
| 8<br>9   |  |
| 10<br>11 |  |
| 12<br>13 |  |
| 14<br>15 |  |
| 16<br>17 |  |
| 18<br>19 |  |
| 20<br>21 |  |
| 22<br>23 |  |
| 24<br>25 |  |
| 26<br>27 |  |
| 28<br>29 |  |
| 30<br>31 |  |
| 32<br>33 |  |
| 34<br>35 |  |
| 36<br>37 |  |
| 38<br>39 |  |
| 40<br>41 |  |
| 42<br>43 |  |
| 44<br>45 |  |
| 46<br>47 |  |
| 48<br>49 |  |
| 50<br>51 |  |
| 52<br>53 |  |
| 54<br>55 |  |
| 56<br>57 |  |
| 58<br>59 |  |
| 60       |  |

| Table S2. | Profile    | of analgesi | c and sedativ | ve within th | ne first 48 hours |
|-----------|------------|-------------|---------------|--------------|-------------------|
|           | I I OI IIC | or unungeon | e una seaun   |              | to mound          |

| Type of Sedatives        | N = 662                   |
|--------------------------|---------------------------|
| Diazepam                 | 1 (0.2)                   |
| Cumulative dose (µg)     | 2000.0                    |
| Midazolam                | 127 (19.2)                |
| Cumulative dose (µg)     | $64253.9 \pm 133338.1$    |
| Lorazepam                | 14 (2.1)                  |
| Cumulative dose (µg)     | $2750 \pm 1868.3$         |
| Other benzodiazepine     | 19 (2.9)                  |
| Cumulative dose (µg)     | $34294.7 \pm 53960.7$     |
| Propofol                 | 173 (26.1)                |
| Cumulative dose (µg)     | $3444220.1 \pm 2752320.0$ |
| Ketamine                 | 53 (8.0)                  |
| Cumulative dose (µg)     | $1450147.2 \pm 1830958.4$ |
| Haloperidol              | 1 (0.2)                   |
| Cumulative dose (µg)     | 5000.0                    |
| Dexmedetomidine          | 253 (38.2)                |
| Cumulative dose (µg)     | $4080.2 \pm 38325.4$      |
| Other non-benzodiazepine | 21 (3.2)                  |
| Cumulative dose (µg)     | $75659.5 \pm 133078.2$    |
| Type of analgesics       | N = 528                   |
| Fentanyl                 | 119 (22.5)                |
| Cumulative dose (µg)     | $30861.1 \pm 315168.1$    |
| Remifentanil             | 388 (73.5)                |
| Cumulative dose (µg)     | 13227.8 ± 10971.7         |
| Morphine                 | 6 (1.1)                   |
| Cumulative dose (µg)     | $24000.0 \pm 38740.2$     |
| Sufentanil               | 15 (2.8)                  |
| Cumulative dose (µg)     | $285.4 \pm 280.6$         |

Data are reported as means  $\pm$  standard deviation for continuous variables and numbers (percentage) for categorical variables.

RASS = Richmond agitation-sedation scale



**Figure S1.** Flow diagram of patients in the present study. MV = mechanical ventilation; RASS = Richmond agitation-sedation scale

|                              |           | copyrigh   |                  |
|------------------------------|-----------|--|------------------|
|                              |           | STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of <i>coport studies</i><br>은 없   |                  |
| Section/Topic                | ltem<br># | Recommendation   | Reported on page |
| Title and abstract           | 1         | (a) Indicate the study's design with a commonly used term in the title or the abstract   | 1                |
|                              |           | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | 2                |
| Introduction                 |           | ate  |                  |
| Background/rationale         | 2         | Explain the scientific background and rationale for the investigation being reported   | 4                |
| Objectives                   | 3         | State specific objectives, including any prespecified hypotheses   | 4                |
| Methods                      | 1         | and a serie and a serie a  |                  |
| Study design                 | 4         | Present key elements of study design early in the paper  | 4                |
| Setting                      | 5         | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, and data collection   | 5                |
| Participants                 | 6         | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up   | 5                |
|                              |           | (b) For matched studies, give matching criteria and number of exposed and unexposed  |                  |
| Variables                    | 7         | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifier Give diagnostic criteria, if applicable   | 5                |
| Data sources/<br>measurement | 8*        | For each variable of interest, give sources of data and details of methods of assessment (meas grendent). Describe comparability of assessment methods if there is more than one group   | 5                |
| Bias                         | 9         | Describe any efforts to address potential sources of bias  |                  |
| Study size                   | 10        | Explain how the study size was arrived at  |                  |
| Quantitative variables       | 11        | Explain how quantitative variables were handled in the analyses. If applicable, describe which gou bongs were chosen and why   | 5                |
| Statistical methods          | 12        | (a) Describe all statistical methods, including those used to control for confounding  | 6                |
|                              |           | (b) Describe any methods used to examine subgroups and interactions  | 6                |
|                              |           | (c) Explain how missing data were addressed  | 6                |
|                              |           | (c) Explain how missing data were addressed     Image: Constraint of the second s | 6                |
|                              |           | (e) Describe any sensitivity analyses     Image: Constraint of the sense of the sen | 6                |

 phique de l

|                   |     | BMJ Open<br>BMJ Open 202  | Page |
|-------------------|-----|---|------|
| Participants      | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, exangine of the stage of study and the study and the study and the stu        | 7    |
|                   |     | eligible, included in the study, completing follow-up, and analysed   | 7    |
|                   |     | (c) Consider use of a flow diagram 호 · · · · · · · · · · · · · · · · · ·  | 7    |
| Descriptive data  | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information of motoosures and potential confounders   | 7    |
|                   |     | (b) Indicate number of participants with missing data for each variable of interest   | 8    |
|                   |     | (c) Summarise follow-up time (eg, average and total amount)   |      |
| Outcome data      | 15* | Report numbers of outcome events or summary measures over time  | 8    |
| Main results      | 16  | ( <i>a</i> ) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their preceding of the section of the se | 8    |
|                   |     | (b) Report category boundaries when continuous variables were categorized   | 8    |
|                   |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful  |      |
| Other analyses    | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  | 9    |
| Discussion        |     |   |      |
| Key results       | 18  | Summarise key results with reference to study objectives  | 9    |
| Limitations       |     |   |      |
| Interpretation    | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence  | 10   |
| Generalisability  | 21  | Discuss the generalisability (external validity) of the study results   | 10   |
| Other information |     | ar te   |      |
| Funding           | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, by the original study on which the present article is based  | 13   |

👋 مې \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in coss-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published exan bless of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine 👼 rg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www. Bobe-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml